{
    "filename": "2917474.pdf",
    "content_type": "application/pdf",
    "file_size": 1994491,
    "metadata": {
        "identifiers": {
            "doi": "10.1155/2020/2917474",
            "url": "http://downloads.hindawi.com/journals/ijn/2020/2917474.pdf"
        },
        "date": 2020,
        "title": "PPAR\u03b3 and Its Agonists in Chronic Kidney Disease",
        "author": "Yuhua Ma, Manman Shi, Yuxin Wang, Jian Liu",
        "affiliations": [
            "Department of Nephrology, Traditional Chinese Medicine Hospital of Kunshan, Kunshan, Jiangsu, China",
            "Department of Nephrology, Traditional Chinese Medicine Hospital of Kunshan, Kunshan, Jiangsu, China",
            "Department of Nephrology, Traditional Chinese Medicine Hospital of Kunshan, Kunshan, Jiangsu, China",
            "Department of Nephrology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"
        ],
        "journal": "International Journal of Nephrology",
        "volume": "2020",
        "abstract": "Chronic kidney disease (CKD) has become a global healthcare issue. CKD can progress to irreversible end-stage renal diseases (ESRD) or renal failure. The major risk factors for CKD include obesity, diabetes, and cardiovascular diseases. Understanding the key process involved in the disease development may lead to novel interventive strategies, which is currently lagging behind. Peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) is one of the ligand-activated transcription factor superfamily members and is globally expressed in human tissues. Its agonists such as thiazolidinediones (TZDs) have been applied as effective antidiabetic drugs as they control insulin sensitivity in multiple metabolic tissues. Besides, TZDs exert protective effects in multiple other CKD risk disease contexts. As PPAR\u03b3 is abundantly expressed in major kidney cells, its physiological roles in those cells have been studied in both cell and animal models. The function of PPAR\u03b3 in the kidney ranges from energy metabolism, cell proliferation to inflammatory suppression, although major renal side effects of existing agonists (including TZDs) have been reported, which limited their application in treating CKD. In the current review, we systemically assess the function of PPAR\u03b3 in CKDs and the benefits and current limitations of its agonists in the clinical applications.",
        "references": "@article{mccullough2019a,\n  author = {McCullough, K.P. and Morgenstern, H. and Saran, R. and Herman, W.H. and Robinson, B.M.},\n  title = {Projecting ESRD incidence and prevalence in the United States through 2030,},\n  journal = {Journal of the American Society of Nephrology},\n  volume = {30},\n  pages = {127\u2013135},\n  date = {2019},\n  number = {1},\n  language = {}\n}\n@article{humphreys2018a,\n  author = {Humphreys, B.D.},\n  title = {Mechanisms of renal fibrosis,},\n  journal = {Annual Review of Physiology},\n  volume = {80},\n  pages = {309\u2013326},\n  date = {2018},\n  number = {1},\n  language = {}\n}\n@article{liang2019a,\n  author = {Liang, N. and Jakobsson, T. and Fan, R. and Treuter, E.},\n  title = {e nuclear receptor-co-repressor complex in control of liver metabolism and disease,},\n  journal = {Frontiers in Endocrinology},\n  volume = {10},\n  pages = {411},\n  date = {2019},\n  language = {}\n}\n@article{fajas1997a,\n  author = {Fajas, L. and Auboeuf, D. and al, E.Raspeet},\n  title = {e organization, promoter analysis, and expression of the human PPARc gene,},\n  journal = {Journal of Biological Chemistry},\n  volume = {272},\n  pages = {18779\u201318789},\n  date = {1997},\n  number = {30},\n  language = {}\n}\n@article{kersten2000a,\n  author = {Kersten, S. and Desvergne, B. and Wahli, W.},\n  title = {Roles of PPARs in health and disease,},\n  journal = {Nature},\n  volume = {405},\n  pages = {421\u2013424},\n  date = {2000},\n  number = {6785},\n  language = {}\n}\n@article{fayyad2019a,\n  author = {Fayyad, A.M. and Khan, A.A. and Abdallah, S.H. and Alomran, S.S. and Bajou, K. and Khattak, M.N.K.},\n  title = {Rosiglitazone enhances browning adipocytes in association with MAPK and PI3-K pathways during the differentiation of telomerase-transformed mesenchymal stromal cells into adipocytes,},\n  journal = {International Journal of Molecular Sciences},\n  volume = {20},\n  pages = {1618},\n  date = {2019},\n  number = {7},\n  language = {}\n}\n@article{liang2019b,\n  author = {Liang, N. and Damdimopoulos, A. and Go\u00f1i, S.},\n  title = {Hepatocytespecific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR\u03b1,},\n  journal = {Nature Communications},\n  volume = {10},\n  pages = {1684},\n  date = {2019},\n  more-authors = {true},\n  number = {1},\n  language = {}\n}\n@article{de2017a,\n  author = {de Vera, I.M.S. and Zheng, J. and Novick, S.},\n  title = {Synergistic regulation of coregulator/nuclear receptor interaction by ligand and DNA,},\n  journal = {Structure},\n  volume = {25},\n  pages = {1506\u20131518},\n  date = {2017},\n  more-authors = {true},\n  number = {10},\n  language = {}\n}\n@article{pascual2005a,\n  author = {Pascual, G. and Fong, A.L. and Ogawa, S.},\n  title = {A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-c,},\n  journal = {Nature},\n  volume = {437},\n  pages = {759\u2013763},\n  date = {2005},\n  more-authors = {true},\n  number = {7059},\n  language = {}\n}\n@article{konstantinopoulos2007a,\n  author = {Konstantinopoulos, P.A. and Vandoros, G.P. and SotiropoulouBonikou, G. and Kominea, A. and G, A.},\n  title = {Papavassiliou, \u201cNF-kappaB/ PPAR c and/or AP-1/PPAR c \u201con/off\u201d switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression,\u201d},\n  journal = {International Journal of Colorectal Disease},\n  volume = {22},\n  pages = {57\u201368},\n  date = {2007},\n  number = {1},\n  language = {}\n}\n@article{lefterova2008a,\n  author = {Lefterova, M.I. and Zhang, Y. and Steger, D.J.},\n  title = {PPAR and C/ EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale,},\n  journal = {Genes & Development},\n  volume = {22},\n  pages = {2941\u20132952},\n  date = {2008},\n  more-authors = {true},\n  number = {21},\n  language = {}\n}\n@article{konig2009a,\n  author = {Konig, B. and Koch, A. and Spielmann, J.},\n  title = {Activation of PPAR\u03b1 and PPARc reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1,},\n  journal = {European Journal of Pharmacology},\n  volume = {605},\n  pages = {23\u201330},\n  date = {2009},\n  more-authors = {true},\n  number = {1\u20133},\n  language = {}\n}\n@article{fontaine2003a,\n  author = {Fontaine, C. and Dubois, G. and Duguay, Y.},\n  title = {e orphan nuclear receptor rev-Erb\u03b1 is a peroxisome proliferator-activated receptor (PPAR) c target gene and promotes PPARcinduced adipocyte differentiation,},\n  journal = {Journal of Biological Chemistry},\n  volume = {278},\n  pages = {37672\u201337680},\n  date = {2003},\n  more-authors = {true},\n  number = {39},\n  language = {}\n}\n@article{cipolletta2012a,\n  author = {Cipolletta, D. and Feuerer, M. and Li, A.},\n  title = {PPAR-c is a major driver of the accumulation and phenotype of adipose tissue Treg cells,},\n  journal = {Nature},\n  volume = {486},\n  pages = {549\u2013553},\n  date = {2012},\n  more-authors = {true},\n  number = {7404},\n  language = {}\n}\n@article{cheng2019a,\n  author = {Cheng, S. and Qian, K. and Wang, Y.},\n  title = {PPARc inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells,},\n  journal = {Journal of Cellular and Molecular Medicine},\n  volume = {23},\n  pages = {3724\u20133736},\n  date = {2019},\n  more-authors = {true},\n  number = {5},\n  language = {}\n}\n@article{gilardi2019a,\n  author = {Gilardi, F. and Winkler, C. and Quignodon, L.},\n  title = {Systemic PPARc deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility,},\n  journal = {Metabolism},\n  volume = {95},\n  pages = {8\u201320},\n  date = {2019},\n  more-authors = {true},\n  language = {}\n}\n@article{demir2016a,\n  author = {Demir, T. and Onay, H. and Savage, D.B.},\n  title = {Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -c (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations,},\n  journal = {Diabetic Medicine},\n  volume = {33},\n  pages = {1445\u20131450},\n  date = {2016},\n  more-authors = {true},\n  number = {10},\n  language = {}\n}\n@article{gu2014a,\n  author = {Gu, S.-J. and Guo, Z.-R. and Zhou, Z.-Y. and Hu, X.-S. and Wu, M. and Zhang, N.},\n  title = {Peroxisome proliferator-activated receptor c polymorphisms as risk factors for dyslipidemia,},\n  journal = {Molecular Medicine Reports},\n  volume = {10},\n  pages = {2759\u20132763},\n  date = {2014},\n  number = {5},\n  language = {}\n}\n@article{yang1999a,\n  author = {Yang, T. and Michele, D.E. and Park, J.},\n  title = {Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,},\n  journal = {American Journal of PhysiologyRenal Physiology},\n  volume = {277},\n  pages = {966\u2013973},\n  date = {1999},\n  more-authors = {true},\n  number = {6},\n  language = {}\n}\n@article{kiss-toth2008a,\n  author = {Kiss-Toth, E. and Roszer, T.},\n  title = {PPARc in kidney physiology and pathophysiology,},\n  journal = {PPAR Research},\n  volume = \"vol.\" # \"183108, 9\",\n  date = {2008},\n  pages = {pages,},\n  unmatched-journal = {Article ID},\n  unmatched-volume = {183108, 9},\n  language = {}\n}\n@article{corrales2018a,\n  author = {Corrales, P. and Izquierdo-Lahuerta, A. and G.},\n  title = {Medina-Gomez, \u201cMaintenance of kidney metabolic homeostasis by PPAR c,\u201d},\n  journal = {International Journal of Molecular Sciences},\n  volume = {19},\n  pages = {2063},\n  date = {2018},\n  number = {7},\n  language = {}\n}\n@article{desch2010a,\n  author = {Desch, M. and Schreiber, A. and Schweda, F.},\n  title = {Increased renin production in mice with deletion of peroxisome proliferatoractivated receptor-c in juxtaglomerular cells,},\n  journal = {Hypertension},\n  volume = {55},\n  pages = {660\u2013666},\n  date = {2010},\n  more-authors = {true},\n  number = {3},\n  language = {}\n}\n@article{zhang2005a,\n  author = {Zhang, H. and Zhang, A. and Kohan, D.E. and Nelson, R.D. and Gonzalez, F.J. and Yang, T.},\n  title = {Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention,},\n  journal = {Proceedings of the National Academy of Sciences},\n  volume = {102},\n  pages = {9406\u20139411},\n  date = {2005},\n  number = {26},\n  language = {}\n}\n@article{chafin2010a,\n  author = {Chafin, C. and Muse, S. and Hontecillas, R.},\n  title = {Deletion of PPARc; in immune cells enhances susceptibility to antiglomerular basement membrane disease,},\n  journal = {Journal of Inflammation Research},\n  volume = {3},\n  pages = {127\u2013134},\n  date = {2010},\n  more-authors = {true},\n  language = {}\n}\n@article{toffoli2017a,\n  author = {Toffoli, B. and Gilardi, F. and Winkler, C.},\n  title = {Nephropathy in Pparg-null mice highlights PPARc systemic activities in metabolism and in the immune system,},\n  journal = {PLoS One},\n  volume = {12},\n  booktitle = {Article ID e0171474},\n  date = {2017},\n  more-authors = {true},\n  number = {2},\n  language = {}\n}\n@article{yang2012a,\n  author = {Yang, G. and Jia, Z. and Aoyagi, T. and McClain, D. and Mortensen, R.M. and Yang, T.},\n  title = {Systemic PPARc deletion impairs circadian rhythms of behavior and metabolism,},\n  journal = {PLoS One},\n  volume = {7},\n  booktitle = {Article ID e38117},\n  date = {2012},\n  number = {8},\n  language = {}\n}\n@article{zhou2015a,\n  author = {Zhou, L. and Panasiuk, A. and Downton, M.},\n  title = {Systemic PPARc deletion causes severe disturbance in fluid homeostasis in mice,},\n  journal = {Physiological Genomics},\n  volume = {47},\n  pages = {541\u2013547},\n  date = {2015},\n  more-authors = {true},\n  number = {11},\n  language = {}\n}\n@article{yang2009a,\n  author = {Yang, H.-C. and Deleuze, S. and Zuo, Y. and Potthoff, S.A. and Ma, L.-J. and Fogo, A.B.},\n  title = {e PPARc agonist pioglitazone ameliorates aging-related progressive renal injury,},\n  journal = {Journal of the American Society of Nephrology},\n  volume = {20},\n  pages = {2380\u20132388},\n  date = {2009},\n  number = {11},\n  language = {}\n}\n@article{ko2008a,\n  author = {Ko, G.J. and Kang, Y.S. and Han, S.Y.},\n  title = {Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats,},\n  journal = {Nephrology Dialysis Transplantation},\n  volume = {23},\n  pages = {2750\u20132760},\n  date = {2008},\n  more-authors = {true},\n  number = {9},\n  language = {}\n}\n@article{isshiki2000a,\n  author = {Isshiki, K. and Haneda, M. and Koya, D. and Maeda, S. and Sugimoto, T. and Kikkawa, R.},\n  title = {iazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats,},\n  journal = {Diabetes},\n  volume = {49},\n  pages = {1022\u20131032},\n  date = {2000},\n  number = {6},\n  language = {}\n}\n@article{efrati2009a,\n  author = {Efrati, S. and Berman, S. and Chachashvili, A.},\n  title = {Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction,},\n  journal = {Nephrology},\n  volume = {14},\n  pages = {189\u2013197},\n  date = {2009},\n  more-authors = {true},\n  number = {2},\n  language = {}\n}\n@article{kawai2009a,\n  author = {Kawai, T. and Masaki, T. and Doi, S.},\n  title = {PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta,},\n  journal = {Laboratory Investigation},\n  volume = {89},\n  pages = {47\u201358},\n  date = {2009},\n  more-authors = {true},\n  number = {1},\n  language = {}\n}\n@article{okada2006a,\n  author = {Okada, T. and Wada, J. and Hida, K.},\n  title = {iazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms,},\n  journal = {Diabetes},\n  volume = {55},\n  pages = {1666\u20131677},\n  date = {2006},\n  more-authors = {true},\n  number = {6},\n  language = {}\n}\n@article{ghosh2003a,\n  author = {Ghosh, S.S. and Gehr, T.W.B. and Ghosh, S.},\n  title = {PPARc ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase,},\n  journal = {Kidney International},\n  volume = {64},\n  pages = {52\u201362},\n  date = {2003},\n  more-authors = {true},\n  number = {1},\n  language = {}\n}\n@article{weissgarten2006a,\n  author = {Weissgarten, J. and Berman, S. and Efrati, S. and Rapoport, M. and Averbukh, Z. and Feldman, L.},\n  title = {Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats,},\n  journal = {Nephrology Dialysis Transplantation},\n  volume = {21},\n  pages = {1198\u20131204},\n  date = {2006},\n  number = {5},\n  language = {}\n}\n@article{kanjanabuch2007a,\n  author = {Kanjanabuch, T. and Ma, L.J. and Chen, J.},\n  title = {PPAR-gamma agonist protects podocytes from injury,},\n  journal = {Kidney International},\n  volume = {71},\n  pages = {1232\u20131239},\n  date = {2007},\n  more-authors = {true},\n  number = {12},\n  language = {}\n}\n@article{artwohl2005a,\n  author = {Artwohl, M. and Holzenbein, T. and Furnsinn, C.},\n  title = {iazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells,},\n  journal = {rombosis and Haemostasis},\n  volume = {93},\n  pages = {810\u2013815},\n  date = {2005},\n  more-authors = {true},\n  number = {5},\n  language = {}\n}\n@article{carrero2008a,\n  author = {Carrero, J.J. and Yilmaz, M.I. and Lindholm, B. and Stenvinkel, P.},\n  title = {Cytokine dysregulation in chronic kidney disease: how can we treat it?,},\n  journal = {Blood Purification},\n  volume = {26},\n  pages = {291\u2013299},\n  date = {2008},\n  number = {3},\n  language = {}\n}\n@article{panzer2008a,\n  author = {Panzer, U. and Zahner, G. and Wienberg, U.},\n  title = {15-Deoxy- 12,14prostaglandin J2 inhibits INF- -induced JAK/STAT1 signalling pathway activation and IP-10/CXCL10 expression in mesangial cells,},\n  journal = {Nephrology Dialysis Transplantation},\n  volume = {23},\n  pages = {3776\u20133785},\n  date = {2008},\n  more-authors = {true},\n  number = {12},\n  language = {}\n}\n@article{lu2013a,\n  author = {Lu, Y. and Zhou, Q. and Shi, Y.},\n  title = {SUMOylation of PPARc by rosiglitazone prevents LPS-induced NCoR degradation mediating down regulation of chemokines expression in renal proximal tubular cells,},\n  journal = {PLoS One},\n  volume = {8},\n  source = {Article ID e79815,},\n  date = {2013},\n  more-authors = {true},\n  number = {11},\n  language = {}\n}\n@article{xiao2009a,\n  author = {Xiao, J. and Leung, J.C.K. and Chan, L.Y.Y. and Guo, H. and Lai, K.N.},\n  title = {Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy,},\n  journal = {Nephrology Dialysis Transplantation},\n  volume = {24},\n  pages = {2067\u20132077},\n  date = {2009},\n  number = {7},\n  language = {}\n}\n@article{henique2016a,\n  author = {Henique, C. and Bollee, G. and Lenoir, O.},\n  title = {Nuclear factor erythroid 2-related factor 2 drives podocyte-specific expression of peroxisome proliferator-activated receptor c essential for resistance to crescentic GN,},\n  journal = {Journal of the American Society of Nephrology},\n  volume = {27},\n  pages = {172\u2013188},\n  date = {2016},\n  more-authors = {true},\n  number = {1},\n  language = {}\n}\n@article{wu2009a,\n  author = {Wu, M. and Melichian, D.S. and Chang, E. and Warner-Blankenship, M. and Ghosh, A.K. and Varga, J.},\n  title = {Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptorc,},\n  journal = {e American Journal of Pathology},\n  volume = {174},\n  pages = {519\u2013533},\n  date = {2009},\n  number = {2},\n  language = {}\n}\n@article{zheng2002a,\n  author = {Zheng, F. and Fornoni, A. and Elliot, S.J.},\n  title = {Upregulation of type I collagen by TGF-\u03b2 in mesangial cells is blocked by PPARc activation,},\n  journal = {American Journal of Physiology-Renal Physiology},\n  volume = {282},\n  pages = {639\u2013648},\n  date = {2002},\n  more-authors = {true},\n  number = {4},\n  language = {}\n}\n@article{ma2001a,\n  author = {Ma, L.-J. and Marcantoni, C. and Linton, M.F. and Fazio, S. and Fogo, A.B.},\n  title = {Peroxisome proliferator-activated receptor-c agonist troglitazone protects against nondiabetic glomerulosclerosis in rats,},\n  journal = {Kidney International},\n  volume = {59},\n  pages = {1899\u20131910},\n  date = {2001},\n  number = {5},\n  language = {}\n}\n@article{li2006a,\n  author = {Li, Y. and Wen, X. and Spataro, B.C. and Hu, K. and Dai, C. and Liu, Y.},\n  title = {Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferatoractivated receptor-gamma agonists,},\n  journal = {Journal of the American Society of Nephrology},\n  volume = {17},\n  pages = {54\u201365},\n  date = {2006},\n  number = {1},\n  language = {}\n}\n@article{wang2007a,\n  author = {Wang, W. and Liu, F. and Chen, N.},\n  title = {Peroxisome proliferatoractivated receptor-gamma (PPAR-c) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts,},\n  journal = {Mediators Inflamm},\n  volume = \"vol.\" # \"62641, 7\",\n  date = {2007},\n  pages = {pages,},\n  unmatched-journal = {Article ID},\n  unmatched-volume = {62641, 7},\n  language = {}\n}\n@article{chen2019a,\n  author = {Chen, Z. and Yuan, P. and Sun, X.},\n  title = {Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-c-miR-23 axis,},\n  journal = {American Journal of Physiology-Renal Physiology},\n  volume = {317},\n  pages = {137\u2013151},\n  date = {2019},\n  more-authors = {true},\n  number = {1},\n  language = {}\n}\n@article{wu2016a,\n  author = {Wu, L. and Wang, Q. and Guo, F.},\n  title = {MicroRNA-27a induces mesangial cell injury by targeting of PPARc, and its in vivo knockdown prevents progression of diabetic nephropathy,},\n  journal = {Scientific Reports},\n  volume = {6},\n  pages = {26072},\n  date = {2016},\n  more-authors = {true},\n  number = {1},\n  language = {}\n}\n@article{zhou2017a,\n  author = {Zhou, Z. and Wan, J. and Hou, X. and Geng, J. and Li, X. and Bai, X.},\n  title = {MicroRNA-27a promotes podocyte injury via PPARcmediated \u03b2-catenin activation in diabetic nephropathy,},\n  journal = {Cell Death & Disease},\n  volume = {8},\n  booktitle = {Article ID e2658},\n  date = {2017},\n  number = {3},\n  language = {}\n}\n@article{samaha2006a,\n  author = {Samaha, F.F. and Szapary, P.O. and Iqbal, N.},\n  title = {Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome,},\n  journal = {Arteriosclerosis, rombosis, and Vascular Biology},\n  volume = {26},\n  pages = {624\u2013630},\n  date = {2006},\n  more-authors = {true},\n  number = {3},\n  language = {}\n}\n@article{eckardt2014a,\n  author = {Eckardt, K. and Gorgens, S.W. and Raschke, S. and Eckel, J.},\n  title = {Myokines in insulin resistance and type 2 diabetes,},\n  journal = {Diabetologia},\n  volume = {57},\n  pages = {1087\u20131099},\n  date = {2014},\n  number = {6},\n  language = {}\n}\n@article{wahli2012a,\n  author = {Wahli, W. and L.},\n  title = {Michalik, \u201cPPARs at the crossroads of lipid signaling and inflammation,\u201d},\n  journal = {Trends in Endocrinology & Metabolism},\n  volume = {23},\n  pages = {351\u2013363},\n  date = {2012},\n  number = {7},\n  language = {}\n}\n@article{ahmadian2013a,\n  author = {Ahmadian, M. and Suh, J.M. and Hah, N.},\n  title = {PPARc signaling and metabolism: the good, the bad and the future,},\n  journal = {Nature Medicine},\n  volume = {19},\n  pages = {557\u2013566},\n  date = {2013},\n  more-authors = {true},\n  number = {5},\n  language = {}\n}\n@article{derlacz2008a,\n  author = {Derlacz, R.A. and Hyc, K. and Usarek, M. and Jagielski, A.K. and Drozak, J. and Jarzyna, R.},\n  title = {PPAR-c-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules,},\n  journal = {Biochemistry and Cell Biology},\n  volume = {86},\n  pages = {396\u2013404},\n  date = {2008},\n  number = {5},\n  language = {}\n}\n@article{mather2011a,\n  author = {Mather, A. and Pollock, C.},\n  title = {Glucose handling by the kidney,},\n  journal = {Kidney International},\n  volume = {79},\n  pages = {1\u20136},\n  date = {2011},\n  language = {}\n}\n@article{santer2003a,\n  author = {Santer, R. and Kinner, M. and Lassen, C.L.},\n  title = {Molecular analysis of the SGLT2 gene in patients with renal glucosuria,},\n  journal = {Journal of the American Society of Nephrology},\n  volume = {14},\n  pages = {2873\u20132882},\n  date = {2003},\n  more-authors = {true},\n  number = {11},\n  language = {}\n}\n@article{bonner2015a,\n  author = {Bonner, C. and Kerr-Conte, J. and Gmyr, V.},\n  title = {Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion,},\n  journal = {Nature Medicine},\n  volume = {21},\n  pages = {512\u2013517},\n  date = {2015},\n  more-authors = {true},\n  number = {5},\n  language = {}\n}\n@article{kim2017a,\n  author = {Kim, M. and Lee, E.J. and Shin, H.M.},\n  title = {e effect of PPARc agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia,},\n  journal = {Journal of Endocrinological Investigation},\n  volume = {40},\n  pages = {1069\u20131076},\n  date = {2017},\n  more-authors = {true},\n  number = {10},\n  language = {}\n}\n@article{lee2010a,\n  author = {Lee, Y.J. and Han, H.J.},\n  title = {Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3\u03b2, Snail1, and \u03b2-catenin in renal proximal tubule cells,},\n  journal = {American Journal of Physiology-Renal Physiology},\n  volume = {298},\n  pages = {1263\u20131275},\n  date = {2010},\n  number = {5},\n  language = {}\n}\n@article{guillam1997a,\n  author = {Guillam, M.-T. and Hummler, E. and Schaerer, E.},\n  title = {Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2,},\n  journal = {Nature Genetics},\n  volume = {17},\n  pages = {327\u2013330},\n  date = {1997},\n  more-authors = {true},\n  number = {3},\n  language = {}\n}\n@article{murakami1998a,\n  author = {Murakami, K. and Tobe, K. and Ide, T.},\n  title = {A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats,},\n  journal = {Diabetes},\n  volume = {47},\n  pages = {1841\u20131847},\n  date = {1998},\n  more-authors = {true},\n  number = {12},\n  language = {}\n}\n@article{mochizukiohashi2017a,\n  author = {MochizukiOhashi, B. and Parim, B. and Chunduri, V.R.},\n  title = {Antiobesity potential of piperonal: promising modulation of body composition, lipid profiles and obesogenic marker expression in HFD-induced obese rats,},\n  journal = {Nutrition & Metabolism},\n  volume = {14},\n  pages = {72},\n  date = {2017},\n  more-authors = {true},\n  number = {1},\n  language = {}\n}\n@article{das2011a,\n  author = {Das, N. and Dhanawat, M. and Shrivastava, S.K.},\n  title = {Benzoxazinones as human peroxisome proliferator activated receptor gamma (PPARc) agonists: a docking study using glide,},\n  journal = {Indian Journal of Pharmaceutical Sciences},\n  volume = {73},\n  pages = {159\u2013164},\n  date = {2011},\n  number = {2},\n  language = {}\n}\n@article{hiraike2017a,\n  author = {Hiraike, Y. and Waki, H. and Yu, J.},\n  title = {NFIA co-localizes with PPARc and transcriptionally controls the brown fat gene program,},\n  journal = {Nature Cell Biology},\n  volume = {19},\n  pages = {1081\u20131092},\n  date = {2017},\n  more-authors = {true},\n  number = {9},\n  language = {}\n}\n@article{kim2016a,\n  author = {Kim, J. and Lee, Y.-J. and M, J.},\n  title = {Kim et al., \u201cPPARc agonists induce adipocyte differentiation by modulating the expression of Lipin-1, which acts as a PPARc phosphatase,\u201d},\n  journal = {e International Journal of Biochemistry & Cell Biology},\n  volume = {81},\n  pages = {57\u201366},\n  date = {2016},\n  language = {}\n}\n@article{huret2000a,\n  author = {Huret, J.-L. and Minor, S.L. and Dorkeld, F. and Dessen, P. and Bernheim, A.},\n  title = {Atlas of genetics and cytogenetics in oncology and haematology, an interactive database,},\n  journal = {Nucleic Acids Research},\n  volume = {28},\n  pages = {349\u2013351},\n  date = {2000},\n  number = {1},\n  language = {}\n}\n@article{lyu2018a,\n  author = {Lyu, Z. and Mao, Z. and Li, Q.},\n  title = {PPARc maintains the metabolic heterogeneity and homeostasis of renal tubules,},\n  journal = {EBioMedicine},\n  volume = {38},\n  pages = {178\u2013190},\n  date = {2018},\n  more-authors = {true},\n  language = {}\n}\n@article{szeto2016a,\n  author = {Szeto, H.H. and Liu, S. and Soong, Y. and Alam, N. and Prusky, G.T. and Seshan, S.V.},\n  title = {Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury,},\n  journal = {Kidney International},\n  volume = {90},\n  pages = {997\u20131011},\n  date = {2016},\n  number = {5},\n  language = {}\n}\n@article{moorhead1982a,\n  author = {Moorhead, J.F. and El-Nahas, M. and Chan, M.K. and Varghese, Z.},\n  title = {Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease,},\n  journal = {e Lancet},\n  volume = {320},\n  pages = {1309\u20131311},\n  date = {1982},\n  number = {8311},\n  language = {}\n}\n@article{a2016a,\n  author = {A. Izquierdo-Lahuerta, C. Mart\u0131nez-Garc\u0131a and G},\n  title = {MedinaGomez, \u201cLipotoxicity as a trigger factor of renal disease,\u201d},\n  journal = {Journal of Nephrology},\n  volume = {29},\n  pages = {603\u2013610},\n  date = {2016},\n  number = {5},\n  language = {}\n}\n@article{martinez-garcia2012a,\n  author = {Martinez-Garcia, C. and Izquierdo, A. and Velagapudi, V.},\n  title = {Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model,},\n  journal = {Disease Models & Mechanisms},\n  volume = {5},\n  pages = {636\u2013648},\n  date = {2012},\n  more-authors = {true},\n  number = {5},\n  language = {}\n}\n@article{medina-gomez2009a,\n  author = {Medina-Gomez, G. and Yetukuri, L. and Velagapudi, V.},\n  title = {Adaptation and failure of pancreatic cells in murine models with different degrees of metabolic syndrome,},\n  journal = {Disease Models & Mechanisms},\n  volume = {2},\n  pages = {582\u2013592},\n  date = {2009},\n  more-authors = {true},\n  number = {11-12},\n  language = {}\n}\n@article{mart2015a,\n  author = {Mart\u0131nez-Garc\u0131a, C. and Izquierdo-Lahuerta, A. and Vivas, Y.},\n  title = {Renal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton organization in podocytes,},\n  journal = {PLoS One},\n  volume = {10},\n  booktitle = {Article ID e0142291},\n  date = {2015},\n  more-authors = {true},\n  number = {11},\n  language = {}\n}\n@article{roszer2011a,\n  author = {Roszer, T. and Menendez-Gutierrez, M.P. and Lefterova, M.I.},\n  title = {Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency,},\n  journal = {Journal of Immunology},\n  volume = {186},\n  pages = {621\u2013631},\n  date = {2011},\n  more-authors = {true},\n  number = {1},\n  language = {}\n}\n@article{fischerricote2007a,\n  author = {FischerRicote, M.A. and Derudas, B. and Rigamonti, E.},\n  title = {PPARc activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties,},\n  journal = {Cell Metabolism},\n  volume = {6},\n  pages = {137\u2013143},\n  date = {2007},\n  more-authors = {true},\n  number = {2},\n  language = {}\n}\n@article{akiyama2002a,\n  author = {Akiyama, T.E. and Sakai, S. and Lambert, G.},\n  title = {Conditional disruption of the peroxisome proliferator-activated receptor gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux,},\n  journal = {Molecular and Cellular Biology},\n  volume = {22},\n  pages = {2607\u20132619},\n  date = {2002},\n  more-authors = {true},\n  number = {8},\n  language = {}\n}\n@article{ricote1998a,\n  author = {Ricote, M. and Li, A.C. and Willson, T.M. and Kelly, C.J. and K, C.},\n  title = {Glass, \u201ce peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation,\u201d},\n  journal = {Nature},\n  volume = {391},\n  pages = {79\u201382},\n  date = {1998},\n  number = {6662},\n  language = {}\n}\n@article{glass2010a,\n  author = {Glass, C.K. and Saijo, K.},\n  title = {Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells,},\n  journal = {Nature Reviews Immunology},\n  volume = {10},\n  pages = {365\u2013376},\n  date = {2010},\n  number = {5},\n  language = {}\n}\n@article{menendez-gutierrez2012a,\n  author = {Menendez-Gutierrez, M.P. and Roszer, T. and Ricote, M.},\n  title = {Biology and therapeutic applications of peroxisome proliferator-activated receptors,},\n  journal = {Current Topics in Medicinal Chemistry},\n  volume = {12},\n  pages = {48\u2013584},\n  date = {2012},\n  number = {6},\n  language = {}\n}\n@article{lash2009a,\n  author = {Lash, J.P. and Go, A.S. and Appel, L.J.},\n  title = {Chronic renal insufficiency cohort (CRIC) study: baseline characteristics and associations with kidney function,},\n  journal = {Clinical Journal of the American Society of Nephrology},\n  volume = {4},\n  pages = {1302\u20131311},\n  date = {2009},\n  more-authors = {true},\n  number = {8},\n  language = {}\n}\n@article{szkup2018a,\n  author = {Szkup, M. and Owczarek, A.J. and Schneider-Matyka, D. and Brodowski, J. and \u0141oo, B. and Grochans, E.},\n  title = {Associations between the components of metabolic syndrome and the polymorphisms in the peroxisome proliferator-activated receptor gamma (PPAR-c), the fat mass and obesity-associated (FTO), and the melanocortin-4 receptor (MC4R) genes,},\n  journal = {Aging},\n  volume = {10},\n  pages = {72\u201382},\n  date = {2018},\n  number = {1},\n  language = {}\n}\n@article{iglarz2003a,\n  author = {Iglarz, M. and Touyz, R.M. and Amiri, F. and Lavoie, M.-F. and Diep, Q.N. and Schiffrin, E.L.},\n  title = {Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension,},\n  journal = {Arteriosclerosis, rombosis, and Vascular Biology},\n  volume = {23},\n  pages = {45\u201351},\n  date = {2003},\n  number = {1},\n  language = {}\n}\n@article{wu2004a,\n  author = {Wu, L. and Wang, R. and Champlain, J.De and Wilson, T.W.},\n  title = {Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats,},\n  journal = {American Journal of Hypertension},\n  volume = {17},\n  pages = {749\u2013756},\n  date = {2004},\n  number = {9},\n  language = {}\n}\n@article{zhang2019a,\n  author = {Zhang, M. and Zhang, J. and Li, L. and Wang, Q. and Feng, L.},\n  title = {Association between peroxisome proliferator-activated receptor c-2 gene Pro12Ala polymorphisms and risk of hypertension: an updated meta-analysis,},\n  journal = {Bioscience Reports},\n  volume = {39},\n  date = {2019},\n  number = {2},\n  language = {}\n}\n@article{nicol2005a,\n  author = {Nicol, C.J. and Adachi, M. and Akiyama, T.E. and Gonzalez, F.J.},\n  title = {PPARgamma in endothelial cells influences high fat dietinduced hypertension,},\n  journal = {American Journal of Hypertension},\n  volume = {18},\n  pages = {549\u2013556},\n  date = {2005},\n  number = {4},\n  language = {}\n}\n@article{benkirane2006a,\n  author = {Benkirane, K. and Viel, E.C. and Amiri, F. and Schiffrin, E.L.},\n  title = {Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo,},\n  journal = {Hypertension},\n  volume = {47},\n  pages = {102\u2013108},\n  date = {2006},\n  number = {1},\n  language = {}\n}\n@article{schiffrin2005a,\n  author = {Schiffrin, E.L.},\n  title = {Peroxisome proliferator-activated receptors and cardiovascular remodeling,},\n  journal = {American Journal of Physiology-Heart and Circulatory Physiology},\n  volume = {288},\n  pages = {1037\u20131043},\n  date = {2005},\n  number = {3},\n  language = {}\n}\n@article{magri2011a,\n  author = {Magri, C.J. and Gatt, N. and Xuereb, R.G. and Fava, S.},\n  title = {Peroxisome proliferator-activated receptor-c and the endothelium: implications in cardiovascular disease,},\n  journal = {Expert Review of Cardiovascular erapy},\n  volume = {9},\n  pages = {1279\u20131294},\n  date = {2011},\n  number = {10},\n  language = {}\n}\n@article{barroso1999a,\n  author = {Barroso, I. and Gurnell, M. and Crowley, V.E.},\n  title = {Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension,},\n  journal = {Nature},\n  volume = {402},\n  pages = {880\u2013883},\n  date = {1999},\n  more-authors = {true},\n  number = {6764},\n  language = {}\n}\n@article{wang2008a,\n  author = {Wang, N. and Yang, G. and Jia, Z.},\n  title = {Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1,},\n  journal = {Cell Metabolism},\n  volume = {8},\n  pages = {482\u2013491},\n  date = {2008},\n  more-authors = {true},\n  number = {6},\n  language = {}\n}\n@article{guan2005a,\n  author = {Guan, Y. and Hao, C. and Cha, D.R.},\n  title = {iazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption,},\n  journal = {Nature Medicine},\n  volume = {11},\n  pages = {861\u2013866},\n  date = {2005},\n  more-authors = {true},\n  number = {8},\n  language = {}\n}\n@article{kliewer2001a,\n  author = {Kliewer, S.A. and Xu, H.E. and Lambert, M.H. and Willson, T.M.},\n  title = {Peroxisome proliferator-activated receptors: from genes to physiology,},\n  journal = {Recent Progress in Hormone Research},\n  volume = {56},\n  pages = {239\u2013263},\n  date = {2001},\n  number = {1},\n  language = {}\n}\n@article{yang2009b,\n  author = {Yang, J. and Zhang, D. and Li, J. and Zhang, X. and Fan, F. and Guan, Y.},\n  title = {Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential,},\n  journal = {Clinical Science},\n  volume = {116},\n  pages = {17\u201326},\n  date = {2009},\n  number = {1},\n  language = {}\n}\n@article{sarafidis2010a,\n  author = {Sarafidis, P.A. and Stafylas, P.C. and Georgianos, P.I. and Saratzis, A.N. and Lasaridis, A.N.},\n  title = {Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis,},\n  journal = {American Journal of Kidney Diseases},\n  volume = {55},\n  pages = {835\u2013847},\n  date = {2010},\n  number = {5},\n  language = {}\n}\n@article{zuo2012a,\n  author = {Zuo, Y. and Yang, H.C. and Potthoff, S.A.},\n  title = {Protective effects of PPARgamma agonist in acute nephrotic syndrome,},\n  journal = {Nephrology Dialysis Transplantation},\n  volume = {27},\n  pages = {174\u2013181},\n  date = {2012},\n  more-authors = {true},\n  number = {1},\n  language = {}\n}\n@article{yoshihara2011a,\n  author = {Yoshihara, D. and Kurahashi, H. and Morita, M.},\n  title = {PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease,},\n  journal = {American Journal of Physiology-Renal Physiology},\n  volume = {300},\n  pages = {465\u2013474},\n  date = {2011},\n  more-authors = {true},\n  number = {2},\n  language = {}\n}\n@article{elshazly2019a,\n  author = {Elshazly, S. and Soliman, E.},\n  title = {PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/ reperfusion injury,},\n  journal = {Toxicology and Applied Pharmacology},\n  volume = {362},\n  pages = {86\u201394},\n  date = {2019},\n  language = {}\n}\n@article{sugawara2010a,\n  author = {Sugawara, A. and Uruno, A. and Kudo, M. and Matsuda, K. and Yang, C.W. and Ito, S.},\n  title = {Effects of PPARgamma on hypertension, atherosclerosis, and chronic kidney disease,},\n  journal = {Endocrine Journal},\n  volume = {57},\n  pages = {847\u2013852},\n  date = {2010},\n  number = {10},\n  language = {}\n}\n@article{iglesias2006a,\n  author = {Iglesias, P. and D\u0131ez, J.J.},\n  title = {Peroxisome proliferator-activated receptor gamma agonists in renal disease,},\n  journal = {European Journal of Endocrinology},\n  volume = {154},\n  pages = {613\u2013621},\n  date = {2006},\n  number = {5},\n  language = {}\n}\n@article{liu2018a,\n  author = {Liu, L. and Liu, Y. and Zhang, Y.},\n  title = {High phosphate-induced downregulation of PPARc contributes to CKD-associated vascular calcification,},\n  journal = {Journal of Molecular and Cellular Cardiology},\n  volume = {114},\n  pages = {264\u2013275},\n  date = {2018},\n  more-authors = {true},\n  language = {}\n}\n@article{zhang2017a,\n  author = {Zhang, Y.-F. and Wang, Q. and Su, Y.-Y.},\n  title = {PPAR-c agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution-induced damage,},\n  journal = {Molecular Medicine Reports},\n  volume = {15},\n  pages = {1786\u20131792},\n  date = {2017},\n  more-authors = {true},\n  number = {4},\n  language = {}\n}\n@article{barnett2006a,\n  author = {Barnett, A.},\n  title = {Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial,},\n  journal = {Journal of the American Society of Nephrology},\n  volume = {17},\n  pages = {132\u2013135},\n  date = {2006},\n  number = {4},\n  language = {}\n}\n@article{arozal2011a,\n  author = {Arozal, W. and Watanabe, K. and Veeraveedu, P.T.},\n  title = {Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-c agonist actions,},\n  journal = {Toxicology},\n  volume = {279},\n  pages = {91\u201399},\n  date = {2011},\n  more-authors = {true},\n  number = {1\u20133},\n  language = {}\n}\n@article{schupp2005a,\n  author = {Schupp, M. and Clemenz, M. and Gineste, R.},\n  title = {Molecular characterization of new selective peroxisome proliferatoractivated receptor c modulators with angiotensin receptor blocking activity,},\n  journal = {Diabetes},\n  volume = {54},\n  pages = {3442\u20133452},\n  date = {2005},\n  more-authors = {true},\n  number = {12},\n  language = {}\n}\n@article{schneider2008a,\n  author = {Schneider, C.A. and Ferrannini, E. and Defronzo, R. and Schernthaner, G. and Yates, J. and Erdmann, E.},\n  title = {Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease,},\n  journal = {Journal of the American Society of Nephrology},\n  volume = {19},\n  pages = {182\u2013187},\n  date = {2008},\n  number = {1},\n  language = {}\n}\n@article{chan2011a,\n  author = {Chan, D.T. and Watts, G.F. and Irish, A.B. and Dogra, G.K.},\n  title = {Rosiglitazone does not improve vascular function in subjects with chronic kidney disease,},\n  journal = {Nephrology Dialysis Transplantation},\n  volume = {26},\n  pages = {3543\u20133549},\n  date = {2011},\n  number = {11},\n  language = {}\n}\n@article{zanchi2014a,\n  author = {Zanchi, A. and Tappy, L. and al, K.-A.Leet},\n  title = {Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study,},\n  journal = {PLoS One},\n  volume = {9},\n  booktitle = {Article ID e109134},\n  date = {2014},\n  number = {10},\n  language = {}\n}\n@article{han2010a,\n  author = {Han, S.J. and Hur, K.Y. and Kim, Y.S.},\n  title = {Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients,},\n  journal = {Nephrology Dialysis Transplantation},\n  volume = {25},\n  pages = {976\u2013984},\n  date = {2010},\n  more-authors = {true},\n  number = {3},\n  language = {}\n}\n@article{kuba2005a,\n  author = {Kuba, K. and Imai, Y. and Rao, S.},\n  title = {A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury,},\n  journal = {Nature Medicine},\n  volume = {11},\n  pages = {875\u2013879},\n  date = {2005},\n  more-authors = {true},\n  number = {8},\n  language = {}\n}\n@article{raptis2012a,\n  author = {Raptis, A.E. and Bacharaki, D. and Mazioti, M.},\n  title = {Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARc agonists in uncomplicated diabetic patients,},\n  journal = {Experimental and Clinical Endocrinology & Diabetes},\n  volume = {120},\n  pages = {416\u2013419},\n  date = {2012},\n  more-authors = {true},\n  number = {7},\n  language = {}\n}\n@article{kung2012a,\n  author = {Kung, J. and Henry, R.R.},\n  title = {iazolidinedione safety,},\n  journal = {Expert Opinion on Drug Safety},\n  volume = {11},\n  pages = {565\u2013579},\n  date = {2012},\n  number = {4},\n  language = {}\n}\n@article{neumann2012a,\n  author = {Neumann, A. and Weill, A. and Ricordeau, P. and Fagot, J.P. and Alla, F. and Allemand, H.},\n  title = {Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study,},\n  journal = {Diabetologia},\n  volume = {55},\n  pages = {1953\u20131962},\n  date = {2012},\n  number = {7},\n  language = {}\n}\n@article{colmers2012a,\n  author = {Colmers, I.N. and Bowker, S.L. and Majumdar, S.R. and Johnson, J.A.},\n  title = {Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a metaanalysis,},\n  journal = {Canadian Medical Association Journal},\n  volume = {184},\n  pages = {675\u2013683},\n  date = {2012},\n  number = {12},\n  language = {}\n}\n@article{nissen2007a,\n  author = {Nissen, S.E. and Wolski, K.},\n  title = {Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,},\n  journal = {New England Journal of Medicine},\n  volume = {356},\n  pages = {2457\u20132471},\n  date = {2007},\n  number = {24},\n  language = {}\n}\n",
        "emails": [
            "rocjom@gmail.com"
        ],
        "pages": "1-10",
        "references_ris": "TY  - JOUR\nAU  - McCullough, K.P.\nAU  - Morgenstern, H.\nAU  - Saran, R.\nAU  - Herman, W.H.\nAU  - Robinson, B.M.\nTI  - Projecting ESRD incidence and prevalence in the United States through 2030,\nT2  - Journal of the American Society of Nephrology\nVL  - 30\nSP  - 127\nEP  - 135\nPY  - 2019\nDA  - 2019\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Humphreys, B.D.\nTI  - Mechanisms of renal fibrosis,\nT2  - Annual Review of Physiology\nVL  - 80\nSP  - 309\nEP  - 326\nPY  - 2018\nDA  - 2018\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Liang, N.\nAU  - Jakobsson, T.\nAU  - Fan, R.\nAU  - Treuter, E.\nTI  - e nuclear receptor-co-repressor complex in control of liver metabolism and disease,\nT2  - Frontiers in Endocrinology\nVL  - 10\nSP  - 411\nPY  - 2019\nDA  - 2019\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Fajas, L.\nAU  - Auboeuf, D.\nAU  - al, E.Raspeet\nTI  - e organization, promoter analysis, and expression of the human PPARc gene,\nT2  - Journal of Biological Chemistry\nVL  - 272\nSP  - 18779\nEP  - 18789\nPY  - 1997\nDA  - 1997\nIS  - 30\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kersten, S.\nAU  - Desvergne, B.\nAU  - Wahli, W.\nTI  - Roles of PPARs in health and disease,\nT2  - Nature\nVL  - 405\nSP  - 421\nEP  - 424\nPY  - 2000\nDA  - 2000\nIS  - 6785\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Fayyad, A.M.\nAU  - Khan, A.A.\nAU  - Abdallah, S.H.\nAU  - Alomran, S.S.\nAU  - Bajou, K.\nAU  - Khattak, M.N.K.\nTI  - Rosiglitazone enhances browning adipocytes in association with MAPK and PI3-K pathways during the differentiation of telomerase-transformed mesenchymal stromal cells into adipocytes,\nT2  - International Journal of Molecular Sciences\nVL  - 20\nSP  - 1618\nPY  - 2019\nDA  - 2019\nIS  - 7\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Liang, N.\nAU  - Damdimopoulos, A.\nAU  - Go\u00f1i, S.\nTI  - Hepatocytespecific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR\u03b1,\nT2  - Nature Communications\nVL  - 10\nSP  - 1684\nPY  - 2019\nDA  - 2019\nC1  - true\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - de Vera, I.M.S.\nAU  - Zheng, J.\nAU  - Novick, S.\nTI  - Synergistic regulation of coregulator/nuclear receptor interaction by ligand and DNA,\nT2  - Structure\nVL  - 25\nSP  - 1506\nEP  - 1518\nPY  - 2017\nDA  - 2017\nC1  - true\nIS  - 10\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Pascual, G.\nAU  - Fong, A.L.\nAU  - Ogawa, S.\nTI  - A SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-c,\nT2  - Nature\nVL  - 437\nSP  - 759\nEP  - 763\nPY  - 2005\nDA  - 2005\nC1  - true\nIS  - 7059\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Konstantinopoulos, P.A.\nAU  - Vandoros, G.P.\nAU  - SotiropoulouBonikou, G.\nAU  - Kominea, A.\nAU  - G, A.\nTI  - Papavassiliou, \u201cNF-kappaB/ PPAR c and/or AP-1/PPAR c \u201con/off\u201d switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression,\u201d\nT2  - International Journal of Colorectal Disease\nVL  - 22\nSP  - 57\nEP  - 68\nPY  - 2007\nDA  - 2007\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lefterova, M.I.\nAU  - Zhang, Y.\nAU  - Steger, D.J.\nTI  - PPAR and C/ EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale,\nT2  - Genes & Development\nVL  - 22\nSP  - 2941\nEP  - 2952\nPY  - 2008\nDA  - 2008\nC1  - true\nIS  - 21\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Konig, B.\nAU  - Koch, A.\nAU  - Spielmann, J.\nTI  - Activation of PPAR\u03b1 and PPARc reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1,\nT2  - European Journal of Pharmacology\nVL  - 605\nSP  - 23\nEP  - 30\nPY  - 2009\nDA  - 2009\nC1  - true\nIS  - 1\u20133\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Fontaine, C.\nAU  - Dubois, G.\nAU  - Duguay, Y.\nTI  - e orphan nuclear receptor rev-Erb\u03b1 is a peroxisome proliferator-activated receptor (PPAR) c target gene and promotes PPARcinduced adipocyte differentiation,\nT2  - Journal of Biological Chemistry\nVL  - 278\nSP  - 37672\nEP  - 37680\nPY  - 2003\nDA  - 2003\nC1  - true\nIS  - 39\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Cipolletta, D.\nAU  - Feuerer, M.\nAU  - Li, A.\nTI  - PPAR-c is a major driver of the accumulation and phenotype of adipose tissue Treg cells,\nT2  - Nature\nVL  - 486\nSP  - 549\nEP  - 553\nPY  - 2012\nDA  - 2012\nC1  - true\nIS  - 7404\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Cheng, S.\nAU  - Qian, K.\nAU  - Wang, Y.\nTI  - PPARc inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells,\nT2  - Journal of Cellular and Molecular Medicine\nVL  - 23\nSP  - 3724\nEP  - 3736\nPY  - 2019\nDA  - 2019\nC1  - true\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Gilardi, F.\nAU  - Winkler, C.\nAU  - Quignodon, L.\nTI  - Systemic PPARc deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility,\nT2  - Metabolism\nVL  - 95\nSP  - 8\nEP  - 20\nPY  - 2019\nDA  - 2019\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Demir, T.\nAU  - Onay, H.\nAU  - Savage, D.B.\nTI  - Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -c (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations,\nT2  - Diabetic Medicine\nVL  - 33\nSP  - 1445\nEP  - 1450\nPY  - 2016\nDA  - 2016\nC1  - true\nIS  - 10\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Gu, S.-J.\nAU  - Guo, Z.-R.\nAU  - Zhou, Z.-Y.\nAU  - Hu, X.-S.\nAU  - Wu, M.\nAU  - Zhang, N.\nTI  - Peroxisome proliferator-activated receptor c polymorphisms as risk factors for dyslipidemia,\nT2  - Molecular Medicine Reports\nVL  - 10\nSP  - 2759\nEP  - 2763\nPY  - 2014\nDA  - 2014\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yang, T.\nAU  - Michele, D.E.\nAU  - Park, J.\nTI  - Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,\nT2  - American Journal of PhysiologyRenal Physiology\nVL  - 277\nSP  - 966\nEP  - 973\nPY  - 1999\nDA  - 1999\nC1  - true\nIS  - 6\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kiss-Toth, E.\nAU  - Roszer, T.\nTI  - PPARc in kidney physiology and pathophysiology,\nT2  - PPAR Research\nVL  - \"vol.\" # \"183108, 9\"\nPY  - 2008\nDA  - 2008\nSP  - pages,\nC1  - Article ID\nC1  - 183108, 9\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Corrales, P.\nAU  - Izquierdo-Lahuerta, A.\nAU  - G.\nTI  - Medina-Gomez, \u201cMaintenance of kidney metabolic homeostasis by PPAR c,\u201d\nT2  - International Journal of Molecular Sciences\nVL  - 19\nSP  - 2063\nPY  - 2018\nDA  - 2018\nIS  - 7\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Desch, M.\nAU  - Schreiber, A.\nAU  - Schweda, F.\nTI  - Increased renin production in mice with deletion of peroxisome proliferatoractivated receptor-c in juxtaglomerular cells,\nT2  - Hypertension\nVL  - 55\nSP  - 660\nEP  - 666\nPY  - 2010\nDA  - 2010\nC1  - true\nIS  - 3\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhang, H.\nAU  - Zhang, A.\nAU  - Kohan, D.E.\nAU  - Nelson, R.D.\nAU  - Gonzalez, F.J.\nAU  - Yang, T.\nTI  - Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention,\nT2  - Proceedings of the National Academy of Sciences\nVL  - 102\nSP  - 9406\nEP  - 9411\nPY  - 2005\nDA  - 2005\nIS  - 26\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chafin, C.\nAU  - Muse, S.\nAU  - Hontecillas, R.\nTI  - Deletion of PPARc; in immune cells enhances susceptibility to antiglomerular basement membrane disease,\nT2  - Journal of Inflammation Research\nVL  - 3\nSP  - 127\nEP  - 134\nPY  - 2010\nDA  - 2010\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Toffoli, B.\nAU  - Gilardi, F.\nAU  - Winkler, C.\nTI  - Nephropathy in Pparg-null mice highlights PPARc systemic activities in metabolism and in the immune system,\nT2  - PLoS One\nVL  - 12\nT2  - Article ID e0171474\nPY  - 2017\nDA  - 2017\nC1  - true\nIS  - 2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yang, G.\nAU  - Jia, Z.\nAU  - Aoyagi, T.\nAU  - McClain, D.\nAU  - Mortensen, R.M.\nAU  - Yang, T.\nTI  - Systemic PPARc deletion impairs circadian rhythms of behavior and metabolism,\nT2  - PLoS One\nVL  - 7\nT2  - Article ID e38117\nPY  - 2012\nDA  - 2012\nIS  - 8\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhou, L.\nAU  - Panasiuk, A.\nAU  - Downton, M.\nTI  - Systemic PPARc deletion causes severe disturbance in fluid homeostasis in mice,\nT2  - Physiological Genomics\nVL  - 47\nSP  - 541\nEP  - 547\nPY  - 2015\nDA  - 2015\nC1  - true\nIS  - 11\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yang, H.-C.\nAU  - Deleuze, S.\nAU  - Zuo, Y.\nAU  - Potthoff, S.A.\nAU  - Ma, L.-J.\nAU  - Fogo, A.B.\nTI  - e PPARc agonist pioglitazone ameliorates aging-related progressive renal injury,\nT2  - Journal of the American Society of Nephrology\nVL  - 20\nSP  - 2380\nEP  - 2388\nPY  - 2009\nDA  - 2009\nIS  - 11\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ko, G.J.\nAU  - Kang, Y.S.\nAU  - Han, S.Y.\nTI  - Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats,\nT2  - Nephrology Dialysis Transplantation\nVL  - 23\nSP  - 2750\nEP  - 2760\nPY  - 2008\nDA  - 2008\nC1  - true\nIS  - 9\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Isshiki, K.\nAU  - Haneda, M.\nAU  - Koya, D.\nAU  - Maeda, S.\nAU  - Sugimoto, T.\nAU  - Kikkawa, R.\nTI  - iazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats,\nT2  - Diabetes\nVL  - 49\nSP  - 1022\nEP  - 1032\nPY  - 2000\nDA  - 2000\nIS  - 6\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Efrati, S.\nAU  - Berman, S.\nAU  - Chachashvili, A.\nTI  - Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction,\nT2  - Nephrology\nVL  - 14\nSP  - 189\nEP  - 197\nPY  - 2009\nDA  - 2009\nC1  - true\nIS  - 2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kawai, T.\nAU  - Masaki, T.\nAU  - Doi, S.\nTI  - PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta,\nT2  - Laboratory Investigation\nVL  - 89\nSP  - 47\nEP  - 58\nPY  - 2009\nDA  - 2009\nC1  - true\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Okada, T.\nAU  - Wada, J.\nAU  - Hida, K.\nTI  - iazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms,\nT2  - Diabetes\nVL  - 55\nSP  - 1666\nEP  - 1677\nPY  - 2006\nDA  - 2006\nC1  - true\nIS  - 6\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ghosh, S.S.\nAU  - Gehr, T.W.B.\nAU  - Ghosh, S.\nTI  - PPARc ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase,\nT2  - Kidney International\nVL  - 64\nSP  - 52\nEP  - 62\nPY  - 2003\nDA  - 2003\nC1  - true\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Weissgarten, J.\nAU  - Berman, S.\nAU  - Efrati, S.\nAU  - Rapoport, M.\nAU  - Averbukh, Z.\nAU  - Feldman, L.\nTI  - Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats,\nT2  - Nephrology Dialysis Transplantation\nVL  - 21\nSP  - 1198\nEP  - 1204\nPY  - 2006\nDA  - 2006\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kanjanabuch, T.\nAU  - Ma, L.J.\nAU  - Chen, J.\nTI  - PPAR-gamma agonist protects podocytes from injury,\nT2  - Kidney International\nVL  - 71\nSP  - 1232\nEP  - 1239\nPY  - 2007\nDA  - 2007\nC1  - true\nIS  - 12\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Artwohl, M.\nAU  - Holzenbein, T.\nAU  - Furnsinn, C.\nTI  - iazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells,\nT2  - rombosis and Haemostasis\nVL  - 93\nSP  - 810\nEP  - 815\nPY  - 2005\nDA  - 2005\nC1  - true\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Carrero, J.J.\nAU  - Yilmaz, M.I.\nAU  - Lindholm, B.\nAU  - Stenvinkel, P.\nTI  - Cytokine dysregulation in chronic kidney disease: how can we treat it?,\nT2  - Blood Purification\nVL  - 26\nSP  - 291\nEP  - 299\nPY  - 2008\nDA  - 2008\nIS  - 3\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Panzer, U.\nAU  - Zahner, G.\nAU  - Wienberg, U.\nTI  - 15-Deoxy- 12,14prostaglandin J2 inhibits INF- -induced JAK/STAT1 signalling pathway activation and IP-10/CXCL10 expression in mesangial cells,\nT2  - Nephrology Dialysis Transplantation\nVL  - 23\nSP  - 3776\nEP  - 3785\nPY  - 2008\nDA  - 2008\nC1  - true\nIS  - 12\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lu, Y.\nAU  - Zhou, Q.\nAU  - Shi, Y.\nTI  - SUMOylation of PPARc by rosiglitazone prevents LPS-induced NCoR degradation mediating down regulation of chemokines expression in renal proximal tubular cells,\nT2  - PLoS One\nVL  - 8\nT2  - Article ID e79815,\nPY  - 2013\nDA  - 2013\nC1  - true\nIS  - 11\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Xiao, J.\nAU  - Leung, J.C.K.\nAU  - Chan, L.Y.Y.\nAU  - Guo, H.\nAU  - Lai, K.N.\nTI  - Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy,\nT2  - Nephrology Dialysis Transplantation\nVL  - 24\nSP  - 2067\nEP  - 2077\nPY  - 2009\nDA  - 2009\nIS  - 7\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Henique, C.\nAU  - Bollee, G.\nAU  - Lenoir, O.\nTI  - Nuclear factor erythroid 2-related factor 2 drives podocyte-specific expression of peroxisome proliferator-activated receptor c essential for resistance to crescentic GN,\nT2  - Journal of the American Society of Nephrology\nVL  - 27\nSP  - 172\nEP  - 188\nPY  - 2016\nDA  - 2016\nC1  - true\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wu, M.\nAU  - Melichian, D.S.\nAU  - Chang, E.\nAU  - Warner-Blankenship, M.\nAU  - Ghosh, A.K.\nAU  - Varga, J.\nTI  - Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptorc,\nT2  - e American Journal of Pathology\nVL  - 174\nSP  - 519\nEP  - 533\nPY  - 2009\nDA  - 2009\nIS  - 2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zheng, F.\nAU  - Fornoni, A.\nAU  - Elliot, S.J.\nTI  - Upregulation of type I collagen by TGF-\u03b2 in mesangial cells is blocked by PPARc activation,\nT2  - American Journal of Physiology-Renal Physiology\nVL  - 282\nSP  - 639\nEP  - 648\nPY  - 2002\nDA  - 2002\nC1  - true\nIS  - 4\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ma, L.-J.\nAU  - Marcantoni, C.\nAU  - Linton, M.F.\nAU  - Fazio, S.\nAU  - Fogo, A.B.\nTI  - Peroxisome proliferator-activated receptor-c agonist troglitazone protects against nondiabetic glomerulosclerosis in rats,\nT2  - Kidney International\nVL  - 59\nSP  - 1899\nEP  - 1910\nPY  - 2001\nDA  - 2001\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, Y.\nAU  - Wen, X.\nAU  - Spataro, B.C.\nAU  - Hu, K.\nAU  - Dai, C.\nAU  - Liu, Y.\nTI  - Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferatoractivated receptor-gamma agonists,\nT2  - Journal of the American Society of Nephrology\nVL  - 17\nSP  - 54\nEP  - 65\nPY  - 2006\nDA  - 2006\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wang, W.\nAU  - Liu, F.\nAU  - Chen, N.\nTI  - Peroxisome proliferatoractivated receptor-gamma (PPAR-c) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts,\nT2  - Mediators Inflamm\nVL  - \"vol.\" # \"62641, 7\"\nPY  - 2007\nDA  - 2007\nSP  - pages,\nC1  - Article ID\nC1  - 62641, 7\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chen, Z.\nAU  - Yuan, P.\nAU  - Sun, X.\nTI  - Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-c-miR-23 axis,\nT2  - American Journal of Physiology-Renal Physiology\nVL  - 317\nSP  - 137\nEP  - 151\nPY  - 2019\nDA  - 2019\nC1  - true\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wu, L.\nAU  - Wang, Q.\nAU  - Guo, F.\nTI  - MicroRNA-27a induces mesangial cell injury by targeting of PPARc, and its in vivo knockdown prevents progression of diabetic nephropathy,\nT2  - Scientific Reports\nVL  - 6\nSP  - 26072\nPY  - 2016\nDA  - 2016\nC1  - true\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhou, Z.\nAU  - Wan, J.\nAU  - Hou, X.\nAU  - Geng, J.\nAU  - Li, X.\nAU  - Bai, X.\nTI  - MicroRNA-27a promotes podocyte injury via PPARcmediated \u03b2-catenin activation in diabetic nephropathy,\nT2  - Cell Death & Disease\nVL  - 8\nT2  - Article ID e2658\nPY  - 2017\nDA  - 2017\nIS  - 3\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Samaha, F.F.\nAU  - Szapary, P.O.\nAU  - Iqbal, N.\nTI  - Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome,\nT2  - Arteriosclerosis, rombosis, and Vascular Biology\nVL  - 26\nSP  - 624\nEP  - 630\nPY  - 2006\nDA  - 2006\nC1  - true\nIS  - 3\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Eckardt, K.\nAU  - Gorgens, S.W.\nAU  - Raschke, S.\nAU  - Eckel, J.\nTI  - Myokines in insulin resistance and type 2 diabetes,\nT2  - Diabetologia\nVL  - 57\nSP  - 1087\nEP  - 1099\nPY  - 2014\nDA  - 2014\nIS  - 6\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wahli, W.\nAU  - L.\nTI  - Michalik, \u201cPPARs at the crossroads of lipid signaling and inflammation,\u201d\nT2  - Trends in Endocrinology & Metabolism\nVL  - 23\nSP  - 351\nEP  - 363\nPY  - 2012\nDA  - 2012\nIS  - 7\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ahmadian, M.\nAU  - Suh, J.M.\nAU  - Hah, N.\nTI  - PPARc signaling and metabolism: the good, the bad and the future,\nT2  - Nature Medicine\nVL  - 19\nSP  - 557\nEP  - 566\nPY  - 2013\nDA  - 2013\nC1  - true\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Derlacz, R.A.\nAU  - Hyc, K.\nAU  - Usarek, M.\nAU  - Jagielski, A.K.\nAU  - Drozak, J.\nAU  - Jarzyna, R.\nTI  - PPAR-c-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules,\nT2  - Biochemistry and Cell Biology\nVL  - 86\nSP  - 396\nEP  - 404\nPY  - 2008\nDA  - 2008\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Mather, A.\nAU  - Pollock, C.\nTI  - Glucose handling by the kidney,\nT2  - Kidney International\nVL  - 79\nSP  - 1\nEP  - 6\nPY  - 2011\nDA  - 2011\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Santer, R.\nAU  - Kinner, M.\nAU  - Lassen, C.L.\nTI  - Molecular analysis of the SGLT2 gene in patients with renal glucosuria,\nT2  - Journal of the American Society of Nephrology\nVL  - 14\nSP  - 2873\nEP  - 2882\nPY  - 2003\nDA  - 2003\nC1  - true\nIS  - 11\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Bonner, C.\nAU  - Kerr-Conte, J.\nAU  - Gmyr, V.\nTI  - Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion,\nT2  - Nature Medicine\nVL  - 21\nSP  - 512\nEP  - 517\nPY  - 2015\nDA  - 2015\nC1  - true\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kim, M.\nAU  - Lee, E.J.\nAU  - Shin, H.M.\nTI  - e effect of PPARc agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia,\nT2  - Journal of Endocrinological Investigation\nVL  - 40\nSP  - 1069\nEP  - 1076\nPY  - 2017\nDA  - 2017\nC1  - true\nIS  - 10\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lee, Y.J.\nAU  - Han, H.J.\nTI  - Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3\u03b2, Snail1, and \u03b2-catenin in renal proximal tubule cells,\nT2  - American Journal of Physiology-Renal Physiology\nVL  - 298\nSP  - 1263\nEP  - 1275\nPY  - 2010\nDA  - 2010\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Guillam, M.-T.\nAU  - Hummler, E.\nAU  - Schaerer, E.\nTI  - Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2,\nT2  - Nature Genetics\nVL  - 17\nSP  - 327\nEP  - 330\nPY  - 1997\nDA  - 1997\nC1  - true\nIS  - 3\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Murakami, K.\nAU  - Tobe, K.\nAU  - Ide, T.\nTI  - A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats,\nT2  - Diabetes\nVL  - 47\nSP  - 1841\nEP  - 1847\nPY  - 1998\nDA  - 1998\nC1  - true\nIS  - 12\nLA  - \nER  - \n\nTY  - JOUR\nAU  - MochizukiOhashi, B.\nAU  - Parim, B.\nAU  - Chunduri, V.R.\nTI  - Antiobesity potential of piperonal: promising modulation of body composition, lipid profiles and obesogenic marker expression in HFD-induced obese rats,\nT2  - Nutrition & Metabolism\nVL  - 14\nSP  - 72\nPY  - 2017\nDA  - 2017\nC1  - true\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Das, N.\nAU  - Dhanawat, M.\nAU  - Shrivastava, S.K.\nTI  - Benzoxazinones as human peroxisome proliferator activated receptor gamma (PPARc) agonists: a docking study using glide,\nT2  - Indian Journal of Pharmaceutical Sciences\nVL  - 73\nSP  - 159\nEP  - 164\nPY  - 2011\nDA  - 2011\nIS  - 2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Hiraike, Y.\nAU  - Waki, H.\nAU  - Yu, J.\nTI  - NFIA co-localizes with PPARc and transcriptionally controls the brown fat gene program,\nT2  - Nature Cell Biology\nVL  - 19\nSP  - 1081\nEP  - 1092\nPY  - 2017\nDA  - 2017\nC1  - true\nIS  - 9\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kim, J.\nAU  - Lee, Y.-J.\nAU  - M, J.\nTI  - Kim et al., \u201cPPARc agonists induce adipocyte differentiation by modulating the expression of Lipin-1, which acts as a PPARc phosphatase,\u201d\nT2  - e International Journal of Biochemistry & Cell Biology\nVL  - 81\nSP  - 57\nEP  - 66\nPY  - 2016\nDA  - 2016\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Huret, J.-L.\nAU  - Minor, S.L.\nAU  - Dorkeld, F.\nAU  - Dessen, P.\nAU  - Bernheim, A.\nTI  - Atlas of genetics and cytogenetics in oncology and haematology, an interactive database,\nT2  - Nucleic Acids Research\nVL  - 28\nSP  - 349\nEP  - 351\nPY  - 2000\nDA  - 2000\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lyu, Z.\nAU  - Mao, Z.\nAU  - Li, Q.\nTI  - PPARc maintains the metabolic heterogeneity and homeostasis of renal tubules,\nT2  - EBioMedicine\nVL  - 38\nSP  - 178\nEP  - 190\nPY  - 2018\nDA  - 2018\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Szeto, H.H.\nAU  - Liu, S.\nAU  - Soong, Y.\nAU  - Alam, N.\nAU  - Prusky, G.T.\nAU  - Seshan, S.V.\nTI  - Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury,\nT2  - Kidney International\nVL  - 90\nSP  - 997\nEP  - 1011\nPY  - 2016\nDA  - 2016\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Moorhead, J.F.\nAU  - El-Nahas, M.\nAU  - Chan, M.K.\nAU  - Varghese, Z.\nTI  - Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease,\nT2  - e Lancet\nVL  - 320\nSP  - 1309\nEP  - 1311\nPY  - 1982\nDA  - 1982\nIS  - 8311\nLA  - \nER  - \n\nTY  - JOUR\nAU  - A. Izquierdo-Lahuerta, C. Mart\u0131nez-Garc\u0131a\nAU  - G\nTI  - MedinaGomez, \u201cLipotoxicity as a trigger factor of renal disease,\u201d\nT2  - Journal of Nephrology\nVL  - 29\nSP  - 603\nEP  - 610\nPY  - 2016\nDA  - 2016\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Martinez-Garcia, C.\nAU  - Izquierdo, A.\nAU  - Velagapudi, V.\nTI  - Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model,\nT2  - Disease Models & Mechanisms\nVL  - 5\nSP  - 636\nEP  - 648\nPY  - 2012\nDA  - 2012\nC1  - true\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Medina-Gomez, G.\nAU  - Yetukuri, L.\nAU  - Velagapudi, V.\nTI  - Adaptation and failure of pancreatic cells in murine models with different degrees of metabolic syndrome,\nT2  - Disease Models & Mechanisms\nVL  - 2\nSP  - 582\nEP  - 592\nPY  - 2009\nDA  - 2009\nC1  - true\nIS  - 11-12\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Mart\u0131nez-Garc\u0131a, C.\nAU  - Izquierdo-Lahuerta, A.\nAU  - Vivas, Y.\nTI  - Renal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton organization in podocytes,\nT2  - PLoS One\nVL  - 10\nT2  - Article ID e0142291\nPY  - 2015\nDA  - 2015\nC1  - true\nIS  - 11\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Roszer, T.\nAU  - Menendez-Gutierrez, M.P.\nAU  - Lefterova, M.I.\nTI  - Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency,\nT2  - Journal of Immunology\nVL  - 186\nSP  - 621\nEP  - 631\nPY  - 2011\nDA  - 2011\nC1  - true\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - FischerRicote, M.A.\nAU  - Derudas, B.\nAU  - Rigamonti, E.\nTI  - PPARc activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties,\nT2  - Cell Metabolism\nVL  - 6\nSP  - 137\nEP  - 143\nPY  - 2007\nDA  - 2007\nC1  - true\nIS  - 2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Akiyama, T.E.\nAU  - Sakai, S.\nAU  - Lambert, G.\nTI  - Conditional disruption of the peroxisome proliferator-activated receptor gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux,\nT2  - Molecular and Cellular Biology\nVL  - 22\nSP  - 2607\nEP  - 2619\nPY  - 2002\nDA  - 2002\nC1  - true\nIS  - 8\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ricote, M.\nAU  - Li, A.C.\nAU  - Willson, T.M.\nAU  - Kelly, C.J.\nAU  - K, C.\nTI  - Glass, \u201ce peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation,\u201d\nT2  - Nature\nVL  - 391\nSP  - 79\nEP  - 82\nPY  - 1998\nDA  - 1998\nIS  - 6662\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Glass, C.K.\nAU  - Saijo, K.\nTI  - Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells,\nT2  - Nature Reviews Immunology\nVL  - 10\nSP  - 365\nEP  - 376\nPY  - 2010\nDA  - 2010\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Menendez-Gutierrez, M.P.\nAU  - Roszer, T.\nAU  - Ricote, M.\nTI  - Biology and therapeutic applications of peroxisome proliferator-activated receptors,\nT2  - Current Topics in Medicinal Chemistry\nVL  - 12\nSP  - 48\nEP  - 584\nPY  - 2012\nDA  - 2012\nIS  - 6\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lash, J.P.\nAU  - Go, A.S.\nAU  - Appel, L.J.\nTI  - Chronic renal insufficiency cohort (CRIC) study: baseline characteristics and associations with kidney function,\nT2  - Clinical Journal of the American Society of Nephrology\nVL  - 4\nSP  - 1302\nEP  - 1311\nPY  - 2009\nDA  - 2009\nC1  - true\nIS  - 8\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Szkup, M.\nAU  - Owczarek, A.J.\nAU  - Schneider-Matyka, D.\nAU  - Brodowski, J.\nAU  - \u0141oo, B.\nAU  - Grochans, E.\nTI  - Associations between the components of metabolic syndrome and the polymorphisms in the peroxisome proliferator-activated receptor gamma (PPAR-c), the fat mass and obesity-associated (FTO), and the melanocortin-4 receptor (MC4R) genes,\nT2  - Aging\nVL  - 10\nSP  - 72\nEP  - 82\nPY  - 2018\nDA  - 2018\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Iglarz, M.\nAU  - Touyz, R.M.\nAU  - Amiri, F.\nAU  - Lavoie, M.-F.\nAU  - Diep, Q.N.\nAU  - Schiffrin, E.L.\nTI  - Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension,\nT2  - Arteriosclerosis, rombosis, and Vascular Biology\nVL  - 23\nSP  - 45\nEP  - 51\nPY  - 2003\nDA  - 2003\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wu, L.\nAU  - Wang, R.\nAU  - Champlain, J.De\nAU  - Wilson, T.W.\nTI  - Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats,\nT2  - American Journal of Hypertension\nVL  - 17\nSP  - 749\nEP  - 756\nPY  - 2004\nDA  - 2004\nIS  - 9\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhang, M.\nAU  - Zhang, J.\nAU  - Li, L.\nAU  - Wang, Q.\nAU  - Feng, L.\nTI  - Association between peroxisome proliferator-activated receptor c-2 gene Pro12Ala polymorphisms and risk of hypertension: an updated meta-analysis,\nT2  - Bioscience Reports\nVL  - 39\nPY  - 2019\nDA  - 2019\nIS  - 2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Nicol, C.J.\nAU  - Adachi, M.\nAU  - Akiyama, T.E.\nAU  - Gonzalez, F.J.\nTI  - PPARgamma in endothelial cells influences high fat dietinduced hypertension,\nT2  - American Journal of Hypertension\nVL  - 18\nSP  - 549\nEP  - 556\nPY  - 2005\nDA  - 2005\nIS  - 4\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Benkirane, K.\nAU  - Viel, E.C.\nAU  - Amiri, F.\nAU  - Schiffrin, E.L.\nTI  - Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo,\nT2  - Hypertension\nVL  - 47\nSP  - 102\nEP  - 108\nPY  - 2006\nDA  - 2006\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Schiffrin, E.L.\nTI  - Peroxisome proliferator-activated receptors and cardiovascular remodeling,\nT2  - American Journal of Physiology-Heart and Circulatory Physiology\nVL  - 288\nSP  - 1037\nEP  - 1043\nPY  - 2005\nDA  - 2005\nIS  - 3\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Magri, C.J.\nAU  - Gatt, N.\nAU  - Xuereb, R.G.\nAU  - Fava, S.\nTI  - Peroxisome proliferator-activated receptor-c and the endothelium: implications in cardiovascular disease,\nT2  - Expert Review of Cardiovascular erapy\nVL  - 9\nSP  - 1279\nEP  - 1294\nPY  - 2011\nDA  - 2011\nIS  - 10\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Barroso, I.\nAU  - Gurnell, M.\nAU  - Crowley, V.E.\nTI  - Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension,\nT2  - Nature\nVL  - 402\nSP  - 880\nEP  - 883\nPY  - 1999\nDA  - 1999\nC1  - true\nIS  - 6764\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wang, N.\nAU  - Yang, G.\nAU  - Jia, Z.\nTI  - Vascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1,\nT2  - Cell Metabolism\nVL  - 8\nSP  - 482\nEP  - 491\nPY  - 2008\nDA  - 2008\nC1  - true\nIS  - 6\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Guan, Y.\nAU  - Hao, C.\nAU  - Cha, D.R.\nTI  - iazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption,\nT2  - Nature Medicine\nVL  - 11\nSP  - 861\nEP  - 866\nPY  - 2005\nDA  - 2005\nC1  - true\nIS  - 8\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kliewer, S.A.\nAU  - Xu, H.E.\nAU  - Lambert, M.H.\nAU  - Willson, T.M.\nTI  - Peroxisome proliferator-activated receptors: from genes to physiology,\nT2  - Recent Progress in Hormone Research\nVL  - 56\nSP  - 239\nEP  - 263\nPY  - 2001\nDA  - 2001\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yang, J.\nAU  - Zhang, D.\nAU  - Li, J.\nAU  - Zhang, X.\nAU  - Fan, F.\nAU  - Guan, Y.\nTI  - Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential,\nT2  - Clinical Science\nVL  - 116\nSP  - 17\nEP  - 26\nPY  - 2009\nDA  - 2009\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Sarafidis, P.A.\nAU  - Stafylas, P.C.\nAU  - Georgianos, P.I.\nAU  - Saratzis, A.N.\nAU  - Lasaridis, A.N.\nTI  - Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis,\nT2  - American Journal of Kidney Diseases\nVL  - 55\nSP  - 835\nEP  - 847\nPY  - 2010\nDA  - 2010\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zuo, Y.\nAU  - Yang, H.C.\nAU  - Potthoff, S.A.\nTI  - Protective effects of PPARgamma agonist in acute nephrotic syndrome,\nT2  - Nephrology Dialysis Transplantation\nVL  - 27\nSP  - 174\nEP  - 181\nPY  - 2012\nDA  - 2012\nC1  - true\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yoshihara, D.\nAU  - Kurahashi, H.\nAU  - Morita, M.\nTI  - PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease,\nT2  - American Journal of Physiology-Renal Physiology\nVL  - 300\nSP  - 465\nEP  - 474\nPY  - 2011\nDA  - 2011\nC1  - true\nIS  - 2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Elshazly, S.\nAU  - Soliman, E.\nTI  - PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/ reperfusion injury,\nT2  - Toxicology and Applied Pharmacology\nVL  - 362\nSP  - 86\nEP  - 94\nPY  - 2019\nDA  - 2019\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Sugawara, A.\nAU  - Uruno, A.\nAU  - Kudo, M.\nAU  - Matsuda, K.\nAU  - Yang, C.W.\nAU  - Ito, S.\nTI  - Effects of PPARgamma on hypertension, atherosclerosis, and chronic kidney disease,\nT2  - Endocrine Journal\nVL  - 57\nSP  - 847\nEP  - 852\nPY  - 2010\nDA  - 2010\nIS  - 10\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Iglesias, P.\nAU  - D\u0131ez, J.J.\nTI  - Peroxisome proliferator-activated receptor gamma agonists in renal disease,\nT2  - European Journal of Endocrinology\nVL  - 154\nSP  - 613\nEP  - 621\nPY  - 2006\nDA  - 2006\nIS  - 5\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Liu, L.\nAU  - Liu, Y.\nAU  - Zhang, Y.\nTI  - High phosphate-induced downregulation of PPARc contributes to CKD-associated vascular calcification,\nT2  - Journal of Molecular and Cellular Cardiology\nVL  - 114\nSP  - 264\nEP  - 275\nPY  - 2018\nDA  - 2018\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhang, Y.-F.\nAU  - Wang, Q.\nAU  - Su, Y.-Y.\nTI  - PPAR-c agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution-induced damage,\nT2  - Molecular Medicine Reports\nVL  - 15\nSP  - 1786\nEP  - 1792\nPY  - 2017\nDA  - 2017\nC1  - true\nIS  - 4\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Barnett, A.\nTI  - Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial,\nT2  - Journal of the American Society of Nephrology\nVL  - 17\nSP  - 132\nEP  - 135\nPY  - 2006\nDA  - 2006\nIS  - 4\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Arozal, W.\nAU  - Watanabe, K.\nAU  - Veeraveedu, P.T.\nTI  - Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-c agonist actions,\nT2  - Toxicology\nVL  - 279\nSP  - 91\nEP  - 99\nPY  - 2011\nDA  - 2011\nC1  - true\nIS  - 1\u20133\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Schupp, M.\nAU  - Clemenz, M.\nAU  - Gineste, R.\nTI  - Molecular characterization of new selective peroxisome proliferatoractivated receptor c modulators with angiotensin receptor blocking activity,\nT2  - Diabetes\nVL  - 54\nSP  - 3442\nEP  - 3452\nPY  - 2005\nDA  - 2005\nC1  - true\nIS  - 12\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Schneider, C.A.\nAU  - Ferrannini, E.\nAU  - Defronzo, R.\nAU  - Schernthaner, G.\nAU  - Yates, J.\nAU  - Erdmann, E.\nTI  - Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease,\nT2  - Journal of the American Society of Nephrology\nVL  - 19\nSP  - 182\nEP  - 187\nPY  - 2008\nDA  - 2008\nIS  - 1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chan, D.T.\nAU  - Watts, G.F.\nAU  - Irish, A.B.\nAU  - Dogra, G.K.\nTI  - Rosiglitazone does not improve vascular function in subjects with chronic kidney disease,\nT2  - Nephrology Dialysis Transplantation\nVL  - 26\nSP  - 3543\nEP  - 3549\nPY  - 2011\nDA  - 2011\nIS  - 11\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zanchi, A.\nAU  - Tappy, L.\nAU  - al, K.-A.Leet\nTI  - Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study,\nT2  - PLoS One\nVL  - 9\nT2  - Article ID e109134\nPY  - 2014\nDA  - 2014\nIS  - 10\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Han, S.J.\nAU  - Hur, K.Y.\nAU  - Kim, Y.S.\nTI  - Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients,\nT2  - Nephrology Dialysis Transplantation\nVL  - 25\nSP  - 976\nEP  - 984\nPY  - 2010\nDA  - 2010\nC1  - true\nIS  - 3\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kuba, K.\nAU  - Imai, Y.\nAU  - Rao, S.\nTI  - A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury,\nT2  - Nature Medicine\nVL  - 11\nSP  - 875\nEP  - 879\nPY  - 2005\nDA  - 2005\nC1  - true\nIS  - 8\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Raptis, A.E.\nAU  - Bacharaki, D.\nAU  - Mazioti, M.\nTI  - Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARc agonists in uncomplicated diabetic patients,\nT2  - Experimental and Clinical Endocrinology & Diabetes\nVL  - 120\nSP  - 416\nEP  - 419\nPY  - 2012\nDA  - 2012\nC1  - true\nIS  - 7\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kung, J.\nAU  - Henry, R.R.\nTI  - iazolidinedione safety,\nT2  - Expert Opinion on Drug Safety\nVL  - 11\nSP  - 565\nEP  - 579\nPY  - 2012\nDA  - 2012\nIS  - 4\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Neumann, A.\nAU  - Weill, A.\nAU  - Ricordeau, P.\nAU  - Fagot, J.P.\nAU  - Alla, F.\nAU  - Allemand, H.\nTI  - Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study,\nT2  - Diabetologia\nVL  - 55\nSP  - 1953\nEP  - 1962\nPY  - 2012\nDA  - 2012\nIS  - 7\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Colmers, I.N.\nAU  - Bowker, S.L.\nAU  - Majumdar, S.R.\nAU  - Johnson, J.A.\nTI  - Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a metaanalysis,\nT2  - Canadian Medical Association Journal\nVL  - 184\nSP  - 675\nEP  - 683\nPY  - 2012\nDA  - 2012\nIS  - 12\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Nissen, S.E.\nAU  - Wolski, K.\nTI  - Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,\nT2  - New England Journal of Medicine\nVL  - 356\nSP  - 2457\nEP  - 2471\nPY  - 2007\nDA  - 2007\nIS  - 24\nLA  - \nER  - \n\n",
        "links": [],
        "author_conclusions": [],
        "table_captions": [
            {
                "id": "1",
                "caption": "Cell type of PPAR gamma deletion and the phenotype"
            }
        ],
        "figure_captions": [
            {
                "id": "1",
                "caption": "PPARc function in kidney"
            },
            {
                "id": "2",
                "caption": "Indirect renal-protective effects"
            }
        ],
        "tables_url": "https://scholarcy.nyc3.digitaloceanspaces.com/tables/docker-test/871f36ccee21d6f5e54d7c41682d8257.xlsx",
        "figure_urls": [
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/871f36ccee21d6f5e54d7c41682d8257/img-000.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/871f36ccee21d6f5e54d7c41682d8257/img-001.png"
        ]
    },
    "sections": {
        "introduction": [
            "Chronic kidney disease (CKD) has become one of the most common diseases in the world. Chronic renal failure is the end stage of the progression of various types of CKD. In Europe and the United States, the number of patients with end-stage renal disease (ESRD) is rapidly increasing at a rate of 5%\u20138% per year [<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>]. ESRD is pathologically characterized by renal fibrosis, including glomerular sclerosis and renal interstitial fibrosis. Renal fibrosis is almost the result of all progressive kidney diseases and is a complex common chronic process involving multiple mechanisms such as extracellular matrix (ECM) and cytokine secretion, energy metabolism, podocyte injury, cell proliferation and differentiation, endoplasmic reticulum stress, autophagy, infiltration of inflammatory cells, and activation of fibroblasts [<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>].<br/><br/>2. PPAR\u03b3 Structure and Function"
        ],
        "conclusion": [
            "Overall, PPARc is one of the ligand-activated transcription factor superfamily members and is abundantly expressed many types of kidney cells. It is involved in renal disease by participating in cell proliferation and apoptosis, TGF-\u03b2 pathway, inflammation and oxidative stress, lipid metabolism, hypertension, and so on. Activation of PPARc improves kidney injury. e application as clinical treatment was restricted by the side effect. And, the cell-specific function of PPARc agonist was still unclear. So, understanding the mechanism of PPARc function, exploring the cell specific reaction to the activation of PPARc agonist, and developing a new type of PPARc agonist with less side-effect may help application of the PPARc agonist into clinical treatment and ameliorate the renal injury."
        ],
        "disclosures": [
            "Conflicts of Interest e authors declare that they have no conflicts of interest."
        ]
    },
    "structured_content": {
        "1. Introduction": [
            "Chronic kidney disease (CKD) has become one of the most common diseases in the world. Chronic renal failure is the end stage of the progression of various types of CKD. In Europe and the United States, the number of patients with end-stage renal disease (ESRD) is rapidly increasing at a rate of 5%\u20138% per year [<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>]. ESRD is pathologically characterized by renal fibrosis, including glomerular sclerosis and renal interstitial fibrosis. Renal fibrosis is almost the result of all progressive kidney diseases and is a complex common chronic process involving multiple mechanisms such as extracellular matrix (ECM) and cytokine secretion, energy metabolism, podocyte injury, cell proliferation and differentiation, endoplasmic reticulum stress, autophagy, infiltration of inflammatory cells, and activation of fibroblasts [<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>]."
        ],
        "2. PPAR\u03b3 Structure and Function": [
            "Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors (TFs) of nuclear hormone receptor superfamily [<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>]. ree PPAR subtypes (PPAR\u03b1, PPAR \u03b2/\u03b4, and PPARc) have been found in different species. In humans, the PPARc gene is located on chromosome 3 (3p25.2) and contains 9 exons expanding more than 100 kb, which generates 4 PPARc variants (c1, c2, c3, and c4) [<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>]. ese isoforms are expressed differently in different tissues. PPAR family proteins share structural similarities, all containing a C-terminus ligand-binding domain which responds to ligand stimulation and controls heterodimerization with retinoid X receptors (RXR) upon activation [<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>]. Ligand stimulation leads to posttranslational modifications in PPARc through MAPK and PI3K pathways [<a class=\"ref-link\" id=\"c6\" href=\"#r6\">6</a>], and this is followed by conformational changes to a proactive form. e N-terminus DNA-binding domain recognizes and binds to specific responsive elements to modulate gene transcription [<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>]. Additional regulatory mechanisms involve coregulator complexes which recruit and release dynamically to control PPAR activation in the chromatin level [<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>]. For PPARc, it interacts with multiple published coregulators in energy metabolism, and these include coactivators of steroid receptor coactivator 2 (SRC-",
            "2), PPARc coactivator 1 (PGC-1) and receptor interacting protein 140 (RIP140), and PR domain containing 16 (PRDM16), as well as corepressors such as nuclear receptor corepressor 1 (NCOR1) and NCOR2 [<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>]. In addition, PPARc represses inflammatory TF activations, a process referred to as transrepression [<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>]. For example, the PPARc agonist inhibits NF-kB, activator protein-1- (AP-1-) mediated inflammatory responses in multiple tissues [<a class=\"ref-link\" id=\"c10\" href=\"#r10\">10</a>]. More TFs have been reported to be coregulated by PPARc, and these include the CCAAT/enhancer binding protein (C/ EBP) family [<a class=\"ref-link\" id=\"c11\" href=\"#r11\">11</a>], SREBP [<a class=\"ref-link\" id=\"c12\" href=\"#r12\">12</a>], REV-ERBa [<a class=\"ref-link\" id=\"c13\" href=\"#r13\">13</a>], and GATA3 [<a class=\"ref-link\" id=\"c14\" href=\"#r14\">14</a>]. Due to its wide-spectrum of regulatory effects, mutations in PPARc have been identified in the humans and led to dysfunctional lipid and glucose metabolism, insulin resistance, which developed into obesity-induced T2DM, dyslipidemia, NAFLD, and cancer [<a class=\"ref-link\" id=\"c15\" href=\"#r15\">15</a>\u2013<a class=\"ref-link\" id=\"c18\" href=\"#r18\">18</a>]."
        ],
        "3. PPAR\u03b3 and Kidney Fibrosis": [
            "PPARc is abundantly expressed in the medullary collecting duct and paraurethral and bladder epithelial cells [<a class=\"ref-link\" id=\"c19\" href=\"#r19\">19</a>], and it is also expressed in podocytes, mesangial cells, and vascular endothelial cells [<a class=\"ref-link\" id=\"c20\" href=\"#r20\">20</a>]. Although not fully delineated, accumulating studies have suggested that PPARc plays an important role in regulating physiological functions of the kidney [<a class=\"ref-link\" id=\"c21\" href=\"#r21\">21</a>]. Current studies using PPARc null mice or agonists have been concluded in Table 1.",
            "e antifibrotic role of PPARc has been well accepted (Figure 1). Treatment of mice with synthetic PPARc ligands was shown to attenuate experimentally induced hepatic, cardiac, and kidney fibrosis [<a class=\"ref-link\" id=\"c28\" href=\"#r28\">28</a>]. e antifibrotic and renoprotective effects of the PPARc agonists pioglitazone and troglitazone were also confirmed in type 2 diabetes (T2D) rat models [<a class=\"ref-link\" id=\"c29\" href=\"#r29\">29</a>, <a class=\"ref-link\" id=\"c30\" href=\"#r30\">30</a>] and unilateral ureteral obstruction (UUO) mice [<a class=\"ref-link\" id=\"c31\" href=\"#r31\">31</a>, <a class=\"ref-link\" id=\"c32\" href=\"#r32\">32</a>] models, respectively.",
            "Multiple mechanisms are potentially involved in the renoprotective effects of PPARc activation.",
            "First, PPARc inhibits cell proliferation and apoptosis. It was reported that PPARc agonist pioglitazone inhibits mesangial cell proliferation and reduces proteinuria by downregulating p27, Bcl-2 (B-cell lymphoma 2) expression, and mitogen-activated protein kinase (MAPK) phosphorylation [<a class=\"ref-link\" id=\"c33\" href=\"#r33\">33</a>]. is was confirmed by a separate study using another PPARc agonist ciglitazone. e in vitro treatment of ciglitazone inhibited the proliferation of mouse mesangial cells induced by the platelet-derived growth factor (PDGF) by directly affecting the MAPK pathways linked with the downregulation of p21 and cyclin D1 and exerting the antiglomerular sclerosis effect [<a class=\"ref-link\" id=\"c34\" href=\"#r34\">34</a>]. Pretreatment with rosiglitazone significantly inhibited mesangial cell hypertrophy and proliferation in diabetic rats [<a class=\"ref-link\" id=\"c35\" href=\"#r35\">35</a>]. e effect of thiazolidinediones (TZDs) on puromycin aminonucleoside nephrosis (PAN) increased WT-1 expression, inhibited its necrosis and apoptosis, which may be related to up-regulation of Bcl-xl expression and inhibition of Caspase-3 activity, and decreased TGF-beta [<a class=\"ref-link\" id=\"c36\" href=\"#r36\">36</a>]. PPARc agonists can not only inhibit the apoptosis of endothelial cells induced by tumor necrosis factor (TNF) but also inhibit the spontaneous apoptosis of endothelial cells and reduce the damage of glomerular capillary endothelium [<a class=\"ref-link\" id=\"c37\" href=\"#r37\">37</a>].",
            "Second, PPARc inhibits inflammation in the kidney diseases.",
            "Inflammation is one of the major causes of the kidney injury and decline of kidney function. Inflammatory markers, such as C-reactive protein and inflammatory cytokines, correlate with the end stage of kidney disease [<a class=\"ref-link\" id=\"c38\" href=\"#r38\">38</a>]. Activation of PPARc alleviates inflammation in different types of kidney cells. A synthesized PPARc ligand 15d-PGJ2 was reported to inhibit the chemokines induced by interferon-7 (INF-7) by inhibiting the JAK/STAT1 signaling pathway in mesangial cells [<a class=\"ref-link\" id=\"c39\" href=\"#r39\">39</a>]. Rosiglitazone activates PPARc SUMOylation, inhibiting NCoR degradation and NF-\u03baB activation in LPS-stimulated renal proximal tubular cells, which in turn decreases IL-8 and MCP1 expression [<a class=\"ref-link\" id=\"c40\" href=\"#r40\">40</a>]. PPARc agonist (rosiglitazone, troglitazone, and thiazolidinedione) attenuates excessive inflammatory response in activated proximal tubular epithelial cells in IgAN through suppressing ATR1 expression [<a class=\"ref-link\" id=\"c41\" href=\"#r41\">41</a>]. Loss of PPARc abundance and transcriptional activity was observed in glomerular podocytes in experimental RPGN. Blunted expression of PPARc in podocyte nuclei was also found in kidneys from patients diagnosed with crescentic GN [<a class=\"ref-link\" id=\"c42\" href=\"#r42\">42</a>].",
            "ird, PPARc represses transforming growth factor-\u03b2 (TGF-\u03b2) pathways. TGF-\u03b2 signaling pathways play an important role in kidney fibrosis. Studies have shown that rosiglitazone effectively blocked fibrotic responses elicited by TGF-\u03b2 in explanted fibroblasts and attenuated bleomycininduced skin fibrosis in vivo [<a class=\"ref-link\" id=\"c43\" href=\"#r43\">43</a>]. Subsequent studies in a variety of cell types and model systems have confirmed and expanded these findings [<a class=\"ref-link\" id=\"c44\" href=\"#r44\">44</a>]. PPARc activation inhibits plasminogen activating-inhibiting factor-1 (PAI-1) and TGF-\u03b2 in human mesangial cells [<a class=\"ref-link\" id=\"c45\" href=\"#r45\">45</a>]. e expression of the extracellular matrix is reduced, and the mechanism may be partly through the positive regulation of PPARc on hepatocyte growth factor (HGF), causing increased endogenous HGF, thereby inhibiting TGF- \u03b2/SMAD pathways [<a class=\"ref-link\" id=\"c46\" href=\"#r46\">46</a>]. PPARc agonists (15d-PGJ2, troglitazone, and ciglitazone) can inhibit TGF-\u03b2/SMAD signaling pathways to alleviate renal fibroblast activation, resulting in decreased expression of connective tissue growth factor (CTGF) and extracellular matrix synthesis [<a class=\"ref-link\" id=\"c47\" href=\"#r47\">47</a>], all contributing to reduced renal fibrosis progression.",
            "Besides, PPARc can be influenced by epigenetic modification in kidney diseases. MicroRNA-27a induces mesangial cell and podocyte injury by PPARc in diabetic nephropathy (DN). And, micro-RNA23 can be mediated by PPARc in renal calcium oxalate crystal formation. lncRNA TUG1 could modulate ECM accumulation in DN by regulating miR-377 targeting PPARc [<a class=\"ref-link\" id=\"c48\" href=\"#r48\">48</a>\u2013<a class=\"ref-link\" id=\"c50\" href=\"#r50\">50</a>]. However, the role of the epigenetic modification in PPARc function in kidney diseases still needs further exploration."
        ],
        "4. PPAR\u03b3 in Renal Glucose Control": [
            "PPAR\u03b3 is important for regulating systemic glucose homeostasis. PPARc activation improves peripheral insulin sensitivity partly by increasing beneficial adipokines [<a class=\"ref-link\" id=\"c51\" href=\"#r51\">51</a>] (i.e., adiponectin, resistin, and leptin) and myokines [<a class=\"ref-link\" id=\"c52\" href=\"#r52\">52</a>] and reducing inflammatory cytokines (such as TNF-\u03b1) in",
            "[<a class=\"ref-link\" id=\"c22\" href=\"#r22\">22</a>].",
            "Zhang et al [<a class=\"ref-link\" id=\"c23\" href=\"#r23\">23</a>].",
            "Chafin et al [<a class=\"ref-link\" id=\"c24\" href=\"#r24\">24</a>].",
            "Toffoli et al [<a class=\"ref-link\" id=\"c25\" href=\"#r25\">25</a>].",
            "Yang et al [<a class=\"ref-link\" id=\"c26\" href=\"#r26\">26</a>].",
            "Zhou et al [<a class=\"ref-link\" id=\"c27\" href=\"#r27\">27</a>].",
            "Reduced PPARgamma expression, stronger renin signal and higher renin mRNA levels and plasma renin concentration in RC-PPARgamma (fl/fl) mice than in littermate control RC-",
            "Mice with CD knockout of PPARG were resistant to the rosiglitazone- (RGZ-) induced increases in body weight and had diminished plasma volume expansion, PPARgamma expression and reduced urinary sodium excretion in response to RGZ",
            "PPARc (\u2013/\u2013) mice had a more severe glomerular and tubulointerstitial disease, decreased CD4(+) CD25(+) regulatory T cells, increased CD8(+) : CD4(+) ratio and plasma interleukin-6 levels compared with the PPARc(+/+)",
            "Renal hypertrophy, glucosuria, albuminuria, renal insufficiency with decreased creatinine clearance progress, renal fibrosis, mesangial expansion, and antiphospholipid syndrome",
            "Suppressed circadian variations in oxygen consumption, CO2 production, food and water intake, locomotor activity, and cardiovascular parameters e null mice developed severe polydipsia and polyuria, reduced urine osmolality, modest hyperphagia, and progressive weight loss; after 24 h of water deprivation, the null mice had a lower urine osmolality, a higher urine volume, a greater weight loss, and a greater rise in hematocrit; the response of urine osmolality to acute and chronic 1desamino-8-D-arginine vasopressin treatment was attenuated",
            "Inflammation cell: (i) lacking macrophage expression of PPAR\u03b3 develop glomerulonephritis (ii) M1 macrophage polarization",
            "Endothelial cell: (i) Apoptosis, cell cycle (ii) Heat shock protein 60, cyclooxygenase-2, klotho (iii) Nitric oxide generation (iv) Vascular remodeling",
            "Podocyte: (i) More severe glomerulonephritis in podocyte-specific PPAR\u03b3 ko mice exposed to a nephrotoxic material (ii) More severe inflammation (iii) Apoptosis (iv) Cytoskeleton (trpc6, nephrin, etc.)",
            "Mesangial cell: (i) Inflammation (Jak/STAT1 signalling pathway) (ii) Ros (iii) Apoptosis and proliferation (MAPK pathway)",
            "Tubular epithelial cell: (i) Epithelial-to-mesenchymal transition (ii) SGLTs function (iii) Transdifferentiation (iv) Hypoxia-inducible factor 1 activation (v) Metabolic homeostasis",
            "adipose tissue and muscles [<a class=\"ref-link\" id=\"c53\" href=\"#r53\">53</a>]. It also induces the expression of key genes involved in glucose-stimulated insulin secretion in pancreatic beta cells [<a class=\"ref-link\" id=\"c54\" href=\"#r54\">54</a>]. Besides, glucose filtration, reabsorption, and gluconeogenesis in the kidney regulated by PPARc are essential for glucose metabolism. A recent study showed that PPARc agonist rosiglitazone induced the hypoglycemic effects through inhibition of gluconeogenesis on proximal tubule cells [<a class=\"ref-link\" id=\"c55\" href=\"#r55\">55</a>]. e transport of glucose in kidney depends on sodium-dependent glucose cotransporters (SGLTs), localized in the epithelial cells of the proximal renal tubules, and glucose transporters (GLUTs), localized in the basolateral membrane [<a class=\"ref-link\" id=\"c56\" href=\"#r56\">56</a>]. SGLT2 is a wellcharacterized cotransporter in SGLTs family and primarily found in renal tissues. About 90% of glucose filtered from glomeruli is absorbed by SGLT2, and mutations of this gene are associated with elevated urine glucose, suggesting that SGLT2 is the key factor for glucose reabsorption in the kidney [<a class=\"ref-link\" id=\"c57\" href=\"#r57\">57</a>]. SGLT2 can inhibit increased secretion of glucagon from pancreatic \u03b1 cells induced in hyperglycemia, which in turn is inhibited by high glucose environment [<a class=\"ref-link\" id=\"c58\" href=\"#r58\">58</a>]. Troglitazone, as a PPARc agonist, can increase the expression of SGTL2 in the renal proximal tubules and reverse the downregulation of SGLT2 expression and upregulation of glucagon secretion induced by high glucose [<a class=\"ref-link\" id=\"c59\" href=\"#r59\">59</a>, <a class=\"ref-link\" id=\"c60\" href=\"#r60\">60</a>]. Accordingly, PPARc antagonist (GW9662) decreased the expression of SGLT2 and increased glucagon, similar with high glucose [<a class=\"ref-link\" id=\"c59\" href=\"#r59\">59</a>]. ose effects were potentially mediated through PI3K/Akt signaling pathways, as hyperglycemia increased both PI3K and Akt phosphorylations (P-AKT) in alpha cells which contributed to the SGLT2 expression [<a class=\"ref-link\" id=\"c59\" href=\"#r59\">59</a>]. Troglitazone treatment decreased PI3K and P-AKT in high glucose-treated alpha cells. In addition, PI3K inhibitor reversed high glucose-induced SGLT2 decrease and glucagon increase in alpha TC cells [<a class=\"ref-link\" id=\"c59\" href=\"#r59\">59</a>].",
            "When glucose has been transported to the renal tubular epithelial cells and the concentration is higher than that in the renal interstitial, it diffuses to the renal interstitial through the GLUTs on the basolateral membrane. Studies have suggested that mice with GLUT2 deletion present with glycosuria and human with GLUT2 mutations present with Fanconi syndrome, glycosuria, and proximal tubule dysfunction [<a class=\"ref-link\" id=\"c61\" href=\"#r61\">61</a>]."
        ],
        "5. PPAR\u03b3 in Renal Lipid Metabolism": [
            "An important biological function of PPARc is its involvement in lipid metabolism. PPARc can be activated by fatty acids and exogenous peroxisome proliferators to regulate the expression of enzymes conducting lipid metabolism [<a class=\"ref-link\" id=\"c62\" href=\"#r62\">62</a>]. Increased expression of PPARc was found in multiple tissues in diet-induced obesity models (DIO) [<a class=\"ref-link\" id=\"c63\" href=\"#r63\">63</a>]. PPARc can be induced before transcription activation of adipocyte genes and plays an important role in adipocyte differentiation [<a class=\"ref-link\" id=\"c64\" href=\"#r64\">64</a>]. PPARc localizes at the brown-fat-specific enhancers, and the binding of nuclear factor I-A (NFIA) to the brown fat enhancers precedes and facilitates the binding of PPARc, leading to increased chromatin accessibility and active transcription [<a class=\"ref-link\" id=\"c65\" href=\"#r65\">65</a>]. PPARc can also regulate the mutual transformation between adipocytes and osteoblasts, thereby affecting lipid metabolism, which can promote the differentiation of bone marrow mesenchymal stem cells into adipocytes and inhibit the differentiation into osteoblasts [<a class=\"ref-link\" id=\"c66\" href=\"#r66\">66</a>]. Several studies which reported mutations in the PPARc protein were related to some diseased states; for example, PPARc P115Q results in severe obesity, and P467L and V290M mutations are partially involved in familial lipodystrophy type 3 [<a class=\"ref-link\" id=\"c67\" href=\"#r67\">67</a>].",
            "e kidney is one of the target organs of PPARc-regulated lipid metabolism. All PPARs have been detected in rodent and human kidney, including glomeruli, medullary collecting duct, and pelvic urothelium. Renal proximal tubule expresses lipid metabolism-related enzymes that can upregulate transcriptional activity by sufficient expression of PPARc [<a class=\"ref-link\" id=\"c68\" href=\"#r68\">68</a>]. Kidney can process free fatty acids (FFAs), including reabsorption by proximal tubule and metabolism within mitochondria of proximal tubule [<a class=\"ref-link\" id=\"c69\" href=\"#r69\">69</a>]. FFAs are usually metabolized with the method of \u03b2-oxidation and then constitute the largest energy pool in the human body. Moorhead et al were the first to report the relationship between lipid metabolism and kidney disease [<a class=\"ref-link\" id=\"c70\" href=\"#r70\">70</a>]. Mutations in lipid metabolism enzymes resulted in lipotoxicity and renal function deterioration [<a class=\"ref-link\" id=\"c71\" href=\"#r71\">71</a>]. Studies about animal models showed that PPARc-deficient mice presented lipid metabolic disorders. One earlier study using PPARc2 and leptin double knockout mice (POKO) showed that those mice presented spontaneous metabolic syndrome, hypertension, albuminuria, and renal dysfunction [<a class=\"ref-link\" id=\"c72\" href=\"#r72\">72</a>, <a class=\"ref-link\" id=\"c73\" href=\"#r73\">73</a>]. Another study showed that lipotoxicity accelerates lipid accumulation and inflammation and then leads to glomerular diseases, which suggested that renal lipid metabolism may serve as a target for specific therapies aimed at slowing the progression of podocyte failure during metabolic syndrome [<a class=\"ref-link\" id=\"c74\" href=\"#r74\">74</a>]."
        ],
        "6. PPAR\u03b3 Activation in Kidney Immune Cells": [
            "Renal resident macrophages play important roles in kidney homeostasis and pathology. Macrophages are involved in the acute kidney disease and chronic kidney disease by adopting different type of phenotypes including M1 macrophage, subtypes of M2 macrophage, and MDSCs. While M1 cell promotes kidney injury, M2 cells contribute to the repairing response to the kidney injury (Figure 2). In kidney, the deletion of PPARc in hematopoietic cells enhances inflammatory renal disease in the anti-GBM antibody-induced glomerulonephritis mouse model [<a class=\"ref-link\" id=\"c24\" href=\"#r24\">24</a>]. Mice lacking macrophage expression of PPARc develop glomerulonephritis similar to autoimmune glomerulonephritis [<a class=\"ref-link\" id=\"c75\" href=\"#r75\">75</a>]. In addition, PPARc agonist pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization [<a class=\"ref-link\" id=\"c48\" href=\"#r48\">48</a>], and it also promotes the differentiation of monocytes into M2-type macrophages [<a class=\"ref-link\" id=\"c76\" href=\"#r76\">76</a>]. Deletion of PPARc in the macrophages leads to impaired phagocytosis and macrophage polarization and altered lipid handling [<a class=\"ref-link\" id=\"c77\" href=\"#r77\">77</a>]. PPARc agonists downregulate the expression of inflammatory factors in monocytes and macrophages by inhibiting NF-kappaB (NF-\u03baB), signal transducer and activator of transcription (STATs), and AP-1",
            "Immune cells: macrophage function: phagocytosis, altered lipid handling? polarization T-cell: di erentiation, T-cell survival and activation?",
            "pathways. PPARc agonists (15d-PGJ2) block the proinflammatory effects of IFN-c by inhibiting the JAK/STAT (Janus kinase/signal transducer and activator of tranions) pathways [<a class=\"ref-link\" id=\"c78\" href=\"#r78\">78</a>]. In the rat model of type 2 diabetes, pioglitazone significantly reduces macrophage infiltration in renal tissue along with inflammatory and fibrotic factors such as NF-\u03baB, chemokine (C-C motif ) ligand 2 (CCL2) TGF-B, PAI, and vascular endothelial growth factor (VEGF) [<a class=\"ref-link\" id=\"c29\" href=\"#r29\">29</a>].",
            "In addition, PPARc activation also modulates the function of other types of kidney-resident immune cells such as T cells [<a class=\"ref-link\" id=\"c79\" href=\"#r79\">79</a>]. Deletion of PPARc in 17 cell caused loss of",
            "17 cell differentiation and predisposes to autoimmune diseases [<a class=\"ref-link\" id=\"c80\" href=\"#r80\">80</a>]."
        ],
        "7. Hypertension and PPAR\u03b3": [
            "Hypertension is both important cause and consequence of kidney diseases. Kidney function is always associated with increasing blood pressure (BP). In CRIC study, the prevalence of hypertension was 86%, much higher than the general population [<a class=\"ref-link\" id=\"c81\" href=\"#r81\">81</a>]. Hypertension was one of the independent risk factors for the progression of CKD.",
            "Besides the wide distribution in adipocytes, adrenal gland, spleen, muscle, etc., PPARc is also widely expressed in vascular endothelial cells and smooth muscle cells and regulates smooth muscle proliferation, migration and apoptosis, inflammation, atherosclerosis, and other pathologic processes [<a class=\"ref-link\" id=\"c82\" href=\"#r82\">82</a>]. Studies both in vivo and in vitro supported that PPARc plays a vital protective role in cardiovascular disorders. In the study of DOCA-salt-hypertensive rats, rosiglitazone was effective in preventing the increased blood pressure and partially improved endothelial dysfunction [<a class=\"ref-link\" id=\"c83\" href=\"#r83\">83</a>]. Recent studies observed increased expression of PPARc in blood vessels of spontaneously hypertensive rats, which is beneficial to the vascular function and lowers the blood pressure [<a class=\"ref-link\" id=\"c84\" href=\"#r84\">84</a>]. PPARc can also inhibit the growth of vascular cells, induce apoptosis of vascular smooth muscle cells (VSMC), and improve the vascular structure [<a class=\"ref-link\" id=\"c85\" href=\"#r85\">85</a>]. Nicol et al has shown the ability of lowering blood pressure (BP) by endothelial-specific PPARc activation in the context of a high-fat diet mouse model [<a class=\"ref-link\" id=\"c86\" href=\"#r86\">86</a>]. Benkirane et al figured out that PPARc might be responsible for the amelioration of vascular remodeling in hypertension, the mechanisms of which may include inhibiting the expression of matrix metalloprotein-9 (MMP-9) and disturbing PI3K and MAPK signaling pathways [<a class=\"ref-link\" id=\"c87\" href=\"#r87\">87</a>, <a class=\"ref-link\" id=\"c88\" href=\"#r88\">88</a>]. Recent studies reported that PPARc can regulate BP through renin-angiotensin-aldosterone system (RAAS), which acts as a negative regulator of Ang II receptor 1 transcription via the following pathways: inhibiting the expression of angiotensinogen, inhibiting Ang II activity, and degrading the angiotensin receptor I expression in the VSMCs [<a class=\"ref-link\" id=\"c21\" href=\"#r21\">21</a>, <a class=\"ref-link\" id=\"c82\" href=\"#r82\">82</a>]. Clinical researchers have found a significant reduction in blood pressure after the rosiglitazone treatment in type 2 diabetic patients [<a class=\"ref-link\" id=\"c89\" href=\"#r89\">89</a>]. e data by Barroso et al figured out that PPARc-dominant negative mutations are associated with hypertension [<a class=\"ref-link\" id=\"c90\" href=\"#r90\">90</a>]. In addition, PPARc is also important to circadian variations of blood pressure and heart rate through Bmal1. It controls cardiovascular rhythms via an influence on sympathetic nerve activity and the molecular clocks. PPARc also protects against age-related hypertension [<a class=\"ref-link\" id=\"c91\" href=\"#r91\">91</a>].",
            "Based on those functions, activators of PPARs (TZDs) may become therapeutic agents useful for the prevention of cardiovascular disease beyond their effects on carbohydrate and lipid metabolism. Although concerns of the side effects, such as the systemic fluid retention, have been proposed, Scnn1g, identified as a critical PPARc target gene, has played an important role in the control of edema [<a class=\"ref-link\" id=\"c23\" href=\"#r23\">23</a>, <a class=\"ref-link\" id=\"c92\" href=\"#r92\">92</a>]."
        ],
        "8. Clinical Application of PPAR\u03b3 Agonist in Kidney Diseases": [
            "PPARc agonists have shown great clinical effects in treating metabolic disorders. Many agonists have been developed, including 15-deoxy-\u039412, 14-prostaglandin J2 (15dPGJ2), and TZDs [<a class=\"ref-link\" id=\"c93\" href=\"#r93\">93</a>]. PPARc agonists appear to be useful in reversing this early stage of the renal fibrosis (epithelialmesenchymal transition, EMT) in the condition of the high glucose and to restore the function of SGLT-proteins mediated glucose uptake [<a class=\"ref-link\" id=\"c56\" href=\"#r56\">56</a>, <a class=\"ref-link\" id=\"c60\" href=\"#r60\">60</a>]. TZDs, which used in the treatment of T2D, were proved to indirectly slow down the progression of renal disease by improving glucose intolerance and reducing the urinary albumin [<a class=\"ref-link\" id=\"c21\" href=\"#r21\">21</a>, <a class=\"ref-link\" id=\"c94\" href=\"#r94\">94</a>]. A metaanalysis involving 2860 diabetic patients demonstrated that TZDs produced significant decreases in the levels of urinary albumin, which was in addition to that of RAS blockade because practically all patients in the latter studies were treated with ACEI or ARBs [<a class=\"ref-link\" id=\"c95\" href=\"#r95\">95</a>].",
            "Accumulating evidence suggested that PPARc agonists could also provide a protection in wider spectrum of kidney diseases, such as the acute nephrotic syndrome, nondiabetic glomerulosclerosis, and the polycystic kidney [<a class=\"ref-link\" id=\"c96\" href=\"#r96\">96</a>, <a class=\"ref-link\" id=\"c97\" href=\"#r97\">97</a>]. Pioglitazone was reported to improve the renal functions in animal models of renal ischemia reperfusion-induced AKI via regulating Tnf and Nrf2 expression [<a class=\"ref-link\" id=\"c98\" href=\"#r98\">98</a>]. Furthermore, recent studies have highlighted beneficial roles of PPARc agonists for patients with chronic renal failure, hemodialysis, as well as peritoneal dialysis (PD) could also benefit from [<a class=\"ref-link\" id=\"c99\" href=\"#r99\">99</a>, <a class=\"ref-link\" id=\"c100\" href=\"#r100\">100</a>]. Liu et al pointed out that rosiglitazone could protect against high phosphate-induced vascular calcification in CKD mice [<a class=\"ref-link\" id=\"c101\" href=\"#r101\">101</a>]. Zhang et al provided the evidence that rosiglitazone had the protective effects on rat peritoneal mesothelial cells against PD solution-induced damage probably by inhibiting inflammation and regulating AQP 1 and ZO 1 gene expressions [<a class=\"ref-link\" id=\"c102\" href=\"#r102\">102</a>].",
            "Interestingly, as a member of the RAAS inhibitors is widely used in the treatment of renal disease, telmisartan (characterized as selective PPARc modulators in 2005) had advantages in reducing albuminuria, serum creatinine, and glomerulosclerosis in a nondiabetic model by its partial agonistic activity on PPARc. Besides, treatment with telmisartan confirmed the protective effects against daunorubicin- (DNR-) induced nephrotoxicity by reducing the level of Ang II and ET-1 expression, which was associated with reduced inflammation and oxidative stress in part through the activation of PPARc [<a class=\"ref-link\" id=\"c103\" href=\"#r103\">103</a>\u2013<a class=\"ref-link\" id=\"c105\" href=\"#r105\">105</a>].",
            "Previous studies have shown that PPARc agonists may have some protective effects on CVD end of CKD. In a PROactive study, CKD patients treated with pioglitazone were less likely to reach a composite end point of all-cause death, MI, and stroke [<a class=\"ref-link\" id=\"c106\" href=\"#r106\">106</a>]. ese effects may be related to anti-inflammation effect and protection of endothelial cells. Short-term rosiglitazone therapy reduced insulin resistance, markers of inflammation, and abnormal endothelial function in patients with CKD [<a class=\"ref-link\" id=\"c107\" href=\"#r107\">107</a>]. In nondiabetic ESRD patients, pioglitazone significantly changes the visceral-subcutaneous fat distribution and improves the adipokine profile with a decrease in hepatic insulin resistance [<a class=\"ref-link\" id=\"c108\" href=\"#r108\">108</a>]. In nondiabetic renal allograft recipients, pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance [<a class=\"ref-link\" id=\"c109\" href=\"#r109\">109</a>]. However, the protective effect of PPARc agonists on the progress of renal function needs further exploration."
        ],
        "9. Side Effects of PPAR\u03b3 Agonists in Kidney": [
            "Despite the evidence that PPARc agonists could obviously bring benefits to renal functions as stated above, these beneficial effects were shadowed by the risk for fluid retention, peripheral edema, or blood volume expansion [<a class=\"ref-link\" id=\"c92\" href=\"#r92\">92</a>], which could increase various degrees of burdens on kidney. For example, some studies proved that TZDs contributed the fluid retention by altered sodium and water reabsorption in the distal collecting ducts of the kidney [<a class=\"ref-link\" id=\"c23\" href=\"#r23\">23</a>, <a class=\"ref-link\" id=\"c110\" href=\"#r110\">110</a>]. Clinical research figured out that uncomplicated diabetic patients\u2019 combined use of RAAS inhibitors and PPARc agonists promotes anemia [<a class=\"ref-link\" id=\"c111\" href=\"#r111\">111</a>]. Besides, people with long-term TZDs drug treatment are also peculiarly prone to the osteoporosis and heart failure [<a class=\"ref-link\" id=\"c112\" href=\"#r112\">112</a>]. Safety warnings and even drug withdrawal in Europe have come out because of the increasing risk in bladder cancer by pioglitazone [<a class=\"ref-link\" id=\"c113\" href=\"#r113\">113</a>\u2013<a class=\"ref-link\" id=\"c115\" href=\"#r115\">115</a>]. A combined therapy including PPARc agonists and other renoprotective measures appears to be more reasonable than one single intervention. Ongoing efforts have been made to identify more selective modulators of PPARc that reduce or eliminate the adverse effects of PPARc agonists."
        ],
        "10. Conclusion": [
            "Overall, PPARc is one of the ligand-activated transcription factor superfamily members and is abundantly expressed many types of kidney cells. It is involved in renal disease by participating in cell proliferation and apoptosis, TGF-\u03b2 pathway, inflammation and oxidative stress, lipid metabolism, hypertension, and so on. Activation of PPARc improves kidney injury. e application as clinical treatment was restricted by the side effect. And, the cell-specific function of PPARc agonist was still unclear. So, understanding the mechanism of PPARc function, exploring the cell specific reaction to the activation of PPARc agonist, and developing a new type of PPARc agonist with less side-effect may help application of the PPARc agonist into clinical treatment and ameliorate the renal injury.",
            "Conflicts of Interest e authors declare that they have no conflicts of interest.",
            "Ma Y andLiu J structured and drafted the review. Shi M and Wang Y provided input. Liu J revised and finalized the manuscript."
        ],
        "References": [
            "[<a class=\"ref-link\" id=\"c1\" href=\"#r1\">1</a>] K. P. McCullough, H. Morgenstern, R. Saran, W. H. Herman, and B. M. Robinson, \u201cProjecting ESRD incidence and prevalence in the United States through 2030,\u201d Journal of the American Society of Nephrology, vol 30, no. 1, pp. 127\u2013135, 2019.",
            "[<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>] B. D. Humphreys, \u201cMechanisms of renal fibrosis,\u201d Annual Review of Physiology, vol 80, no. 1, pp. 309\u2013326, 2018.",
            "[<a class=\"ref-link\" id=\"c3\" href=\"#r3\">3</a>] N. Liang, T. Jakobsson, R. Fan, and E. Treuter, \u201c e nuclear receptor-co-repressor complex in control of liver metabolism and disease,\u201d Frontiers in Endocrinology, vol 10, p. 411, 2019.",
            "[<a class=\"ref-link\" id=\"c4\" href=\"#r4\">4</a>] L. Fajas, D. Auboeuf, E. Raspeet al., \u201c e organization, promoter analysis, and expression of the human PPARc gene,\u201d Journal of Biological Chemistry, vol 272, no. 30, pp. 18779\u201318789, 1997.",
            "[<a class=\"ref-link\" id=\"c5\" href=\"#r5\">5</a>] S. Kersten, B. Desvergne, and W. Wahli, \u201cRoles of PPARs in health and disease,\u201d Nature, vol 405, no. 6785, pp. 421\u2013424, 2000.",
            "[<a class=\"ref-link\" id=\"c6\" href=\"#r6\">6</a>] A. M. Fayyad, A. A. Khan, S. H. Abdallah, S. S. Alomran, K. Bajou, and M. N. K. Khattak, \u201cRosiglitazone enhances browning adipocytes in association with MAPK and PI3-K pathways during the differentiation of telomerase-transformed mesenchymal stromal cells into adipocytes,\u201d International Journal of Molecular Sciences, vol 20, no. 7, p. 1618, 2019.",
            "[<a class=\"ref-link\" id=\"c7\" href=\"#r7\">7</a>] N. Liang, A. Damdimopoulos, S. Go\u00f1i et al, \u201cHepatocytespecific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR\u03b1,\u201d Nature Communications, vol 10, no. 1, p. 1684, 2019.",
            "[<a class=\"ref-link\" id=\"c8\" href=\"#r8\">8</a>] I. M. S. de Vera, J. Zheng, S. Novick et al, \u201cSynergistic regulation of coregulator/nuclear receptor interaction by ligand and DNA,\u201d Structure, vol 25, no. 10, pp. 1506\u20131518, 2017.",
            "[<a class=\"ref-link\" id=\"c9\" href=\"#r9\">9</a>] G. Pascual, A. L. Fong, S. Ogawa et al, \u201cA SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-c,\u201d Nature, vol 437, no. 7059, pp. 759\u2013763, 2005.",
            "[<a class=\"ref-link\" id=\"c10\" href=\"#r10\">10</a>] P. A. Konstantinopoulos, G. P. Vandoros, G. SotiropoulouBonikou, A. Kominea, and A. G. Papavassiliou, \u201cNF-kappaB/ PPAR c and/or AP-1/PPAR c \u201con/off\u201d switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression,\u201d International Journal of Colorectal Disease, vol 22, no. 1, pp. 57\u201368, 2007.",
            "[<a class=\"ref-link\" id=\"c11\" href=\"#r11\">11</a>] M. I. Lefterova, Y. Zhang, D. J. Steger et al, \u201cPPAR and C/ EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale,\u201d Genes & Development, vol 22, no. 21, pp. 2941\u20132952, 2008.",
            "[<a class=\"ref-link\" id=\"c12\" href=\"#r12\">12</a>] B. Konig, A. Koch, J. Spielmann et al, \u201cActivation of PPAR\u03b1 and PPARc reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1,\u201d European Journal of Pharmacology, vol 605, no. 1\u20133, pp. 23\u201330, 2009.",
            "[<a class=\"ref-link\" id=\"c13\" href=\"#r13\">13</a>] C. Fontaine, G. Dubois, Y. Duguay et al, \u201c e orphan nuclear receptor rev-Erb\u03b1 is a peroxisome proliferator-activated receptor (PPAR) c target gene and promotes PPARcinduced adipocyte differentiation,\u201d Journal of Biological Chemistry, vol 278, no. 39, pp. 37672\u201337680, 2003.",
            "[<a class=\"ref-link\" id=\"c14\" href=\"#r14\">14</a>] D. Cipolletta, M. Feuerer, A. Li et al, \u201cPPAR-c is a major driver of the accumulation and phenotype of adipose tissue Treg cells,\u201d Nature, vol 486, no. 7404, pp. 549\u2013553, 2012.",
            "[<a class=\"ref-link\" id=\"c15\" href=\"#r15\">15</a>] S. Cheng, K. Qian, Y. Wang et al, \u201cPPARc inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells,\u201d Journal of Cellular and Molecular Medicine, vol 23, no. 5, pp. 3724\u20133736, 2019.",
            "[<a class=\"ref-link\" id=\"c16\" href=\"#r16\">16</a>] F. Gilardi, C. Winkler, L. Quignodon et al, \u201cSystemic PPARc deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility,\u201d Metabolism, vol 95, pp. 8\u201320, 2019.",
            "[<a class=\"ref-link\" id=\"c17\" href=\"#r17\">17</a>] T. Demir, H. Onay, D. B. Savage et al, \u201cFamilial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -c (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations,\u201d Diabetic Medicine, vol 33, no. 10, pp. 1445\u20131450, 2016.",
            "[<a class=\"ref-link\" id=\"c18\" href=\"#r18\">18</a>] S.-J. Gu, Z.-R. Guo, Z.-Y. Zhou, X.-S. Hu, M. Wu, and N. Zhang, \u201cPeroxisome proliferator-activated receptor c polymorphisms as risk factors for dyslipidemia,\u201d Molecular Medicine Reports, vol 10, no. 5, pp. 2759\u20132763, 2014.",
            "[<a class=\"ref-link\" id=\"c19\" href=\"#r19\">19</a>] T. Yang, D. E. Michele, J. Park et al, \u201cExpression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,\u201d American Journal of PhysiologyRenal Physiology, vol 277, no. 6, pp. F966\u2013F973, 1999. [<a class=\"ref-link\" id=\"c20\" href=\"#r20\">20</a>] E. Kiss-Toth and T. Roszer, \u201cPPARc in kidney physiology and pathophysiology,\u201d PPAR Research, vol 2008, Article ID 183108, 9 pages, 2008. [<a class=\"ref-link\" id=\"c21\" href=\"#r21\">21</a>] P. Corrales, A. Izquierdo-Lahuerta, and G. Medina-Gomez, \u201cMaintenance of kidney metabolic homeostasis by PPAR c,\u201d International Journal of Molecular Sciences, vol 19, no. 7, p. 2063, 2018. [<a class=\"ref-link\" id=\"c22\" href=\"#r22\">22</a>] M. Desch, A. Schreiber, F. Schweda et al, \u201cIncreased renin production in mice with deletion of peroxisome proliferatoractivated receptor-c in juxtaglomerular cells,\u201d Hypertension, vol 55, no. 3, pp. 660\u2013666, 2010. [<a class=\"ref-link\" id=\"c23\" href=\"#r23\">23</a>] H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, \u201cCollecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention,\u201d Proceedings of the National Academy of Sciences, vol 102, no. 26, pp. 9406\u20139411, 2005. [<a class=\"ref-link\" id=\"c24\" href=\"#r24\">24</a>] C. Chafin, S. Muse, R. Hontecillas et al, \u201cDeletion of PPARc; in immune cells enhances susceptibility to antiglomerular basement membrane disease,\u201d Journal of Inflammation Research, vol 3, pp. 127\u2013134, 2010. [<a class=\"ref-link\" id=\"c25\" href=\"#r25\">25</a>] B. Toffoli, F. Gilardi, C. Winkler et al, \u201cNephropathy in Pparg-null mice highlights PPARc systemic activities in metabolism and in the immune system,\u201d PLoS One, vol 12, no. 2, Article ID e0171474, 2017. [<a class=\"ref-link\" id=\"c26\" href=\"#r26\">26</a>] G. Yang, Z. Jia, T. Aoyagi, D. McClain, R. M. Mortensen, and T. Yang, \u201cSystemic PPARc deletion impairs circadian rhythms of behavior and metabolism,\u201d PLoS One, vol 7, no. 8, Article ID e38117, 2012. [<a class=\"ref-link\" id=\"c27\" href=\"#r27\">27</a>] L. Zhou, A. Panasiuk, M. Downton et al, \u201cSystemic PPARc deletion causes severe disturbance in fluid homeostasis in mice,\u201d Physiological Genomics, vol 47, no. 11, pp. 541\u2013547, 2015. [<a class=\"ref-link\" id=\"c28\" href=\"#r28\">28</a>] H.-C. Yang, S. Deleuze, Y. Zuo, S. A. Potthoff, L.-J. Ma, and A. B. Fogo, \u201c e PPARc agonist pioglitazone ameliorates aging-related progressive renal injury,\u201d Journal of the American Society of Nephrology, vol 20, no. 11, pp. 2380\u20132388, 2009. [<a class=\"ref-link\" id=\"c29\" href=\"#r29\">29</a>] G. J. Ko, Y. S. Kang, S. Y. Han et al, \u201cPioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats,\u201d Nephrology Dialysis Transplantation, vol 23, no. 9, pp. 2750\u20132760, 2008. [<a class=\"ref-link\" id=\"c30\" href=\"#r30\">30</a>] K. Isshiki, M. Haneda, D. Koya, S. Maeda, T. Sugimoto, and R. Kikkawa, \u201c iazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats,\u201d Diabetes, vol 49, no. 6, pp. 1022\u20131032, 2000. [<a class=\"ref-link\" id=\"c31\" href=\"#r31\">31</a>] S. Efrati, S. Berman, A. Chachashvili et al, \u201cRosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction,\u201d Nephrology, vol 14, no. 2, pp. 189\u2013197, 2009. [<a class=\"ref-link\" id=\"c32\" href=\"#r32\">32</a>] T. Kawai, T. Masaki, S. Doi et al, \u201cPPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta,\u201d Laboratory Investigation, vol 89, no. 1, pp. 47\u201358, 2009. [<a class=\"ref-link\" id=\"c33\" href=\"#r33\">33</a>] T. Okada, J. Wada, K. Hida et al, \u201c iazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms,\u201d Diabetes, vol 55, no. 6, pp. 1666\u20131677, 2006. [<a class=\"ref-link\" id=\"c34\" href=\"#r34\">34</a>] S. S. Ghosh, T. W. B. Gehr, S. Ghosh et al, \u201cPPARc ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase,\u201d Kidney International, vol 64, no. 1, pp. 52\u201362, 2003.",
            "[<a class=\"ref-link\" id=\"c35\" href=\"#r35\">35</a>] J. Weissgarten, S. Berman, S. Efrati, M. Rapoport, Z. Averbukh, and L. Feldman, \u201cApoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats,\u201d Nephrology Dialysis Transplantation, vol 21, no. 5, pp. 1198\u20131204, 2006.",
            "[<a class=\"ref-link\" id=\"c36\" href=\"#r36\">36</a>] T. Kanjanabuch, L. J. Ma, J. Chen et al, \u201cPPAR-gamma agonist protects podocytes from injury,\u201d Kidney International, vol 71, no. 12, pp. 1232\u20131239, 2007.",
            "[<a class=\"ref-link\" id=\"c37\" href=\"#r37\">37</a>] M. Artwohl, T. Holzenbein, C. Furnsinn et al, \u201c iazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells,\u201d rombosis and Haemostasis, vol 93, no. 5, pp. 810\u2013815, 2005.",
            "[<a class=\"ref-link\" id=\"c38\" href=\"#r38\">38</a>] J. J. Carrero, M. I. Yilmaz, B. Lindholm, and P. Stenvinkel, \u201cCytokine dysregulation in chronic kidney disease: how can we treat it?,\u201d Blood Purification, vol 26, no. 3, pp. 291\u2013299, 2008.",
            "[<a class=\"ref-link\" id=\"c39\" href=\"#r39\">39</a>] U. Panzer, G. Zahner, U. Wienberg et al, \u201c15-Deoxy- 12,14prostaglandin J2 inhibits INF- -induced JAK/STAT1 signalling pathway activation and IP-10/CXCL10 expression in mesangial cells,\u201d Nephrology Dialysis Transplantation, vol 23, no. 12, pp. 3776\u20133785, 2008.",
            "[<a class=\"ref-link\" id=\"c40\" href=\"#r40\">40</a>] Y. Lu, Q. Zhou, Y. Shi et al, \u201cSUMOylation of PPARc by rosiglitazone prevents LPS-induced NCoR degradation mediating down regulation of chemokines expression in renal proximal tubular cells,\u201d PLoS One, vol 8, no. 11, Article ID e79815, 2013.",
            "[<a class=\"ref-link\" id=\"c41\" href=\"#r41\">41</a>] J. Xiao, J. C. K. Leung, L. Y. Y. Chan, H. Guo, and K. N. Lai, \u201cProtective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy,\u201d Nephrology Dialysis Transplantation, vol 24, no. 7, pp. 2067\u20132077, 2009.",
            "[<a class=\"ref-link\" id=\"c42\" href=\"#r42\">42</a>] C. Henique, G. Bollee, O. Lenoir et al, \u201cNuclear factor erythroid 2-related factor 2 drives podocyte-specific expression of peroxisome proliferator-activated receptor c essential for resistance to crescentic GN,\u201d Journal of the American Society of Nephrology, vol 27, no. 1, pp. 172\u2013188, 2016.",
            "[<a class=\"ref-link\" id=\"c43\" href=\"#r43\">43</a>] M. Wu, D. S. Melichian, E. Chang, M. Warner-Blankenship, A. K. Ghosh, and J. Varga, \u201cRosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptorc,\u201d e American Journal of Pathology, vol 174, no. 2, pp. 519\u2013533, 2009.",
            "[<a class=\"ref-link\" id=\"c44\" href=\"#r44\">44</a>] F. Zheng, A. Fornoni, S. J. Elliot et al, \u201cUpregulation of type I collagen by TGF-\u03b2 in mesangial cells is blocked by PPARc activation,\u201d American Journal of Physiology-Renal Physiology, vol 282, no. 4, pp. F639\u2013F648, 2002.",
            "[<a class=\"ref-link\" id=\"c45\" href=\"#r45\">45</a>] L.-J. Ma, C. Marcantoni, M. F. Linton, S. Fazio, and A. B. Fogo, \u201cPeroxisome proliferator-activated receptor-c agonist troglitazone protects against nondiabetic glomerulosclerosis in rats,\u201d Kidney International, vol 59, no. 5, pp. 1899\u20131910, 2001.",
            "[<a class=\"ref-link\" id=\"c46\" href=\"#r46\">46</a>] Y. Li, X. Wen, B. C. Spataro, K. Hu, C. Dai, and Y. Liu, \u201cHepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferatoractivated receptor-gamma agonists,\u201d Journal of the American Society of Nephrology, vol 17, no. 1, pp. 54\u201365, 2006.",
            "[<a class=\"ref-link\" id=\"c47\" href=\"#r47\">47</a>] W. Wang, F. Liu, and N. Chen, \u201cPeroxisome proliferatoractivated receptor-gamma (PPAR-c) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts,\u201d Mediators Inflamm, vol 2007, Article ID 62641, 7 pages, 2007.",
            "[<a class=\"ref-link\" id=\"c48\" href=\"#r48\">48</a>] Z. Chen, P. Yuan, X. Sun et al, \u201cPioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-c-miR-23 axis,\u201d",
            "American Journal of Physiology-Renal Physiology, vol 317, no. 1, pp. F137\u2013F151, 2019. [<a class=\"ref-link\" id=\"c49\" href=\"#r49\">49</a>] L. Wu, Q. Wang, F. Guo et al, \u201cMicroRNA-27a induces mesangial cell injury by targeting of PPARc, and its in vivo knockdown prevents progression of diabetic nephropathy,\u201d Scientific Reports, vol 6, no. 1, p. 26072, 2016. [<a class=\"ref-link\" id=\"c50\" href=\"#r50\">50</a>] Z. Zhou, J. Wan, X. Hou, J. Geng, X. Li, and X. Bai, \u201cMicroRNA-27a promotes podocyte injury via PPARcmediated \u03b2-catenin activation in diabetic nephropathy,\u201d Cell Death & Disease, vol 8, no. 3, Article ID e2658, 2017. [<a class=\"ref-link\" id=\"c51\" href=\"#r51\">51</a>] F. F. Samaha, P. O. Szapary, N. Iqbal et al, \u201cEffects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome,\u201d Arteriosclerosis, rombosis, and Vascular Biology, vol 26, no. 3, pp. 624\u2013630, 2006. [<a class=\"ref-link\" id=\"c52\" href=\"#r52\">52</a>] K. Eckardt, S. W. Gorgens, S. Raschke, and J. Eckel, \u201cMyokines in insulin resistance and type 2 diabetes,\u201d Diabetologia, vol 57, no. 6, pp. 1087\u20131099, 2014. [<a class=\"ref-link\" id=\"c53\" href=\"#r53\">53</a>] W. Wahli and L. Michalik, \u201cPPARs at the crossroads of lipid signaling and inflammation,\u201d Trends in Endocrinology & Metabolism, vol 23, no. 7, pp. 351\u2013363, 2012. [<a class=\"ref-link\" id=\"c54\" href=\"#r54\">54</a>] M. Ahmadian, J. M. Suh, N. Hah et al, \u201cPPARc signaling and metabolism: the good, the bad and the future,\u201d Nature Medicine, vol 19, no. 5, pp. 557\u2013566, 2013. [<a class=\"ref-link\" id=\"c55\" href=\"#r55\">55</a>] R. A. Derlacz, K. Hyc, M. Usarek, A. K. Jagielski, J. Drozak, and R. Jarzyna, \u201cPPAR-c-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules,\u201d Biochemistry and Cell Biology, vol 86, no. 5, pp. 396\u2013404, 2008. [<a class=\"ref-link\" id=\"c56\" href=\"#r56\">56</a>] A. Mather and C. Pollock, \u201cGlucose handling by the kidney,\u201d Kidney International, vol 79, pp. 1\u20136, 2011. [<a class=\"ref-link\" id=\"c57\" href=\"#r57\">57</a>] R. Santer, M. Kinner, C. L. Lassen et al, \u201cMolecular analysis of the SGLT2 gene in patients with renal glucosuria,\u201d Journal of the American Society of Nephrology, vol 14, no. 11, pp. 2873\u20132882, 2003. [<a class=\"ref-link\" id=\"c58\" href=\"#r58\">58</a>] C. Bonner, J. Kerr-Conte, V. Gmyr et al, \u201cInhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion,\u201d Nature Medicine, vol 21, no. 5, pp. 512\u2013517, 2015. [<a class=\"ref-link\" id=\"c59\" href=\"#r59\">59</a>] M. Kim, E. J. Lee, H. M. Shin et al, \u201c e effect of PPARc agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia,\u201d Journal of Endocrinological Investigation, vol 40, no. 10, pp. 1069\u20131076, 2017. [<a class=\"ref-link\" id=\"c60\" href=\"#r60\">60</a>] Y. J. Lee and H. J. Han, \u201cTroglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3\u03b2, Snail1, and \u03b2-catenin in renal proximal tubule cells,\u201d American Journal of Physiology-Renal Physiology, vol 298, no. 5, pp. F1263\u2013F1275, 2010. [<a class=\"ref-link\" id=\"c61\" href=\"#r61\">61</a>] M.-T. Guillam, E. Hummler, E. Schaerer et al, \u201cEarly diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2,\u201d Nature Genetics, vol 17, no. 3, pp. 327\u2013330, 1997. [<a class=\"ref-link\" id=\"c62\" href=\"#r62\">62</a>] K. Murakami, K. Tobe, T. Ide et al, \u201cA novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats,\u201d Diabetes, vol 47, no. 12, pp. 1841\u20131847, 1998. [<a class=\"ref-link\" id=\"c63\" href=\"#r63\">63</a>] B. MochizukiOhashi, B. Parim, V. R. Chunduri et al, \u201cAntiobesity potential of piperonal: promising modulation of body composition, lipid profiles and obesogenic marker expression in HFD-induced obese rats,\u201d Nutrition & Metabolism, vol 14, no. 1, p. 72, 2017.",
            "[<a class=\"ref-link\" id=\"c64\" href=\"#r64\">64</a>] N. Das, M. Dhanawat, and S. K. Shrivastava, \u201cBenzoxazinones as human peroxisome proliferator activated receptor gamma (PPARc) agonists: a docking study using glide,\u201d Indian Journal of Pharmaceutical Sciences, vol 73, no. 2, pp. 159\u2013164, 2011.",
            "[<a class=\"ref-link\" id=\"c65\" href=\"#r65\">65</a>] Y. Hiraike, H. Waki, J. Yu et al, \u201cNFIA co-localizes with PPARc and transcriptionally controls the brown fat gene program,\u201d Nature Cell Biology, vol 19, no. 9, pp. 1081\u20131092, 2017.",
            "[<a class=\"ref-link\" id=\"c66\" href=\"#r66\">66</a>] J. Kim, Y.-J. Lee, J. M. Kim et al, \u201cPPARc agonists induce adipocyte differentiation by modulating the expression of Lipin-1, which acts as a PPARc phosphatase,\u201d e International Journal of Biochemistry & Cell Biology, vol 81, pp. 57\u201366, 2016.",
            "[<a class=\"ref-link\" id=\"c67\" href=\"#r67\">67</a>] J.-L. Huret, S. L. Minor, F. Dorkeld, P. Dessen, and A. Bernheim, \u201cAtlas of genetics and cytogenetics in oncology and haematology, an interactive database,\u201d Nucleic Acids Research, vol 28, no. 1, pp. 349\u2013351, 2000.",
            "[<a class=\"ref-link\" id=\"c68\" href=\"#r68\">68</a>] Z. Lyu, Z. Mao, Q. Li et al, \u201cPPARc maintains the metabolic heterogeneity and homeostasis of renal tubules,\u201d EBioMedicine, vol 38, pp. 178\u2013190, 2018.",
            "[<a class=\"ref-link\" id=\"c69\" href=\"#r69\">69</a>] H. H. Szeto, S. Liu, Y. Soong, N. Alam, G. T. Prusky, and S. V. Seshan, \u201cProtection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury,\u201d Kidney International, vol 90, no. 5, pp. 997\u20131011, 2016.",
            "[<a class=\"ref-link\" id=\"c70\" href=\"#r70\">70</a>] J. F. Moorhead, M. El-Nahas, M. K. Chan, and Z. Varghese, \u201cLipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease,\u201d e Lancet, vol 320, no. 8311, pp. 1309\u20131311, 1982.",
            "[<a class=\"ref-link\" id=\"c71\" href=\"#r71\">71</a>] A. Izquierdo-Lahuerta, C. Mart\u0131nez-Garc\u0131a, and G. MedinaGomez, \u201cLipotoxicity as a trigger factor of renal disease,\u201d Journal of Nephrology, vol 29, no. 5, pp. 603\u2013610, 2016.",
            "[<a class=\"ref-link\" id=\"c72\" href=\"#r72\">72</a>] C. Martinez-Garcia, A. Izquierdo, V. Velagapudi et al, \u201cAccelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model,\u201d Disease Models & Mechanisms, vol 5, no. 5, pp. 636\u2013648, 2012.",
            "[<a class=\"ref-link\" id=\"c73\" href=\"#r73\">73</a>] G. Medina-Gomez, L. Yetukuri, V. Velagapudi et al, \u201cAdaptation and failure of pancreatic cells in murine models with different degrees of metabolic syndrome,\u201d Disease Models & Mechanisms, vol 2, no. 11-12, pp. 582\u2013592, 2009.",
            "[<a class=\"ref-link\" id=\"c74\" href=\"#r74\">74</a>] C. Mart\u0131nez-Garc\u0131a, A. Izquierdo-Lahuerta, Y. Vivas et al, \u201cRenal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton organization in podocytes,\u201d PLoS One, vol 10, no. 11, Article ID e0142291, 2015.",
            "[<a class=\"ref-link\" id=\"c75\" href=\"#r75\">75</a>] T. Roszer, M. P. Menendez-Gutierrez, M. I. Lefterova et al, \u201cAutoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency,\u201d Journal of Immunology, vol 186, no. 1, pp. 621\u2013631, 2011.",
            "[<a class=\"ref-link\" id=\"c76\" href=\"#r76\">76</a>] M. A. FischerRicote, B. Derudas, E. Rigamonti et al, \u201cPPARc activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties,\u201d Cell Metabolism, vol 6, no. 2, pp. 137\u2013143, 2007.",
            "[<a class=\"ref-link\" id=\"c77\" href=\"#r77\">77</a>] T. E. Akiyama, S. Sakai, G. Lambert et al, \u201cConditional disruption of the peroxisome proliferator-activated receptor gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux,\u201d Molecular and Cellular Biology, vol 22, no. 8, pp. 2607\u20132619, 2002.",
            "[<a class=\"ref-link\" id=\"c78\" href=\"#r78\">78</a>] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, \u201c e peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation,\u201d Nature, vol 391, no. 6662, pp. 79\u201382, 1998. [<a class=\"ref-link\" id=\"c79\" href=\"#r79\">79</a>] C. K. Glass and K. Saijo, \u201cNuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells,\u201d Nature Reviews Immunology, vol 10, no. 5, pp. 365\u2013376, 2010. [<a class=\"ref-link\" id=\"c80\" href=\"#r80\">80</a>] M. P. Menendez-Gutierrez, T. Roszer, and M. Ricote, \u201cBiology and therapeutic applications of peroxisome proliferator-activated receptors,\u201d Current Topics in Medicinal Chemistry, vol 12, no. 6, pp. 48\u2013584, 2012. [<a class=\"ref-link\" id=\"c81\" href=\"#r81\">81</a>] J. P. Lash, A. S. Go, L. J. Appel et al, \u201cChronic renal insufficiency cohort (CRIC) study: baseline characteristics and associations with kidney function,\u201d Clinical Journal of the American Society of Nephrology, vol 4, no. 8, pp. 1302\u20131311, 2009. [<a class=\"ref-link\" id=\"c82\" href=\"#r82\">82</a>] M. Szkup, A. J. Owczarek, D. Schneider-Matyka, J. Brodowski, B. \u0141oo, and E. Grochans, \u201cAssociations between the components of metabolic syndrome and the polymorphisms in the peroxisome proliferator-activated receptor gamma (PPAR-c), the fat mass and obesity-associated (FTO), and the melanocortin-4 receptor (MC4R) genes,\u201d Aging, vol 10, no. 1, pp. 72\u201382, 2018. [<a class=\"ref-link\" id=\"c83\" href=\"#r83\">83</a>] M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin, \u201cEffect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension,\u201d Arteriosclerosis, rombosis, and Vascular Biology, vol 23, no. 1, pp. 45\u201351, 2003. [<a class=\"ref-link\" id=\"c84\" href=\"#r84\">84</a>] L. Wu, R. Wang, J. De Champlain, and T. W. Wilson, \u201cBeneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats,\u201d American Journal of Hypertension, vol 17, no. 9, pp. 749\u2013756, 2004. [<a class=\"ref-link\" id=\"c85\" href=\"#r85\">85</a>] M. Zhang, J. Zhang, L. Li, Q. Wang, and L. Feng, \u201cAssociation between peroxisome proliferator-activated receptor c-2 gene Pro12Ala polymorphisms and risk of hypertension: an updated meta-analysis,\u201d Bioscience Reports, vol 39, no. 2, 2019. [<a class=\"ref-link\" id=\"c86\" href=\"#r86\">86</a>] C. J. Nicol, M. Adachi, T. E. Akiyama, and F. J. Gonzalez, \u201cPPARgamma in endothelial cells influences high fat dietinduced hypertension,\u201d American Journal of Hypertension, vol 18, no. 4, pp. 549\u2013556, 2005. [<a class=\"ref-link\" id=\"c87\" href=\"#r87\">87</a>] K. Benkirane, E. C. Viel, F. Amiri, and E. L. Schiffrin, \u201cPeroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo,\u201d Hypertension, vol 47, no. 1, pp. 102\u2013108, 2006. [<a class=\"ref-link\" id=\"c88\" href=\"#r88\">88</a>] E. L. Schiffrin, \u201cPeroxisome proliferator-activated receptors and cardiovascular remodeling,\u201d American Journal of Physiology-Heart and Circulatory Physiology, vol 288, no. 3, pp. H1037\u2013H1043, 2005. [<a class=\"ref-link\" id=\"c89\" href=\"#r89\">89</a>] C. J. Magri, N. Gatt, R. G. Xuereb, and S. Fava, \u201cPeroxisome proliferator-activated receptor-c and the endothelium: implications in cardiovascular disease,\u201d Expert Review of Cardiovascular erapy, vol 9, no. 10, pp. 1279\u20131294, 2011. [<a class=\"ref-link\" id=\"c90\" href=\"#r90\">90</a>] I. Barroso, M. Gurnell, V. E. Crowley et al, \u201cDominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension,\u201d Nature, vol 402, no. 6764, pp. 880\u2013883, 1999. [<a class=\"ref-link\" id=\"c91\" href=\"#r91\">91</a>] N. Wang, G. Yang, Z. Jia et al, \u201cVascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1,\u201d Cell Metabolism, vol 8, no. 6, pp. 482\u2013491, 2008. [<a class=\"ref-link\" id=\"c92\" href=\"#r92\">92</a>] Y. Guan, C. Hao, D. R. Cha et al, \u201c iazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption,\u201d Nature Medicine, vol 11, no. 8, pp. 861\u2013866, 2005. [<a class=\"ref-link\" id=\"c93\" href=\"#r93\">93</a>] S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, \u201cPeroxisome proliferator-activated receptors: from genes to physiology,\u201d Recent Progress in Hormone Research, vol 56, no. 1, pp. 239\u2013263, 2001. [<a class=\"ref-link\" id=\"c94\" href=\"#r94\">94</a>] J. Yang, D. Zhang, J. Li, X. Zhang, F. Fan, and Y. Guan, \u201cRole of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential,\u201d Clinical Science, vol 116, no. 1, pp. 17\u201326, 2009. [<a class=\"ref-link\" id=\"c95\" href=\"#r95\">95</a>] P. A. Sarafidis, P. C. Stafylas, P. I. Georgianos, A. N. Saratzis, and A. N. Lasaridis, \u201cEffect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis,\u201d American Journal of Kidney Diseases, vol 55, no. 5, pp. 835\u2013847, 2010. [<a class=\"ref-link\" id=\"c96\" href=\"#r96\">96</a>] Y. Zuo, H. C. Yang, S. A. Potthoff et al, \u201cProtective effects of PPARgamma agonist in acute nephrotic syndrome,\u201d Nephrology Dialysis Transplantation, vol 27, no. 1, pp. 174\u2013181, 2012. [<a class=\"ref-link\" id=\"c97\" href=\"#r97\">97</a>] D. Yoshihara, H. Kurahashi, M. Morita et al, \u201cPPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease,\u201d American Journal of Physiology-Renal Physiology, vol 300, no. 2, pp. F465\u2013F474, 2011. [<a class=\"ref-link\" id=\"c98\" href=\"#r98\">98</a>] S. Elshazly and E. Soliman, \u201cPPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/ reperfusion injury,\u201d Toxicology and Applied Pharmacology, vol 362, pp. 86\u201394, 2019. [<a class=\"ref-link\" id=\"c99\" href=\"#r99\">99</a>] A. Sugawara, A. Uruno, M. Kudo, K. Matsuda, C. W. Yang, and S. Ito, \u201cEffects of PPARgamma on hypertension, atherosclerosis, and chronic kidney disease,\u201d Endocrine Journal, vol 57, no. 10, pp. 847\u2013852, 2010. [<a class=\"ref-link\" id=\"c100\" href=\"#r100\">100</a>] P. Iglesias and J. J. D\u0131ez, \u201cPeroxisome proliferator-activated receptor gamma agonists in renal disease,\u201d European Journal of Endocrinology, vol 154, no. 5, pp. 613\u2013621, 2006. [<a class=\"ref-link\" id=\"c101\" href=\"#r101\">101</a>] L. Liu, Y. Liu, Y. Zhang et al, \u201cHigh phosphate-induced downregulation of PPARc contributes to CKD-associated vascular calcification,\u201d Journal of Molecular and Cellular Cardiology, vol 114, pp. 264\u2013275, 2018. [<a class=\"ref-link\" id=\"c102\" href=\"#r102\">102</a>] Y.-F. Zhang, Q. Wang, Y.-Y. Su et al, \u201cPPAR-c agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution-induced damage,\u201d Molecular Medicine Reports, vol 15, no. 4, pp. 1786\u20131792, 2017. [<a class=\"ref-link\" id=\"c103\" href=\"#r103\">103</a>] A. Barnett, \u201cPreventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial,\u201d Journal of the American Society of Nephrology, vol 17, no. 4, pp. S132\u2013S135, 2006. [<a class=\"ref-link\" id=\"c104\" href=\"#r104\">104</a>] W. Arozal, K. Watanabe, P. T. Veeraveedu et al, \u201cTelmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-c agonist actions,\u201d Toxicology, vol 279, no. 1\u20133, pp. 91\u201399, 2011. [<a class=\"ref-link\" id=\"c105\" href=\"#r105\">105</a>] M. Schupp, M. Clemenz, R. Gineste et al, \u201cMolecular characterization of new selective peroxisome proliferatoractivated receptor c modulators with angiotensin receptor blocking activity,\u201d Diabetes, vol 54, no. 12, pp. 3442\u20133452, 2005. [<a class=\"ref-link\" id=\"c106\" href=\"#r106\">106</a>] C. A. Schneider, E. Ferrannini, R. Defronzo, G. Schernthaner, J. Yates, and E. Erdmann, \u201cEffect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease,\u201d Journal of the American Society of Nephrology, vol 19, no. 1, pp. 182\u2013187, 2008. [<a class=\"ref-link\" id=\"c107\" href=\"#r107\">107</a>] D. T. Chan, G. F. Watts, A. B. Irish, and G. K. Dogra, \u201cRosiglitazone does not improve vascular function in subjects with chronic kidney disease,\u201d Nephrology Dialysis Transplantation, vol 26, no. 11, pp. 3543\u20133549, 2011. [<a class=\"ref-link\" id=\"c108\" href=\"#r108\">108</a>] A. Zanchi, L. Tappy, K.-A. Leet al., \u201cPioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study,\u201d PLoS One, vol 9, no. 10, Article ID e109134, 2014. [<a class=\"ref-link\" id=\"c109\" href=\"#r109\">109</a>] S. J. Han, K. Y. Hur, Y. S. Kim et al, \u201cEffects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients,\u201d Nephrology Dialysis Transplantation, vol 25, no. 3, pp. 976\u2013984, 2010. [<a class=\"ref-link\" id=\"c110\" href=\"#r110\">110</a>] K. Kuba, Y. Imai, S. Rao et al, \u201cA crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury,\u201d Nature Medicine, vol 11, no. 8, pp. 875\u2013879, 2005. [<a class=\"ref-link\" id=\"c111\" href=\"#r111\">111</a>] A. E. Raptis, D. Bacharaki, M. Mazioti et al, \u201cAnemia due to coadministration of renin-angiotensin-system inhibitors and PPARc agonists in uncomplicated diabetic patients,\u201d Experimental and Clinical Endocrinology & Diabetes, vol 120, no. 7, pp. 416\u2013419, 2012. [<a class=\"ref-link\" id=\"c112\" href=\"#r112\">112</a>] J. Kung and R. R. Henry, \u201c iazolidinedione safety,\u201d Expert Opinion on Drug Safety, vol 11, no. 4, pp. 565\u2013579, 2012. [<a class=\"ref-link\" id=\"c113\" href=\"#r113\">113</a>] A. Neumann, A. Weill, P. Ricordeau, J. P. Fagot, F. Alla, and H. Allemand, \u201cPioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study,\u201d Diabetologia, vol 55, no. 7, pp. 1953\u20131962, 2012. [<a class=\"ref-link\" id=\"c114\" href=\"#r114\">114</a>] I. N. Colmers, S. L. Bowker, S. R. Majumdar, and J. A. Johnson, \u201cUse of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a metaanalysis,\u201d Canadian Medical Association Journal, vol 184, no. 12, pp. E675\u2013E683, 2012. [<a class=\"ref-link\" id=\"c115\" href=\"#r115\">115</a>] S. E. Nissen and K. Wolski, \u201cEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,\u201d New England Journal of Medicine, vol 356, no. 24, pp. 2457\u20132471, 2007."
        ]
    },
    "participants": [
        {
            "participant": "diabetic patients",
            "number": 2,
            "context": "Recent studies reported that PPARc can regulate BP through renin-angiotensin-aldosterone system (RAAS), which acts as a negative regulator of Ang II receptor 1 transcription via the following pathways: inhibiting the expression of angiotensinogen, inhibiting Ang II activity, and degrading the angiotensin receptor I expression in the VSMCs [<a class=\"ref-link\" id=\"c21\" href=\"#r21\">21</a>, <a class=\"ref-link\" id=\"c82\" href=\"#r82\">82</a>]. <mark class=\"stats\">Clinical researchers have found a significant reduction in blood pressure after the rosiglitazone treatment in type 2 diabetic patients [<a class=\"ref-link\" id=\"c89\" href=\"#r89\">89</a>]. e data by Barroso et al figured out that PPARc-dominant negative mutations are associated with hypertension [<a class=\"ref-link\" id=\"c90\" href=\"#r90\">90</a>]</mark>. In addition, PPARc is also important to circadian variations of blood pressure and heart rate through Bmal1"
        },
        {
            "participant": "diabetic patients",
            "number": 2860,
            "context": "TZDs, which used in the treatment of T2D, were proved to indirectly slow down the progression of renal disease by improving glucose intolerance and reducing the urinary albumin [<a class=\"ref-link\" id=\"c21\" href=\"#r21\">21</a>, <a class=\"ref-link\" id=\"c94\" href=\"#r94\">94</a>]. <mark class=\"stats\">A metaanalysis involving 2860 diabetic patients demonstrated that TZDs produced significant decreases in the levels of urinary albumin, which was in addition to that of RAS blockade because practically all patients in the latter studies were treated with ACEI or ARBs [<a class=\"ref-link\" id=\"c95\" href=\"#r95\">95</a>]</mark>. Accumulating evidence suggested that PPARc agonists could also provide a protection in wider spectrum of kidney diseases, such as the acute nephrotic syndrome, nondiabetic glomerulosclerosis, and the polycystic kidney [<a class=\"ref-link\" id=\"c96\" href=\"#r96\">96</a>, <a class=\"ref-link\" id=\"c97\" href=\"#r97\">97</a>]"
        }
    ],
    "statistics": [],
    "keywords": [
        "peroxisome proliferator",
        "systemic pparc deletion",
        "renal fibrosis",
        "PPAR-c",
        "free fatty acids",
        "diabetic nephropathy",
        "cell proliferation",
        "plasminogen activating-inhibiting factor-1",
        "extracellular matrix",
        "sodium-dependent glucose cotransporters",
        "renin-angiotensin-aldosterone system",
        "metabolism",
        "matrix metalloprotein-9",
        "Peroxisome proliferator-activated receptor \u03b3",
        "glucose",
        "vascular endothelial growth factor",
        "type 2 diabetes",
        "SGLT2",
        "mitogen-activated protein kinase",
        "ureteral obstruction",
        "puromycin aminonucleoside nephrosis",
        "hepatocyte growth factor",
        "chronic kidney disease",
        "fibrosis",
        "peritoneal dialysis",
        "diabetes",
        "platelet-derived growth factor",
        "vascular smooth muscle cells",
        "kidney disease",
        "connective tissue growth factor",
        "transforming growth factor-\u03b2",
        "diet-induced obesity models",
        "PPARc2 and leptin double knockout mice",
        "nuclear receptor",
        "renal disease",
        "blood pressure",
        "end stage",
        "tumor necrosis factor",
        "nephropathy",
        "end-stage renal disease",
        "signal transducer and activator of transcription",
        "glucose transporters",
        "nuclear factor I-A"
    ],
    "keyword_relevance": {
        "glucose": 0.06990881458966565,
        "metabolism": 0.06382978723404255,
        "peroxisome proliferator": 0.057750759878419454,
        "kidney disease": 0.0547112462006079,
        "sodium-dependent glucose cotransporters": 0.05167173252279635,
        "blood pressure": 0.05167173252279635,
        "Chronic kidney disease": 0.0425531914893617,
        "Peroxisome proliferator-activated receptor \u03b3": 0.03951367781155015,
        "diabetes": 0.0364741641337386,
        "PPAR-c": 0.03343465045592705,
        "SGLT2": 0.03343465045592705,
        "fibrosis": 0.03343465045592705,
        "diabetic nephropathy": 0.030395136778115502,
        "renal disease": 0.030395136778115502,
        "type 2 diabetes": 0.02735562310030395,
        "mitogen-activated protein kinase": 0.0243161094224924,
        "transforming growth factor-\u03b2": 0.0243161094224924,
        "end-stage renal disease": 0.0243161094224924,
        "signal transducer and activator of transcription": 0.02127659574468085,
        "cell proliferation": 0.0182370820668693,
        "peritoneal dialysis": 0.0182370820668693,
        "nephropathy": 0.0182370820668693,
        "renal fibrosis": 0.015197568389057751,
        "extracellular matrix": 0.015197568389057751,
        "chronic kidney disease": 0.015197568389057751,
        "glucose transporters": 0.015197568389057751,
        "renin-angiotensin-aldosterone system": 0.0121580547112462,
        "nuclear receptor": 0.0121580547112462,
        "free fatty acids": 0.00911854103343465,
        "hepatocyte growth factor": 0.00911854103343465,
        "platelet-derived growth factor": 0.00911854103343465,
        "vascular smooth muscle cells": 0.00911854103343465,
        "tumor necrosis factor": 0.00911854103343465,
        "nuclear factor I-A": 0.00911854103343465,
        "plasminogen activating-inhibiting factor-1": 0.0060790273556231,
        "matrix metalloprotein-9": 0.0060790273556231,
        "vascular endothelial growth factor": 0.0060790273556231,
        "ureteral obstruction": 0.0060790273556231,
        "puromycin aminonucleoside nephrosis": 0.0060790273556231,
        "connective tissue growth factor": 0.0060790273556231,
        "diet-induced obesity models": 0.0060790273556231,
        "PPARc2 and leptin double knockout mice": 0.0060790273556231,
        "end stage": 0.0060790273556231,
        "systemic pparc deletion": 0.0
    },
    "species": [],
    "summary": [
        "<h2 style=\"display: inline\">Introduction:</h2> Chronic kidney disease (CKD) has become one of the most common diseases in the world.",
        "Chronic renal failure is the end stage of the progression of various types of CKD.",
        "Renal fibrosis is almost the result of all progressive kidney diseases and is a complex common chronic process involving multiple mechanisms such as extracellular matrix (ECM) and cytokine secretion, energy metabolism, podocyte injury, cell proliferation and differentiation, endoplasmic reticulum stress, autophagy, infiltration of inflammatory cells, and activation of fibroblasts [<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>].",
        "<h2 style=\"display: inline\">Conclusion:</h2> PPARc is one of the ligand-activated transcription factor superfamily members and is abundantly expressed many types of kidney cells",
        "It is involved in renal disease by participating in cell proliferation and apoptosis, TGF-\u03b2 pathway, inflammation and oxidative stress, lipid metabolism, hypertension, and so on.",
        "Understanding the mechanism of PPARc function, exploring the cell specific reaction to the activation of PPARc agonist, and developing a new type of PPARc agonist with less side-effect may help application of the PPARc agonist into clinical treatment and ameliorate the renal injury"
    ],
    "structured_summary": {
        "Introduction": [
            "Chronic kidney disease (CKD) has become one of the most common diseases in the world.",
            "Chronic renal failure is the end stage of the progression of various types of CKD.",
            "Renal fibrosis is almost the result of all progressive kidney diseases and is a complex common chronic process involving multiple mechanisms such as extracellular matrix (ECM) and cytokine secretion, energy metabolism, podocyte injury, cell proliferation and differentiation, endoplasmic reticulum stress, autophagy, infiltration of inflammatory cells, and activation of fibroblasts [<a class=\"ref-link\" id=\"c2\" href=\"#r2\">2</a>]."
        ],
        "Conclusion": [
            "PPARc is one of the ligand-activated transcription factor superfamily members and is abundantly expressed many types of kidney cells",
            "It is involved in renal disease by participating in cell proliferation and apoptosis, TGF-\u03b2 pathway, inflammation and oxidative stress, lipid metabolism, hypertension, and so on.",
            "Understanding the mechanism of PPARc function, exploring the cell specific reaction to the activation of PPARc agonist, and developing a new type of PPARc agonist with less side-effect may help application of the PPARc agonist into clinical treatment and ameliorate the renal injury"
        ]
    },
    "reference_links": [
        {
            "id": "1",
            "alt_id": "Mccullough_et+al_2019_a",
            "entry": "[1] K. P. McCullough, H. Morgenstern, R. Saran, W. H. Herman, and B. M. Robinson, \u201cProjecting ESRD incidence and prevalence in the United States through 2030,\u201d Journal of the American Society of Nephrology, vol. 30, no. 1, pp. 127\u2013135, 2019.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=McCullough%2C%20K.P.%20Morgenstern%2C%20H.%20Saran%2C%20R.%20Herman%2C%20W.H.%20Projecting%20ESRD%20incidence%20and%20prevalence%20in%20the%20United%20States%20through%202030%2C%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=McCullough%2C%20K.P.%20Morgenstern%2C%20H.%20Saran%2C%20R.%20Herman%2C%20W.H.%20Projecting%20ESRD%20incidence%20and%20prevalence%20in%20the%20United%20States%20through%202030%2C%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=McCullough%2C%20K.P.%20Morgenstern%2C%20H.%20Saran%2C%20R.%20Herman%2C%20W.H.%20Projecting%20ESRD%20incidence%20and%20prevalence%20in%20the%20United%20States%20through%202030%2C%202019"
        },
        {
            "id": "2",
            "alt_id": "Humphreys_2018_a",
            "entry": "[2] B. D. Humphreys, \u201cMechanisms of renal fibrosis,\u201d Annual Review of Physiology, vol. 80, no. 1, pp. 309\u2013326, 2018.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Humphreys%2C%20B.D.%20Mechanisms%20of%20renal%20fibrosis%2C%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Humphreys%2C%20B.D.%20Mechanisms%20of%20renal%20fibrosis%2C%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Humphreys%2C%20B.D.%20Mechanisms%20of%20renal%20fibrosis%2C%202018"
        },
        {
            "id": "3",
            "alt_id": "Liang_et+al_2019_a",
            "entry": "[3] N. Liang, T. Jakobsson, R. Fan, and E. Treuter, \u201c e nuclear receptor-co-repressor complex in control of liver metabolism and disease,\u201d Frontiers in Endocrinology, vol. 10, p. 411, 2019.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Liang%2C%20N.%20Jakobsson%2C%20T.%20Fan%2C%20R.%20Treuter%2C%20E.%20e%20nuclear%20receptor-co-repressor%20complex%20in%20control%20of%20liver%20metabolism%20and%20disease%2C%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Liang%2C%20N.%20Jakobsson%2C%20T.%20Fan%2C%20R.%20Treuter%2C%20E.%20e%20nuclear%20receptor-co-repressor%20complex%20in%20control%20of%20liver%20metabolism%20and%20disease%2C%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Liang%2C%20N.%20Jakobsson%2C%20T.%20Fan%2C%20R.%20Treuter%2C%20E.%20e%20nuclear%20receptor-co-repressor%20complex%20in%20control%20of%20liver%20metabolism%20and%20disease%2C%202019"
        },
        {
            "id": "4",
            "alt_id": "Fajas_et+al_1997_a",
            "entry": "[4] L. Fajas, D. Auboeuf, E. Raspeet al., \u201c e organization, promoter analysis, and expression of the human PPARc gene,\u201d Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779\u201318789, 1997.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Fajas%2C%20L.%20Auboeuf%2C%20D.%20al%2C%20E.Raspeet%20e%20organization%2C%20promoter%20analysis%2C%20and%20expression%20of%20the%20human%20PPARc%20gene%2C%201997",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Fajas%2C%20L.%20Auboeuf%2C%20D.%20al%2C%20E.Raspeet%20e%20organization%2C%20promoter%20analysis%2C%20and%20expression%20of%20the%20human%20PPARc%20gene%2C%201997",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Fajas%2C%20L.%20Auboeuf%2C%20D.%20al%2C%20E.Raspeet%20e%20organization%2C%20promoter%20analysis%2C%20and%20expression%20of%20the%20human%20PPARc%20gene%2C%201997"
        },
        {
            "id": "5",
            "alt_id": "Kersten_et+al_2000_a",
            "entry": "[5] S. Kersten, B. Desvergne, and W. Wahli, \u201cRoles of PPARs in health and disease,\u201d Nature, vol. 405, no. 6785, pp. 421\u2013424, 2000.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kersten%2C%20S.%20Desvergne%2C%20B.%20Wahli%2C%20W.%20Roles%20of%20PPARs%20in%20health%20and%20disease%2C%202000",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kersten%2C%20S.%20Desvergne%2C%20B.%20Wahli%2C%20W.%20Roles%20of%20PPARs%20in%20health%20and%20disease%2C%202000",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kersten%2C%20S.%20Desvergne%2C%20B.%20Wahli%2C%20W.%20Roles%20of%20PPARs%20in%20health%20and%20disease%2C%202000"
        },
        {
            "id": "6",
            "alt_id": "Fayyad_et+al_2019_a",
            "entry": "[6] A. M. Fayyad, A. A. Khan, S. H. Abdallah, S. S. Alomran, K. Bajou, and M. N. K. Khattak, \u201cRosiglitazone enhances browning adipocytes in association with MAPK and PI3-K pathways during the differentiation of telomerase-transformed mesenchymal stromal cells into adipocytes,\u201d International Journal of Molecular Sciences, vol. 20, no. 7, p. 1618, 2019.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Fayyad%2C%20A.M.%20Khan%2C%20A.A.%20Abdallah%2C%20S.H.%20Alomran%2C%20S.S.%20Rosiglitazone%20enhances%20browning%20adipocytes%20in%20association%20with%20MAPK%20and%20PI3-K%20pathways%20during%20the%20differentiation%20of%20telomerase-transformed%20mesenchymal%20stromal%20cells%20into%20adipocytes%2C%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Fayyad%2C%20A.M.%20Khan%2C%20A.A.%20Abdallah%2C%20S.H.%20Alomran%2C%20S.S.%20Rosiglitazone%20enhances%20browning%20adipocytes%20in%20association%20with%20MAPK%20and%20PI3-K%20pathways%20during%20the%20differentiation%20of%20telomerase-transformed%20mesenchymal%20stromal%20cells%20into%20adipocytes%2C%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Fayyad%2C%20A.M.%20Khan%2C%20A.A.%20Abdallah%2C%20S.H.%20Alomran%2C%20S.S.%20Rosiglitazone%20enhances%20browning%20adipocytes%20in%20association%20with%20MAPK%20and%20PI3-K%20pathways%20during%20the%20differentiation%20of%20telomerase-transformed%20mesenchymal%20stromal%20cells%20into%20adipocytes%2C%202019"
        },
        {
            "id": "7",
            "alt_id": "Liang_et+al_2019_b",
            "entry": "[7] N. Liang, A. Damdimopoulos, S. Go\u00f1i et al., \u201cHepatocytespecific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR\u03b1,\u201d Nature Communications, vol. 10, no. 1, p. 1684, 2019.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Liang%2C%20N.%20Damdimopoulos%2C%20A.%20Go%C3%B1i%2C%20S.%20Hepatocytespecific%20loss%20of%20GPS2%20in%20mice%20reduces%20non-alcoholic%20steatohepatitis%20via%20activation%20of%20PPAR%CE%B1%2C%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Liang%2C%20N.%20Damdimopoulos%2C%20A.%20Go%C3%B1i%2C%20S.%20Hepatocytespecific%20loss%20of%20GPS2%20in%20mice%20reduces%20non-alcoholic%20steatohepatitis%20via%20activation%20of%20PPAR%CE%B1%2C%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Liang%2C%20N.%20Damdimopoulos%2C%20A.%20Go%C3%B1i%2C%20S.%20Hepatocytespecific%20loss%20of%20GPS2%20in%20mice%20reduces%20non-alcoholic%20steatohepatitis%20via%20activation%20of%20PPAR%CE%B1%2C%202019"
        },
        {
            "id": "8",
            "alt_id": "de_Vera_et+al_2017_a",
            "entry": "[8] I. M. S. de Vera, J. Zheng, S. Novick et al., \u201cSynergistic regulation of coregulator/nuclear receptor interaction by ligand and DNA,\u201d Structure, vol. 25, no. 10, pp. 1506\u20131518, 2017.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=de%20Vera%2C%20I.M.S.%20Zheng%2C%20J.%20Novick%2C%20S.%20Synergistic%20regulation%20of%20coregulator/nuclear%20receptor%20interaction%20by%20ligand%20and%20DNA%2C%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=de%20Vera%2C%20I.M.S.%20Zheng%2C%20J.%20Novick%2C%20S.%20Synergistic%20regulation%20of%20coregulator/nuclear%20receptor%20interaction%20by%20ligand%20and%20DNA%2C%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=de%20Vera%2C%20I.M.S.%20Zheng%2C%20J.%20Novick%2C%20S.%20Synergistic%20regulation%20of%20coregulator/nuclear%20receptor%20interaction%20by%20ligand%20and%20DNA%2C%202017"
        },
        {
            "id": "9",
            "alt_id": "Pascual_et+al_2005_a",
            "entry": "[9] G. Pascual, A. L. Fong, S. Ogawa et al., \u201cA SUMOylationdependent pathway mediates transrepression of inflammatory response genes by PPAR-c,\u201d Nature, vol. 437, no. 7059, pp. 759\u2013763, 2005.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Pascual%2C%20G.%20Fong%2C%20A.L.%20Ogawa%2C%20S.%20A%20SUMOylationdependent%20pathway%20mediates%20transrepression%20of%20inflammatory%20response%20genes%20by%20PPAR-c%2C%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Pascual%2C%20G.%20Fong%2C%20A.L.%20Ogawa%2C%20S.%20A%20SUMOylationdependent%20pathway%20mediates%20transrepression%20of%20inflammatory%20response%20genes%20by%20PPAR-c%2C%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Pascual%2C%20G.%20Fong%2C%20A.L.%20Ogawa%2C%20S.%20A%20SUMOylationdependent%20pathway%20mediates%20transrepression%20of%20inflammatory%20response%20genes%20by%20PPAR-c%2C%202005"
        },
        {
            "id": "10",
            "alt_id": "Konstantinopoulos_et+al_2007_a",
            "entry": "[10] P. A. Konstantinopoulos, G. P. Vandoros, G. SotiropoulouBonikou, A. Kominea, and A. G. Papavassiliou, \u201cNF-kappaB/ PPAR c and/or AP-1/PPAR c \u201con/off\u201d switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression,\u201d International Journal of Colorectal Disease, vol. 22, no. 1, pp. 57\u201368, 2007.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Konstantinopoulos%2C%20P.A.%20Vandoros%2C%20G.P.%20SotiropoulouBonikou%2C%20G.%20Kominea%2C%20A.%20Papavassiliou%2C%20%E2%80%9CNF-kappaB/%20PPAR%20c%20and/or%20AP-1/PPAR%20c%20%E2%80%9Con/off%E2%80%9D%20switches%20and%20induction%20of%20CBP%20in%20colon%20adenocarcinomas%3A%20correlation%20with%20COX-2%20expression%2C%E2%80%9D%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Konstantinopoulos%2C%20P.A.%20Vandoros%2C%20G.P.%20SotiropoulouBonikou%2C%20G.%20Kominea%2C%20A.%20Papavassiliou%2C%20%E2%80%9CNF-kappaB/%20PPAR%20c%20and/or%20AP-1/PPAR%20c%20%E2%80%9Con/off%E2%80%9D%20switches%20and%20induction%20of%20CBP%20in%20colon%20adenocarcinomas%3A%20correlation%20with%20COX-2%20expression%2C%E2%80%9D%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Konstantinopoulos%2C%20P.A.%20Vandoros%2C%20G.P.%20SotiropoulouBonikou%2C%20G.%20Kominea%2C%20A.%20Papavassiliou%2C%20%E2%80%9CNF-kappaB/%20PPAR%20c%20and/or%20AP-1/PPAR%20c%20%E2%80%9Con/off%E2%80%9D%20switches%20and%20induction%20of%20CBP%20in%20colon%20adenocarcinomas%3A%20correlation%20with%20COX-2%20expression%2C%E2%80%9D%202007"
        },
        {
            "id": "11",
            "alt_id": "Lefterova_et+al_2008_a",
            "entry": "[11] M. I. Lefterova, Y. Zhang, D. J. Steger et al., \u201cPPAR and C/ EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale,\u201d Genes & Development, vol. 22, no. 21, pp. 2941\u20132952, 2008.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lefterova%2C%20M.I.%20Zhang%2C%20Y.%20Steger%2C%20D.J.%20PPAR%20and%20C/%20EBP%20factors%20orchestrate%20adipocyte%20biology%20via%20adjacent%20binding%20on%20a%20genome-wide%20scale%2C%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lefterova%2C%20M.I.%20Zhang%2C%20Y.%20Steger%2C%20D.J.%20PPAR%20and%20C/%20EBP%20factors%20orchestrate%20adipocyte%20biology%20via%20adjacent%20binding%20on%20a%20genome-wide%20scale%2C%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lefterova%2C%20M.I.%20Zhang%2C%20Y.%20Steger%2C%20D.J.%20PPAR%20and%20C/%20EBP%20factors%20orchestrate%20adipocyte%20biology%20via%20adjacent%20binding%20on%20a%20genome-wide%20scale%2C%202008"
        },
        {
            "id": "12",
            "alt_id": "Konig_et+al_2009_a",
            "entry": "[12] B. Konig, A. Koch, J. Spielmann et al., \u201cActivation of PPAR\u03b1 and PPARc reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1,\u201d European Journal of Pharmacology, vol. 605, no. 1\u20133, pp. 23\u201330, 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Konig%2C%20B.%20Koch%2C%20A.%20Spielmann%2C%20J.%20Activation%20of%20PPAR%CE%B1%20and%20PPARc%20reduces%20triacylglycerol%20synthesis%20in%20rat%20hepatoma%20cells%20by%20reduction%20of%20nuclear%20SREBP-1%2C%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Konig%2C%20B.%20Koch%2C%20A.%20Spielmann%2C%20J.%20Activation%20of%20PPAR%CE%B1%20and%20PPARc%20reduces%20triacylglycerol%20synthesis%20in%20rat%20hepatoma%20cells%20by%20reduction%20of%20nuclear%20SREBP-1%2C%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Konig%2C%20B.%20Koch%2C%20A.%20Spielmann%2C%20J.%20Activation%20of%20PPAR%CE%B1%20and%20PPARc%20reduces%20triacylglycerol%20synthesis%20in%20rat%20hepatoma%20cells%20by%20reduction%20of%20nuclear%20SREBP-1%2C%202009"
        },
        {
            "id": "13",
            "alt_id": "Fontaine_et+al_2003_a",
            "entry": "[13] C. Fontaine, G. Dubois, Y. Duguay et al., \u201c e orphan nuclear receptor rev-Erb\u03b1 is a peroxisome proliferator-activated receptor (PPAR) c target gene and promotes PPARcinduced adipocyte differentiation,\u201d Journal of Biological Chemistry, vol. 278, no. 39, pp. 37672\u201337680, 2003.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Fontaine%2C%20C.%20Dubois%2C%20G.%20Duguay%2C%20Y.%20e%20orphan%20nuclear%20receptor%20rev-Erb%CE%B1%20is%20a%20peroxisome%20proliferator-activated%20receptor%20%28PPAR%29%20c%20target%20gene%20and%20promotes%20PPARcinduced%20adipocyte%20differentiation%2C%202003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Fontaine%2C%20C.%20Dubois%2C%20G.%20Duguay%2C%20Y.%20e%20orphan%20nuclear%20receptor%20rev-Erb%CE%B1%20is%20a%20peroxisome%20proliferator-activated%20receptor%20%28PPAR%29%20c%20target%20gene%20and%20promotes%20PPARcinduced%20adipocyte%20differentiation%2C%202003",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Fontaine%2C%20C.%20Dubois%2C%20G.%20Duguay%2C%20Y.%20e%20orphan%20nuclear%20receptor%20rev-Erb%CE%B1%20is%20a%20peroxisome%20proliferator-activated%20receptor%20%28PPAR%29%20c%20target%20gene%20and%20promotes%20PPARcinduced%20adipocyte%20differentiation%2C%202003"
        },
        {
            "id": "14",
            "alt_id": "Cipolletta_et+al_2012_a",
            "entry": "[14] D. Cipolletta, M. Feuerer, A. Li et al., \u201cPPAR-c is a major driver of the accumulation and phenotype of adipose tissue Treg cells,\u201d Nature, vol. 486, no. 7404, pp. 549\u2013553, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Cipolletta%2C%20D.%20Feuerer%2C%20M.%20Li%2C%20A.%20PPAR-c%20is%20a%20major%20driver%20of%20the%20accumulation%20and%20phenotype%20of%20adipose%20tissue%20Treg%20cells%2C%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Cipolletta%2C%20D.%20Feuerer%2C%20M.%20Li%2C%20A.%20PPAR-c%20is%20a%20major%20driver%20of%20the%20accumulation%20and%20phenotype%20of%20adipose%20tissue%20Treg%20cells%2C%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Cipolletta%2C%20D.%20Feuerer%2C%20M.%20Li%2C%20A.%20PPAR-c%20is%20a%20major%20driver%20of%20the%20accumulation%20and%20phenotype%20of%20adipose%20tissue%20Treg%20cells%2C%202012"
        },
        {
            "id": "15",
            "alt_id": "Cheng_et+al_2019_a",
            "entry": "[15] S. Cheng, K. Qian, Y. Wang et al., \u201cPPARc inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells,\u201d Journal of Cellular and Molecular Medicine, vol. 23, no. 5, pp. 3724\u20133736, 2019.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Cheng%2C%20S.%20Qian%2C%20K.%20Wang%2C%20Y.%20PPARc%20inhibition%20regulates%20the%20cell%20cycle%2C%20proliferation%20and%20motility%20of%20bladder%20cancer%20cells%2C%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Cheng%2C%20S.%20Qian%2C%20K.%20Wang%2C%20Y.%20PPARc%20inhibition%20regulates%20the%20cell%20cycle%2C%20proliferation%20and%20motility%20of%20bladder%20cancer%20cells%2C%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Cheng%2C%20S.%20Qian%2C%20K.%20Wang%2C%20Y.%20PPARc%20inhibition%20regulates%20the%20cell%20cycle%2C%20proliferation%20and%20motility%20of%20bladder%20cancer%20cells%2C%202019"
        },
        {
            "id": "16",
            "alt_id": "Gilardi_et+al_2019_a",
            "entry": "[16] F. Gilardi, C. Winkler, L. Quignodon et al., \u201cSystemic PPARc deletion in mice provokes lipoatrophy, organomegaly, severe type 2 diabetes and metabolic inflexibility,\u201d Metabolism, vol. 95, pp. 8\u201320, 2019.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Gilardi%2C%20F.%20Winkler%2C%20C.%20Quignodon%2C%20L.%20Systemic%20PPARc%20deletion%20in%20mice%20provokes%20lipoatrophy%2C%20organomegaly%2C%20severe%20type%202%20diabetes%20and%20metabolic%20inflexibility%2C%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Gilardi%2C%20F.%20Winkler%2C%20C.%20Quignodon%2C%20L.%20Systemic%20PPARc%20deletion%20in%20mice%20provokes%20lipoatrophy%2C%20organomegaly%2C%20severe%20type%202%20diabetes%20and%20metabolic%20inflexibility%2C%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Gilardi%2C%20F.%20Winkler%2C%20C.%20Quignodon%2C%20L.%20Systemic%20PPARc%20deletion%20in%20mice%20provokes%20lipoatrophy%2C%20organomegaly%2C%20severe%20type%202%20diabetes%20and%20metabolic%20inflexibility%2C%202019"
        },
        {
            "id": "17",
            "alt_id": "Demir_et+al_2016_a",
            "entry": "[17] T. Demir, H. Onay, D. B. Savage et al., \u201cFamilial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -c (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations,\u201d Diabetic Medicine, vol. 33, no. 10, pp. 1445\u20131450, 2016.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Demir%2C%20T.%20Onay%2C%20H.%20Savage%2C%20D.B.%20Familial%20partial%20lipodystrophy%20linked%20to%20a%20novel%20peroxisome%20proliferator%20activator%20receptor%20-c%20%28PPARG%29%20mutation%2C%20H449L%3A%20a%20comparison%20of%20people%20with%20this%20mutation%20and%20those%20with%20classic%20codon%20482%20Lamin%20A/C%20%28LMNA%29%20mutations%2C%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Demir%2C%20T.%20Onay%2C%20H.%20Savage%2C%20D.B.%20Familial%20partial%20lipodystrophy%20linked%20to%20a%20novel%20peroxisome%20proliferator%20activator%20receptor%20-c%20%28PPARG%29%20mutation%2C%20H449L%3A%20a%20comparison%20of%20people%20with%20this%20mutation%20and%20those%20with%20classic%20codon%20482%20Lamin%20A/C%20%28LMNA%29%20mutations%2C%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Demir%2C%20T.%20Onay%2C%20H.%20Savage%2C%20D.B.%20Familial%20partial%20lipodystrophy%20linked%20to%20a%20novel%20peroxisome%20proliferator%20activator%20receptor%20-c%20%28PPARG%29%20mutation%2C%20H449L%3A%20a%20comparison%20of%20people%20with%20this%20mutation%20and%20those%20with%20classic%20codon%20482%20Lamin%20A/C%20%28LMNA%29%20mutations%2C%202016"
        },
        {
            "id": "18",
            "alt_id": "Gu_et+al_2014_a",
            "entry": "[18] S.-J. Gu, Z.-R. Guo, Z.-Y. Zhou, X.-S. Hu, M. Wu, and N. Zhang, \u201cPeroxisome proliferator-activated receptor c polymorphisms as risk factors for dyslipidemia,\u201d Molecular Medicine Reports, vol. 10, no. 5, pp. 2759\u20132763, 2014.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Gu%2C%20S.-J.%20Guo%2C%20Z.-R.%20Zhou%2C%20Z.-Y.%20Hu%2C%20X.-S.%20Peroxisome%20proliferator-activated%20receptor%20c%20polymorphisms%20as%20risk%20factors%20for%20dyslipidemia%2C%202014",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Gu%2C%20S.-J.%20Guo%2C%20Z.-R.%20Zhou%2C%20Z.-Y.%20Hu%2C%20X.-S.%20Peroxisome%20proliferator-activated%20receptor%20c%20polymorphisms%20as%20risk%20factors%20for%20dyslipidemia%2C%202014",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Gu%2C%20S.-J.%20Guo%2C%20Z.-R.%20Zhou%2C%20Z.-Y.%20Hu%2C%20X.-S.%20Peroxisome%20proliferator-activated%20receptor%20c%20polymorphisms%20as%20risk%20factors%20for%20dyslipidemia%2C%202014"
        },
        {
            "id": "19",
            "alt_id": "Yang_et+al_1999_a",
            "entry": "[19] T. Yang, D. E. Michele, J. Park et al., \u201cExpression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney,\u201d American Journal of PhysiologyRenal Physiology, vol. 277, no. 6, pp. F966\u2013F973, 1999.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Yang%2C%20T.%20Michele%2C%20D.E.%20Park%2C%20J.%20Expression%20of%20peroxisomal%20proliferator-activated%20receptors%20and%20retinoid%20X%20receptors%20in%20the%20kidney%2C%201999",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Yang%2C%20T.%20Michele%2C%20D.E.%20Park%2C%20J.%20Expression%20of%20peroxisomal%20proliferator-activated%20receptors%20and%20retinoid%20X%20receptors%20in%20the%20kidney%2C%201999",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Yang%2C%20T.%20Michele%2C%20D.E.%20Park%2C%20J.%20Expression%20of%20peroxisomal%20proliferator-activated%20receptors%20and%20retinoid%20X%20receptors%20in%20the%20kidney%2C%201999"
        },
        {
            "id": "20",
            "alt_id": "Kiss-Toth_2008_a",
            "entry": "[20] E. Kiss-Toth and T. Roszer, \u201cPPARc in kidney physiology and pathophysiology,\u201d PPAR Research, vol. 2008, Article ID 183108, 9 pages, 2008.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kiss-Toth%2C%20E.%20Roszer%2C%20T.%20PPARc%20in%20kidney%20physiology%20and%20pathophysiology%2C%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kiss-Toth%2C%20E.%20Roszer%2C%20T.%20PPARc%20in%20kidney%20physiology%20and%20pathophysiology%2C%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kiss-Toth%2C%20E.%20Roszer%2C%20T.%20PPARc%20in%20kidney%20physiology%20and%20pathophysiology%2C%202008"
        },
        {
            "id": "21",
            "alt_id": "Corrales_et+al_2018_a",
            "entry": "[21] P. Corrales, A. Izquierdo-Lahuerta, and G. Medina-Gomez, \u201cMaintenance of kidney metabolic homeostasis by PPAR c,\u201d International Journal of Molecular Sciences, vol. 19, no. 7, p. 2063, 2018.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Corrales%2C%20P.%20Izquierdo-Lahuerta%2C%20A.%20G.%20Medina-Gomez%2C%20%E2%80%9CMaintenance%20of%20kidney%20metabolic%20homeostasis%20by%20PPAR%20c%2C%E2%80%9D%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Corrales%2C%20P.%20Izquierdo-Lahuerta%2C%20A.%20G.%20Medina-Gomez%2C%20%E2%80%9CMaintenance%20of%20kidney%20metabolic%20homeostasis%20by%20PPAR%20c%2C%E2%80%9D%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Corrales%2C%20P.%20Izquierdo-Lahuerta%2C%20A.%20G.%20Medina-Gomez%2C%20%E2%80%9CMaintenance%20of%20kidney%20metabolic%20homeostasis%20by%20PPAR%20c%2C%E2%80%9D%202018"
        },
        {
            "id": "22",
            "alt_id": "Desch_et+al_2010_a",
            "entry": "[22] M. Desch, A. Schreiber, F. Schweda et al., \u201cIncreased renin production in mice with deletion of peroxisome proliferatoractivated receptor-c in juxtaglomerular cells,\u201d Hypertension, vol. 55, no. 3, pp. 660\u2013666, 2010.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Desch%2C%20M.%20Schreiber%2C%20A.%20Schweda%2C%20F.%20Increased%20renin%20production%20in%20mice%20with%20deletion%20of%20peroxisome%20proliferatoractivated%20receptor-c%20in%20juxtaglomerular%20cells%2C%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Desch%2C%20M.%20Schreiber%2C%20A.%20Schweda%2C%20F.%20Increased%20renin%20production%20in%20mice%20with%20deletion%20of%20peroxisome%20proliferatoractivated%20receptor-c%20in%20juxtaglomerular%20cells%2C%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Desch%2C%20M.%20Schreiber%2C%20A.%20Schweda%2C%20F.%20Increased%20renin%20production%20in%20mice%20with%20deletion%20of%20peroxisome%20proliferatoractivated%20receptor-c%20in%20juxtaglomerular%20cells%2C%202010"
        },
        {
            "id": "23",
            "alt_id": "Zhang_et+al_2005_a",
            "entry": "[23] H. Zhang, A. Zhang, D. E. Kohan, R. D. Nelson, F. J. Gonzalez, and T. Yang, \u201cCollecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention,\u201d Proceedings of the National Academy of Sciences, vol. 102, no. 26, pp. 9406\u20139411, 2005.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhang%2C%20H.%20Zhang%2C%20A.%20Kohan%2C%20D.E.%20Nelson%2C%20R.D.%20Collecting%20duct-specific%20deletion%20of%20peroxisome%20proliferator-activated%20receptor%20gamma%20blocks%20thiazolidinedione-induced%20fluid%20retention%2C%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhang%2C%20H.%20Zhang%2C%20A.%20Kohan%2C%20D.E.%20Nelson%2C%20R.D.%20Collecting%20duct-specific%20deletion%20of%20peroxisome%20proliferator-activated%20receptor%20gamma%20blocks%20thiazolidinedione-induced%20fluid%20retention%2C%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhang%2C%20H.%20Zhang%2C%20A.%20Kohan%2C%20D.E.%20Nelson%2C%20R.D.%20Collecting%20duct-specific%20deletion%20of%20peroxisome%20proliferator-activated%20receptor%20gamma%20blocks%20thiazolidinedione-induced%20fluid%20retention%2C%202005"
        },
        {
            "id": "24",
            "alt_id": "Chafin_et+al_2010_a",
            "entry": "[24] C. Chafin, S. Muse, R. Hontecillas et al., \u201cDeletion of PPARc; in immune cells enhances susceptibility to antiglomerular basement membrane disease,\u201d Journal of Inflammation Research, vol. 3, pp. 127\u2013134, 2010.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Chafin%2C%20C.%20Muse%2C%20S.%20Hontecillas%2C%20R.%20Deletion%20of%20PPARc%3B%20in%20immune%20cells%20enhances%20susceptibility%20to%20antiglomerular%20basement%20membrane%20disease%2C%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Chafin%2C%20C.%20Muse%2C%20S.%20Hontecillas%2C%20R.%20Deletion%20of%20PPARc%3B%20in%20immune%20cells%20enhances%20susceptibility%20to%20antiglomerular%20basement%20membrane%20disease%2C%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Chafin%2C%20C.%20Muse%2C%20S.%20Hontecillas%2C%20R.%20Deletion%20of%20PPARc%3B%20in%20immune%20cells%20enhances%20susceptibility%20to%20antiglomerular%20basement%20membrane%20disease%2C%202010"
        },
        {
            "id": "25",
            "alt_id": "Toffoli_et+al_2017_a",
            "entry": "[25] B. Toffoli, F. Gilardi, C. Winkler et al., \u201cNephropathy in Pparg-null mice highlights PPARc systemic activities in metabolism and in the immune system,\u201d PLoS One, vol. 12, no. 2, Article ID e0171474, 2017.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Toffoli%2C%20B.%20Gilardi%2C%20F.%20Winkler%2C%20C.%20Nephropathy%20in%20Pparg-null%20mice%20highlights%20PPARc%20systemic%20activities%20in%20metabolism%20and%20in%20the%20immune%20system%2C%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Toffoli%2C%20B.%20Gilardi%2C%20F.%20Winkler%2C%20C.%20Nephropathy%20in%20Pparg-null%20mice%20highlights%20PPARc%20systemic%20activities%20in%20metabolism%20and%20in%20the%20immune%20system%2C%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Toffoli%2C%20B.%20Gilardi%2C%20F.%20Winkler%2C%20C.%20Nephropathy%20in%20Pparg-null%20mice%20highlights%20PPARc%20systemic%20activities%20in%20metabolism%20and%20in%20the%20immune%20system%2C%202017"
        },
        {
            "id": "26",
            "alt_id": "Yang_et+al_2012_a",
            "entry": "[26] G. Yang, Z. Jia, T. Aoyagi, D. McClain, R. M. Mortensen, and T. Yang, \u201cSystemic PPARc deletion impairs circadian rhythms of behavior and metabolism,\u201d PLoS One, vol. 7, no. 8, Article ID e38117, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Yang%2C%20G.%20Jia%2C%20Z.%20Aoyagi%2C%20T.%20McClain%2C%20D.%20Systemic%20PPARc%20deletion%20impairs%20circadian%20rhythms%20of%20behavior%20and%20metabolism%2C%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Yang%2C%20G.%20Jia%2C%20Z.%20Aoyagi%2C%20T.%20McClain%2C%20D.%20Systemic%20PPARc%20deletion%20impairs%20circadian%20rhythms%20of%20behavior%20and%20metabolism%2C%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Yang%2C%20G.%20Jia%2C%20Z.%20Aoyagi%2C%20T.%20McClain%2C%20D.%20Systemic%20PPARc%20deletion%20impairs%20circadian%20rhythms%20of%20behavior%20and%20metabolism%2C%202012"
        },
        {
            "id": "27",
            "alt_id": "Zhou_et+al_2015_a",
            "entry": "[27] L. Zhou, A. Panasiuk, M. Downton et al., \u201cSystemic PPARc deletion causes severe disturbance in fluid homeostasis in mice,\u201d Physiological Genomics, vol. 47, no. 11, pp. 541\u2013547, 2015.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhou%2C%20L.%20Panasiuk%2C%20A.%20Downton%2C%20M.%20Systemic%20PPARc%20deletion%20causes%20severe%20disturbance%20in%20fluid%20homeostasis%20in%20mice%2C%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhou%2C%20L.%20Panasiuk%2C%20A.%20Downton%2C%20M.%20Systemic%20PPARc%20deletion%20causes%20severe%20disturbance%20in%20fluid%20homeostasis%20in%20mice%2C%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhou%2C%20L.%20Panasiuk%2C%20A.%20Downton%2C%20M.%20Systemic%20PPARc%20deletion%20causes%20severe%20disturbance%20in%20fluid%20homeostasis%20in%20mice%2C%202015"
        },
        {
            "id": "28",
            "alt_id": "Yang_et+al_2009_a",
            "entry": "[28] H.-C. Yang, S. Deleuze, Y. Zuo, S. A. Potthoff, L.-J. Ma, and A. B. Fogo, \u201c e PPARc agonist pioglitazone ameliorates aging-related progressive renal injury,\u201d Journal of the American Society of Nephrology, vol. 20, no. 11, pp. 2380\u20132388, 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Yang%2C%20H.-C.%20Deleuze%2C%20S.%20Zuo%2C%20Y.%20Potthoff%2C%20S.A.%20e%20PPARc%20agonist%20pioglitazone%20ameliorates%20aging-related%20progressive%20renal%20injury%2C%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Yang%2C%20H.-C.%20Deleuze%2C%20S.%20Zuo%2C%20Y.%20Potthoff%2C%20S.A.%20e%20PPARc%20agonist%20pioglitazone%20ameliorates%20aging-related%20progressive%20renal%20injury%2C%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Yang%2C%20H.-C.%20Deleuze%2C%20S.%20Zuo%2C%20Y.%20Potthoff%2C%20S.A.%20e%20PPARc%20agonist%20pioglitazone%20ameliorates%20aging-related%20progressive%20renal%20injury%2C%202009"
        },
        {
            "id": "29",
            "alt_id": "Ko_et+al_2008_a",
            "entry": "[29] G. J. Ko, Y. S. Kang, S. Y. Han et al., \u201cPioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats,\u201d Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2750\u20132760, 2008.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Ko%2C%20G.J.%20Kang%2C%20Y.S.%20Han%2C%20S.Y.%20Pioglitazone%20attenuates%20diabetic%20nephropathy%20through%20an%20anti-inflammatory%20mechanism%20in%20type%202%20diabetic%20rats%2C%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Ko%2C%20G.J.%20Kang%2C%20Y.S.%20Han%2C%20S.Y.%20Pioglitazone%20attenuates%20diabetic%20nephropathy%20through%20an%20anti-inflammatory%20mechanism%20in%20type%202%20diabetic%20rats%2C%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Ko%2C%20G.J.%20Kang%2C%20Y.S.%20Han%2C%20S.Y.%20Pioglitazone%20attenuates%20diabetic%20nephropathy%20through%20an%20anti-inflammatory%20mechanism%20in%20type%202%20diabetic%20rats%2C%202008"
        },
        {
            "id": "30",
            "alt_id": "Isshiki_et+al_2000_a",
            "entry": "[30] K. Isshiki, M. Haneda, D. Koya, S. Maeda, T. Sugimoto, and R. Kikkawa, \u201c iazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats,\u201d Diabetes, vol. 49, no. 6, pp. 1022\u20131032, 2000.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Isshiki%2C%20K.%20Haneda%2C%20M.%20Koya%2C%20D.%20Maeda%2C%20S.%20iazolidinedione%20compounds%20ameliorate%20glomerular%20dysfunction%20independent%20of%20their%20insulin-sensitizing%20action%20in%20diabetic%20rats%2C%202000",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Isshiki%2C%20K.%20Haneda%2C%20M.%20Koya%2C%20D.%20Maeda%2C%20S.%20iazolidinedione%20compounds%20ameliorate%20glomerular%20dysfunction%20independent%20of%20their%20insulin-sensitizing%20action%20in%20diabetic%20rats%2C%202000",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Isshiki%2C%20K.%20Haneda%2C%20M.%20Koya%2C%20D.%20Maeda%2C%20S.%20iazolidinedione%20compounds%20ameliorate%20glomerular%20dysfunction%20independent%20of%20their%20insulin-sensitizing%20action%20in%20diabetic%20rats%2C%202000"
        },
        {
            "id": "31",
            "alt_id": "Efrati_et+al_2009_a",
            "entry": "[31] S. Efrati, S. Berman, A. Chachashvili et al., \u201cRosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction,\u201d Nephrology, vol. 14, no. 2, pp. 189\u2013197, 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Efrati%2C%20S.%20Berman%2C%20S.%20Chachashvili%2C%20A.%20Rosiglitazone%20treatment%20attenuates%20renal%20tissue%20inflammation%20generated%20by%20urinary%20tract%20obstruction%2C%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Efrati%2C%20S.%20Berman%2C%20S.%20Chachashvili%2C%20A.%20Rosiglitazone%20treatment%20attenuates%20renal%20tissue%20inflammation%20generated%20by%20urinary%20tract%20obstruction%2C%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Efrati%2C%20S.%20Berman%2C%20S.%20Chachashvili%2C%20A.%20Rosiglitazone%20treatment%20attenuates%20renal%20tissue%20inflammation%20generated%20by%20urinary%20tract%20obstruction%2C%202009"
        },
        {
            "id": "32",
            "alt_id": "Kawai_et+al_2009_a",
            "entry": "[32] T. Kawai, T. Masaki, S. Doi et al., \u201cPPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta,\u201d Laboratory Investigation, vol. 89, no. 1, pp. 47\u201358, 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kawai%2C%20T.%20Masaki%2C%20T.%20Doi%2C%20S.%20PPAR-gamma%20agonist%20attenuates%20renal%20interstitial%20fibrosis%20and%20inflammation%20through%20reduction%20of%20TGF-beta%2C%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kawai%2C%20T.%20Masaki%2C%20T.%20Doi%2C%20S.%20PPAR-gamma%20agonist%20attenuates%20renal%20interstitial%20fibrosis%20and%20inflammation%20through%20reduction%20of%20TGF-beta%2C%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kawai%2C%20T.%20Masaki%2C%20T.%20Doi%2C%20S.%20PPAR-gamma%20agonist%20attenuates%20renal%20interstitial%20fibrosis%20and%20inflammation%20through%20reduction%20of%20TGF-beta%2C%202009"
        },
        {
            "id": "33",
            "alt_id": "Okada_et+al_2006_a",
            "entry": "[33] T. Okada, J. Wada, K. Hida et al., \u201c iazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms,\u201d Diabetes, vol. 55, no. 6, pp. 1666\u20131677, 2006.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Okada%2C%20T.%20Wada%2C%20J.%20Hida%2C%20K.%20iazolidinediones%20ameliorate%20diabetic%20nephropathy%20via%20cell%20cycle-dependent%20mechanisms%2C%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Okada%2C%20T.%20Wada%2C%20J.%20Hida%2C%20K.%20iazolidinediones%20ameliorate%20diabetic%20nephropathy%20via%20cell%20cycle-dependent%20mechanisms%2C%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Okada%2C%20T.%20Wada%2C%20J.%20Hida%2C%20K.%20iazolidinediones%20ameliorate%20diabetic%20nephropathy%20via%20cell%20cycle-dependent%20mechanisms%2C%202006"
        },
        {
            "id": "34",
            "alt_id": "Ghosh_et+al_2003_a",
            "entry": "[34] S. S. Ghosh, T. W. B. Gehr, S. Ghosh et al., \u201cPPARc ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase,\u201d Kidney International, vol. 64, no. 1, pp. 52\u201362, 2003.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Ghosh%2C%20S.S.%20Gehr%2C%20T.W.B.%20Ghosh%2C%20S.%20PPARc%20ligand%20attenuates%20PDGF-induced%20mesangial%20cell%20proliferation%3A%20role%20of%20MAP%20kinase%2C%202003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Ghosh%2C%20S.S.%20Gehr%2C%20T.W.B.%20Ghosh%2C%20S.%20PPARc%20ligand%20attenuates%20PDGF-induced%20mesangial%20cell%20proliferation%3A%20role%20of%20MAP%20kinase%2C%202003",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Ghosh%2C%20S.S.%20Gehr%2C%20T.W.B.%20Ghosh%2C%20S.%20PPARc%20ligand%20attenuates%20PDGF-induced%20mesangial%20cell%20proliferation%3A%20role%20of%20MAP%20kinase%2C%202003"
        },
        {
            "id": "35",
            "alt_id": "Weissgarten_et+al_2006_a",
            "entry": "[35] J. Weissgarten, S. Berman, S. Efrati, M. Rapoport, Z. Averbukh, and L. Feldman, \u201cApoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats,\u201d Nephrology Dialysis Transplantation, vol. 21, no. 5, pp. 1198\u20131204, 2006.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Weissgarten%2C%20J.%20Berman%2C%20S.%20Efrati%2C%20S.%20Rapoport%2C%20M.%20Apoptosis%20and%20proliferation%20of%20cultured%20mesangial%20cells%20isolated%20from%20kidneys%20of%20rosiglitazone-treated%20pregnant%20diabetic%20rats%2C%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Weissgarten%2C%20J.%20Berman%2C%20S.%20Efrati%2C%20S.%20Rapoport%2C%20M.%20Apoptosis%20and%20proliferation%20of%20cultured%20mesangial%20cells%20isolated%20from%20kidneys%20of%20rosiglitazone-treated%20pregnant%20diabetic%20rats%2C%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Weissgarten%2C%20J.%20Berman%2C%20S.%20Efrati%2C%20S.%20Rapoport%2C%20M.%20Apoptosis%20and%20proliferation%20of%20cultured%20mesangial%20cells%20isolated%20from%20kidneys%20of%20rosiglitazone-treated%20pregnant%20diabetic%20rats%2C%202006"
        },
        {
            "id": "36",
            "alt_id": "Kanjanabuch_et+al_2007_a",
            "entry": "[36] T. Kanjanabuch, L. J. Ma, J. Chen et al., \u201cPPAR-gamma agonist protects podocytes from injury,\u201d Kidney International, vol. 71, no. 12, pp. 1232\u20131239, 2007.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kanjanabuch%2C%20T.%20Ma%2C%20L.J.%20Chen%2C%20J.%20PPAR-gamma%20agonist%20protects%20podocytes%20from%20injury%2C%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kanjanabuch%2C%20T.%20Ma%2C%20L.J.%20Chen%2C%20J.%20PPAR-gamma%20agonist%20protects%20podocytes%20from%20injury%2C%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kanjanabuch%2C%20T.%20Ma%2C%20L.J.%20Chen%2C%20J.%20PPAR-gamma%20agonist%20protects%20podocytes%20from%20injury%2C%202007"
        },
        {
            "id": "37",
            "alt_id": "Artwohl_et+al_2005_a",
            "entry": "[37] M. Artwohl, T. Holzenbein, C. Furnsinn et al., \u201c iazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells,\u201d rombosis and Haemostasis, vol. 93, no. 5, pp. 810\u2013815, 2005.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Artwohl%2C%20M.%20Holzenbein%2C%20T.%20Furnsinn%2C%20C.%20iazolidinediones%20inhibit%20apoptosis%20and%20heat%20shock%20protein%2060%20expression%20in%20human%20vascular%20endothelial%20cells%2C%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Artwohl%2C%20M.%20Holzenbein%2C%20T.%20Furnsinn%2C%20C.%20iazolidinediones%20inhibit%20apoptosis%20and%20heat%20shock%20protein%2060%20expression%20in%20human%20vascular%20endothelial%20cells%2C%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Artwohl%2C%20M.%20Holzenbein%2C%20T.%20Furnsinn%2C%20C.%20iazolidinediones%20inhibit%20apoptosis%20and%20heat%20shock%20protein%2060%20expression%20in%20human%20vascular%20endothelial%20cells%2C%202005"
        },
        {
            "id": "38",
            "alt_id": "Carrero_et+al_2008_a",
            "entry": "[38] J. J. Carrero, M. I. Yilmaz, B. Lindholm, and P. Stenvinkel, \u201cCytokine dysregulation in chronic kidney disease: how can we treat it?,\u201d Blood Purification, vol. 26, no. 3, pp. 291\u2013299, 2008.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Carrero%2C%20J.J.%20Yilmaz%2C%20M.I.%20Lindholm%2C%20B.%20Stenvinkel%2C%20P.%20Cytokine%20dysregulation%20in%20chronic%20kidney%20disease%3A%20how%20can%20we%20treat%20it%3F%2C%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Carrero%2C%20J.J.%20Yilmaz%2C%20M.I.%20Lindholm%2C%20B.%20Stenvinkel%2C%20P.%20Cytokine%20dysregulation%20in%20chronic%20kidney%20disease%3A%20how%20can%20we%20treat%20it%3F%2C%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Carrero%2C%20J.J.%20Yilmaz%2C%20M.I.%20Lindholm%2C%20B.%20Stenvinkel%2C%20P.%20Cytokine%20dysregulation%20in%20chronic%20kidney%20disease%3A%20how%20can%20we%20treat%20it%3F%2C%202008"
        },
        {
            "id": "39",
            "alt_id": "Panzer_et+al_2008_a",
            "entry": "[39] U. Panzer, G. Zahner, U. Wienberg et al., \u201c15-Deoxy- 12,14prostaglandin J2 inhibits INF- -induced JAK/STAT1 signalling pathway activation and IP-10/CXCL10 expression in mesangial cells,\u201d Nephrology Dialysis Transplantation, vol. 23, no. 12, pp. 3776\u20133785, 2008.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Panzer%2C%20U.%20Zahner%2C%20G.%20Wienberg%2C%20U.%2015-Deoxy-%2012%2C14prostaglandin%20J2%20inhibits%20INF-%20-induced%20JAK/STAT1%20signalling%20pathway%20activation%20and%20IP-10/CXCL10%20expression%20in%20mesangial%20cells%2C%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Panzer%2C%20U.%20Zahner%2C%20G.%20Wienberg%2C%20U.%2015-Deoxy-%2012%2C14prostaglandin%20J2%20inhibits%20INF-%20-induced%20JAK/STAT1%20signalling%20pathway%20activation%20and%20IP-10/CXCL10%20expression%20in%20mesangial%20cells%2C%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Panzer%2C%20U.%20Zahner%2C%20G.%20Wienberg%2C%20U.%2015-Deoxy-%2012%2C14prostaglandin%20J2%20inhibits%20INF-%20-induced%20JAK/STAT1%20signalling%20pathway%20activation%20and%20IP-10/CXCL10%20expression%20in%20mesangial%20cells%2C%202008"
        },
        {
            "id": "40",
            "alt_id": "Lu_et+al_2013_a",
            "entry": "[40] Y. Lu, Q. Zhou, Y. Shi et al., \u201cSUMOylation of PPARc by rosiglitazone prevents LPS-induced NCoR degradation mediating down regulation of chemokines expression in renal proximal tubular cells,\u201d PLoS One, vol. 8, no. 11, Article ID e79815, 2013.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lu%2C%20Y.%20Zhou%2C%20Q.%20Shi%2C%20Y.%20SUMOylation%20of%20PPARc%20by%20rosiglitazone%20prevents%20LPS-induced%20NCoR%20degradation%20mediating%20down%20regulation%20of%20chemokines%20expression%20in%20renal%20proximal%20tubular%20cells%2C%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lu%2C%20Y.%20Zhou%2C%20Q.%20Shi%2C%20Y.%20SUMOylation%20of%20PPARc%20by%20rosiglitazone%20prevents%20LPS-induced%20NCoR%20degradation%20mediating%20down%20regulation%20of%20chemokines%20expression%20in%20renal%20proximal%20tubular%20cells%2C%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lu%2C%20Y.%20Zhou%2C%20Q.%20Shi%2C%20Y.%20SUMOylation%20of%20PPARc%20by%20rosiglitazone%20prevents%20LPS-induced%20NCoR%20degradation%20mediating%20down%20regulation%20of%20chemokines%20expression%20in%20renal%20proximal%20tubular%20cells%2C%202013"
        },
        {
            "id": "41",
            "alt_id": "Xiao_et+al_2009_a",
            "entry": "[41] J. Xiao, J. C. K. Leung, L. Y. Y. Chan, H. Guo, and K. N. Lai, \u201cProtective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy,\u201d Nephrology Dialysis Transplantation, vol. 24, no. 7, pp. 2067\u20132077, 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Xiao%2C%20J.%20Leung%2C%20J.C.K.%20Chan%2C%20L.Y.Y.%20Guo%2C%20H.%20Protective%20effect%20of%20peroxisome%20proliferator-activated%20receptor-gamma%20agonists%20on%20activated%20renal%20proximal%20tubular%20epithelial%20cells%20in%20IgA%20nephropathy%2C%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Xiao%2C%20J.%20Leung%2C%20J.C.K.%20Chan%2C%20L.Y.Y.%20Guo%2C%20H.%20Protective%20effect%20of%20peroxisome%20proliferator-activated%20receptor-gamma%20agonists%20on%20activated%20renal%20proximal%20tubular%20epithelial%20cells%20in%20IgA%20nephropathy%2C%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Xiao%2C%20J.%20Leung%2C%20J.C.K.%20Chan%2C%20L.Y.Y.%20Guo%2C%20H.%20Protective%20effect%20of%20peroxisome%20proliferator-activated%20receptor-gamma%20agonists%20on%20activated%20renal%20proximal%20tubular%20epithelial%20cells%20in%20IgA%20nephropathy%2C%202009"
        },
        {
            "id": "42",
            "alt_id": "Henique_et+al_2016_a",
            "entry": "[42] C. Henique, G. Bollee, O. Lenoir et al., \u201cNuclear factor erythroid 2-related factor 2 drives podocyte-specific expression of peroxisome proliferator-activated receptor c essential for resistance to crescentic GN,\u201d Journal of the American Society of Nephrology, vol. 27, no. 1, pp. 172\u2013188, 2016.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Henique%2C%20C.%20Bollee%2C%20G.%20Lenoir%2C%20O.%20Nuclear%20factor%20erythroid%202-related%20factor%202%20drives%20podocyte-specific%20expression%20of%20peroxisome%20proliferator-activated%20receptor%20c%20essential%20for%20resistance%20to%20crescentic%20GN%2C%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Henique%2C%20C.%20Bollee%2C%20G.%20Lenoir%2C%20O.%20Nuclear%20factor%20erythroid%202-related%20factor%202%20drives%20podocyte-specific%20expression%20of%20peroxisome%20proliferator-activated%20receptor%20c%20essential%20for%20resistance%20to%20crescentic%20GN%2C%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Henique%2C%20C.%20Bollee%2C%20G.%20Lenoir%2C%20O.%20Nuclear%20factor%20erythroid%202-related%20factor%202%20drives%20podocyte-specific%20expression%20of%20peroxisome%20proliferator-activated%20receptor%20c%20essential%20for%20resistance%20to%20crescentic%20GN%2C%202016"
        },
        {
            "id": "43",
            "alt_id": "Wu_et+al_2009_a",
            "entry": "[43] M. Wu, D. S. Melichian, E. Chang, M. Warner-Blankenship, A. K. Ghosh, and J. Varga, \u201cRosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptorc,\u201d e American Journal of Pathology, vol. 174, no. 2, pp. 519\u2013533, 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wu%2C%20M.%20Melichian%2C%20D.S.%20Chang%2C%20E.%20Warner-Blankenship%2C%20M.%20Rosiglitazone%20abrogates%20bleomycin-induced%20scleroderma%20and%20blocks%20profibrotic%20responses%20through%20peroxisome%20proliferator-activated%20receptorc%2C%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Wu%2C%20M.%20Melichian%2C%20D.S.%20Chang%2C%20E.%20Warner-Blankenship%2C%20M.%20Rosiglitazone%20abrogates%20bleomycin-induced%20scleroderma%20and%20blocks%20profibrotic%20responses%20through%20peroxisome%20proliferator-activated%20receptorc%2C%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Wu%2C%20M.%20Melichian%2C%20D.S.%20Chang%2C%20E.%20Warner-Blankenship%2C%20M.%20Rosiglitazone%20abrogates%20bleomycin-induced%20scleroderma%20and%20blocks%20profibrotic%20responses%20through%20peroxisome%20proliferator-activated%20receptorc%2C%202009"
        },
        {
            "id": "44",
            "alt_id": "Zheng_et+al_2002_a",
            "entry": "[44] F. Zheng, A. Fornoni, S. J. Elliot et al., \u201cUpregulation of type I collagen by TGF-\u03b2 in mesangial cells is blocked by PPARc activation,\u201d American Journal of Physiology-Renal Physiology, vol. 282, no. 4, pp. F639\u2013F648, 2002.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zheng%2C%20F.%20Fornoni%2C%20A.%20Elliot%2C%20S.J.%20Upregulation%20of%20type%20I%20collagen%20by%20TGF-%CE%B2%20in%20mesangial%20cells%20is%20blocked%20by%20PPARc%20activation%2C%202002",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zheng%2C%20F.%20Fornoni%2C%20A.%20Elliot%2C%20S.J.%20Upregulation%20of%20type%20I%20collagen%20by%20TGF-%CE%B2%20in%20mesangial%20cells%20is%20blocked%20by%20PPARc%20activation%2C%202002",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zheng%2C%20F.%20Fornoni%2C%20A.%20Elliot%2C%20S.J.%20Upregulation%20of%20type%20I%20collagen%20by%20TGF-%CE%B2%20in%20mesangial%20cells%20is%20blocked%20by%20PPARc%20activation%2C%202002"
        },
        {
            "id": "45",
            "alt_id": "Ma_et+al_2001_a",
            "entry": "[45] L.-J. Ma, C. Marcantoni, M. F. Linton, S. Fazio, and A. B. Fogo, \u201cPeroxisome proliferator-activated receptor-c agonist troglitazone protects against nondiabetic glomerulosclerosis in rats,\u201d Kidney International, vol. 59, no. 5, pp. 1899\u20131910, 2001.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Ma%2C%20L.-J.%20Marcantoni%2C%20C.%20Linton%2C%20M.F.%20Fazio%2C%20S.%20Peroxisome%20proliferator-activated%20receptor-c%20agonist%20troglitazone%20protects%20against%20nondiabetic%20glomerulosclerosis%20in%20rats%2C%202001",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Ma%2C%20L.-J.%20Marcantoni%2C%20C.%20Linton%2C%20M.F.%20Fazio%2C%20S.%20Peroxisome%20proliferator-activated%20receptor-c%20agonist%20troglitazone%20protects%20against%20nondiabetic%20glomerulosclerosis%20in%20rats%2C%202001",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Ma%2C%20L.-J.%20Marcantoni%2C%20C.%20Linton%2C%20M.F.%20Fazio%2C%20S.%20Peroxisome%20proliferator-activated%20receptor-c%20agonist%20troglitazone%20protects%20against%20nondiabetic%20glomerulosclerosis%20in%20rats%2C%202001"
        },
        {
            "id": "46",
            "alt_id": "Li_et+al_2006_a",
            "entry": "[46] Y. Li, X. Wen, B. C. Spataro, K. Hu, C. Dai, and Y. Liu, \u201cHepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferatoractivated receptor-gamma agonists,\u201d Journal of the American Society of Nephrology, vol. 17, no. 1, pp. 54\u201365, 2006.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Li%2C%20Y.%20Wen%2C%20X.%20Spataro%2C%20B.C.%20Hu%2C%20K.%20Hepatocyte%20growth%20factor%20is%20a%20downstream%20effector%20that%20mediates%20the%20antifibrotic%20action%20of%20peroxisome%20proliferatoractivated%20receptor-gamma%20agonists%2C%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Li%2C%20Y.%20Wen%2C%20X.%20Spataro%2C%20B.C.%20Hu%2C%20K.%20Hepatocyte%20growth%20factor%20is%20a%20downstream%20effector%20that%20mediates%20the%20antifibrotic%20action%20of%20peroxisome%20proliferatoractivated%20receptor-gamma%20agonists%2C%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Li%2C%20Y.%20Wen%2C%20X.%20Spataro%2C%20B.C.%20Hu%2C%20K.%20Hepatocyte%20growth%20factor%20is%20a%20downstream%20effector%20that%20mediates%20the%20antifibrotic%20action%20of%20peroxisome%20proliferatoractivated%20receptor-gamma%20agonists%2C%202006"
        },
        {
            "id": "47",
            "alt_id": "Wang_et+al_2007_a",
            "entry": "[47] W. Wang, F. Liu, and N. Chen, \u201cPeroxisome proliferatoractivated receptor-gamma (PPAR-c) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts,\u201d Mediators Inflamm, vol. 2007, Article ID 62641, 7 pages, 2007.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wang%2C%20W.%20Liu%2C%20F.%20Chen%2C%20N.%20Peroxisome%20proliferatoractivated%20receptor-gamma%20%28PPAR-c%29%20agonists%20attenuate%20the%20profibrotic%20response%20induced%20by%20TGF-beta1%20in%20renal%20interstitial%20fibroblasts%2C%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Wang%2C%20W.%20Liu%2C%20F.%20Chen%2C%20N.%20Peroxisome%20proliferatoractivated%20receptor-gamma%20%28PPAR-c%29%20agonists%20attenuate%20the%20profibrotic%20response%20induced%20by%20TGF-beta1%20in%20renal%20interstitial%20fibroblasts%2C%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Wang%2C%20W.%20Liu%2C%20F.%20Chen%2C%20N.%20Peroxisome%20proliferatoractivated%20receptor-gamma%20%28PPAR-c%29%20agonists%20attenuate%20the%20profibrotic%20response%20induced%20by%20TGF-beta1%20in%20renal%20interstitial%20fibroblasts%2C%202007"
        },
        {
            "id": "48",
            "alt_id": "Chen_et+al_2019_a",
            "entry": "[48] Z. Chen, P. Yuan, X. Sun et al., \u201cPioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-c-miR-23 axis,\u201d American Journal of Physiology-Renal Physiology, vol. 317, no. 1, pp. F137\u2013F151, 2019.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Chen%2C%20Z.%20Yuan%2C%20P.%20Sun%2C%20X.%20Pioglitazone%20decreased%20renal%20calcium%20oxalate%20crystal%20formation%20by%20suppressing%20M1%20macrophage%20polarization%20via%20the%20PPAR-c-miR-23%20axis%2C%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Chen%2C%20Z.%20Yuan%2C%20P.%20Sun%2C%20X.%20Pioglitazone%20decreased%20renal%20calcium%20oxalate%20crystal%20formation%20by%20suppressing%20M1%20macrophage%20polarization%20via%20the%20PPAR-c-miR-23%20axis%2C%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Chen%2C%20Z.%20Yuan%2C%20P.%20Sun%2C%20X.%20Pioglitazone%20decreased%20renal%20calcium%20oxalate%20crystal%20formation%20by%20suppressing%20M1%20macrophage%20polarization%20via%20the%20PPAR-c-miR-23%20axis%2C%202019"
        },
        {
            "id": "49",
            "alt_id": "Wu_et+al_2016_a",
            "entry": "[49] L. Wu, Q. Wang, F. Guo et al., \u201cMicroRNA-27a induces mesangial cell injury by targeting of PPARc, and its in vivo knockdown prevents progression of diabetic nephropathy,\u201d Scientific Reports, vol. 6, no. 1, p. 26072, 2016.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wu%2C%20L.%20Wang%2C%20Q.%20Guo%2C%20F.%20MicroRNA-27a%20induces%20mesangial%20cell%20injury%20by%20targeting%20of%20PPARc%2C%20and%20its%20in%20vivo%20knockdown%20prevents%20progression%20of%20diabetic%20nephropathy%2C%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Wu%2C%20L.%20Wang%2C%20Q.%20Guo%2C%20F.%20MicroRNA-27a%20induces%20mesangial%20cell%20injury%20by%20targeting%20of%20PPARc%2C%20and%20its%20in%20vivo%20knockdown%20prevents%20progression%20of%20diabetic%20nephropathy%2C%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Wu%2C%20L.%20Wang%2C%20Q.%20Guo%2C%20F.%20MicroRNA-27a%20induces%20mesangial%20cell%20injury%20by%20targeting%20of%20PPARc%2C%20and%20its%20in%20vivo%20knockdown%20prevents%20progression%20of%20diabetic%20nephropathy%2C%202016"
        },
        {
            "id": "50",
            "alt_id": "Zhou_et+al_2017_a",
            "entry": "[50] Z. Zhou, J. Wan, X. Hou, J. Geng, X. Li, and X. Bai, \u201cMicroRNA-27a promotes podocyte injury via PPARcmediated \u03b2-catenin activation in diabetic nephropathy,\u201d Cell Death & Disease, vol. 8, no. 3, Article ID e2658, 2017.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhou%2C%20Z.%20Wan%2C%20J.%20Hou%2C%20X.%20Geng%2C%20J.%20MicroRNA-27a%20promotes%20podocyte%20injury%20via%20PPARcmediated%20%CE%B2-catenin%20activation%20in%20diabetic%20nephropathy%2C%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhou%2C%20Z.%20Wan%2C%20J.%20Hou%2C%20X.%20Geng%2C%20J.%20MicroRNA-27a%20promotes%20podocyte%20injury%20via%20PPARcmediated%20%CE%B2-catenin%20activation%20in%20diabetic%20nephropathy%2C%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhou%2C%20Z.%20Wan%2C%20J.%20Hou%2C%20X.%20Geng%2C%20J.%20MicroRNA-27a%20promotes%20podocyte%20injury%20via%20PPARcmediated%20%CE%B2-catenin%20activation%20in%20diabetic%20nephropathy%2C%202017"
        },
        {
            "id": "51",
            "alt_id": "Samaha_et+al_2006_a",
            "entry": "[51] F. F. Samaha, P. O. Szapary, N. Iqbal et al., \u201cEffects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome,\u201d Arteriosclerosis, rombosis, and Vascular Biology, vol. 26, no. 3, pp. 624\u2013630, 2006.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Samaha%2C%20F.F.%20Szapary%2C%20P.O.%20Iqbal%2C%20N.%20Effects%20of%20rosiglitazone%20on%20lipids%2C%20adipokines%2C%20and%20inflammatory%20markers%20in%20nondiabetic%20patients%20with%20low%20high-density%20lipoprotein%20cholesterol%20and%20metabolic%20syndrome%2C%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Samaha%2C%20F.F.%20Szapary%2C%20P.O.%20Iqbal%2C%20N.%20Effects%20of%20rosiglitazone%20on%20lipids%2C%20adipokines%2C%20and%20inflammatory%20markers%20in%20nondiabetic%20patients%20with%20low%20high-density%20lipoprotein%20cholesterol%20and%20metabolic%20syndrome%2C%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Samaha%2C%20F.F.%20Szapary%2C%20P.O.%20Iqbal%2C%20N.%20Effects%20of%20rosiglitazone%20on%20lipids%2C%20adipokines%2C%20and%20inflammatory%20markers%20in%20nondiabetic%20patients%20with%20low%20high-density%20lipoprotein%20cholesterol%20and%20metabolic%20syndrome%2C%202006"
        },
        {
            "id": "52",
            "alt_id": "Eckardt_et+al_2014_a",
            "entry": "[52] K. Eckardt, S. W. Gorgens, S. Raschke, and J. Eckel, \u201cMyokines in insulin resistance and type 2 diabetes,\u201d Diabetologia, vol. 57, no. 6, pp. 1087\u20131099, 2014.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Eckardt%2C%20K.%20Gorgens%2C%20S.W.%20Raschke%2C%20S.%20Eckel%2C%20J.%20Myokines%20in%20insulin%20resistance%20and%20type%202%20diabetes%2C%202014",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Eckardt%2C%20K.%20Gorgens%2C%20S.W.%20Raschke%2C%20S.%20Eckel%2C%20J.%20Myokines%20in%20insulin%20resistance%20and%20type%202%20diabetes%2C%202014",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Eckardt%2C%20K.%20Gorgens%2C%20S.W.%20Raschke%2C%20S.%20Eckel%2C%20J.%20Myokines%20in%20insulin%20resistance%20and%20type%202%20diabetes%2C%202014"
        },
        {
            "id": "53",
            "alt_id": "Wahli_2012_a",
            "entry": "[53] W. Wahli and L. Michalik, \u201cPPARs at the crossroads of lipid signaling and inflammation,\u201d Trends in Endocrinology & Metabolism, vol. 23, no. 7, pp. 351\u2013363, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wahli%2C%20W.%20L.%20Michalik%2C%20%E2%80%9CPPARs%20at%20the%20crossroads%20of%20lipid%20signaling%20and%20inflammation%2C%E2%80%9D%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Wahli%2C%20W.%20L.%20Michalik%2C%20%E2%80%9CPPARs%20at%20the%20crossroads%20of%20lipid%20signaling%20and%20inflammation%2C%E2%80%9D%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Wahli%2C%20W.%20L.%20Michalik%2C%20%E2%80%9CPPARs%20at%20the%20crossroads%20of%20lipid%20signaling%20and%20inflammation%2C%E2%80%9D%202012"
        },
        {
            "id": "54",
            "alt_id": "Ahmadian_et+al_2013_a",
            "entry": "[54] M. Ahmadian, J. M. Suh, N. Hah et al., \u201cPPARc signaling and metabolism: the good, the bad and the future,\u201d Nature Medicine, vol. 19, no. 5, pp. 557\u2013566, 2013.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Ahmadian%2C%20M.%20Suh%2C%20J.M.%20Hah%2C%20N.%20PPARc%20signaling%20and%20metabolism%3A%20the%20good%2C%20the%20bad%20and%20the%20future%2C%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Ahmadian%2C%20M.%20Suh%2C%20J.M.%20Hah%2C%20N.%20PPARc%20signaling%20and%20metabolism%3A%20the%20good%2C%20the%20bad%20and%20the%20future%2C%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Ahmadian%2C%20M.%20Suh%2C%20J.M.%20Hah%2C%20N.%20PPARc%20signaling%20and%20metabolism%3A%20the%20good%2C%20the%20bad%20and%20the%20future%2C%202013"
        },
        {
            "id": "55",
            "alt_id": "Derlacz_et+al_2008_a",
            "entry": "[55] R. A. Derlacz, K. Hyc, M. Usarek, A. K. Jagielski, J. Drozak, and R. Jarzyna, \u201cPPAR-c-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules,\u201d Biochemistry and Cell Biology, vol. 86, no. 5, pp. 396\u2013404, 2008.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Derlacz%2C%20R.A.%20Hyc%2C%20K.%20Usarek%2C%20M.%20Jagielski%2C%20A.K.%20PPAR-c-independent%20inhibitory%20effect%20of%20rosiglitazone%20on%20glucose%20synthesis%20in%20primary%20cultured%20rabbit%20kidney-cortex%20tubules%2C%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Derlacz%2C%20R.A.%20Hyc%2C%20K.%20Usarek%2C%20M.%20Jagielski%2C%20A.K.%20PPAR-c-independent%20inhibitory%20effect%20of%20rosiglitazone%20on%20glucose%20synthesis%20in%20primary%20cultured%20rabbit%20kidney-cortex%20tubules%2C%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Derlacz%2C%20R.A.%20Hyc%2C%20K.%20Usarek%2C%20M.%20Jagielski%2C%20A.K.%20PPAR-c-independent%20inhibitory%20effect%20of%20rosiglitazone%20on%20glucose%20synthesis%20in%20primary%20cultured%20rabbit%20kidney-cortex%20tubules%2C%202008"
        },
        {
            "id": "56",
            "alt_id": "Mather_2011_a",
            "entry": "[56] A. Mather and C. Pollock, \u201cGlucose handling by the kidney,\u201d Kidney International, vol. 79, pp. 1\u20136, 2011.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Mather%2C%20A.%20Pollock%2C%20C.%20Glucose%20handling%20by%20the%20kidney%2C%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Mather%2C%20A.%20Pollock%2C%20C.%20Glucose%20handling%20by%20the%20kidney%2C%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Mather%2C%20A.%20Pollock%2C%20C.%20Glucose%20handling%20by%20the%20kidney%2C%202011"
        },
        {
            "id": "57",
            "alt_id": "Santer_et+al_2003_a",
            "entry": "[57] R. Santer, M. Kinner, C. L. Lassen et al., \u201cMolecular analysis of the SGLT2 gene in patients with renal glucosuria,\u201d Journal of the American Society of Nephrology, vol. 14, no. 11, pp. 2873\u20132882, 2003.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Santer%2C%20R.%20Kinner%2C%20M.%20Lassen%2C%20C.L.%20Molecular%20analysis%20of%20the%20SGLT2%20gene%20in%20patients%20with%20renal%20glucosuria%2C%202003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Santer%2C%20R.%20Kinner%2C%20M.%20Lassen%2C%20C.L.%20Molecular%20analysis%20of%20the%20SGLT2%20gene%20in%20patients%20with%20renal%20glucosuria%2C%202003",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Santer%2C%20R.%20Kinner%2C%20M.%20Lassen%2C%20C.L.%20Molecular%20analysis%20of%20the%20SGLT2%20gene%20in%20patients%20with%20renal%20glucosuria%2C%202003"
        },
        {
            "id": "58",
            "alt_id": "Bonner_et+al_2015_a",
            "entry": "[58] C. Bonner, J. Kerr-Conte, V. Gmyr et al., \u201cInhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion,\u201d Nature Medicine, vol. 21, no. 5, pp. 512\u2013517, 2015.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Bonner%2C%20C.%20Kerr-Conte%2C%20J.%20Gmyr%2C%20V.%20Inhibition%20of%20the%20glucose%20transporter%20SGLT2%20with%20dapagliflozin%20in%20pancreatic%20alpha%20cells%20triggers%20glucagon%20secretion%2C%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Bonner%2C%20C.%20Kerr-Conte%2C%20J.%20Gmyr%2C%20V.%20Inhibition%20of%20the%20glucose%20transporter%20SGLT2%20with%20dapagliflozin%20in%20pancreatic%20alpha%20cells%20triggers%20glucagon%20secretion%2C%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Bonner%2C%20C.%20Kerr-Conte%2C%20J.%20Gmyr%2C%20V.%20Inhibition%20of%20the%20glucose%20transporter%20SGLT2%20with%20dapagliflozin%20in%20pancreatic%20alpha%20cells%20triggers%20glucagon%20secretion%2C%202015"
        },
        {
            "id": "59",
            "alt_id": "Kim_et+al_2017_a",
            "entry": "[59] M. Kim, E. J. Lee, H. M. Shin et al., \u201c e effect of PPARc agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia,\u201d Journal of Endocrinological Investigation, vol. 40, no. 10, pp. 1069\u20131076, 2017.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kim%2C%20M.%20Lee%2C%20E.J.%20Shin%2C%20H.M.%20e%20effect%20of%20PPARc%20agonist%20on%20SGLT2%20and%20glucagon%20expressions%20in%20alpha%20cells%20under%20hyperglycemia%2C%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kim%2C%20M.%20Lee%2C%20E.J.%20Shin%2C%20H.M.%20e%20effect%20of%20PPARc%20agonist%20on%20SGLT2%20and%20glucagon%20expressions%20in%20alpha%20cells%20under%20hyperglycemia%2C%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kim%2C%20M.%20Lee%2C%20E.J.%20Shin%2C%20H.M.%20e%20effect%20of%20PPARc%20agonist%20on%20SGLT2%20and%20glucagon%20expressions%20in%20alpha%20cells%20under%20hyperglycemia%2C%202017"
        },
        {
            "id": "60",
            "alt_id": "Lee_2010_a",
            "entry": "[60] Y. J. Lee and H. J. Han, \u201cTroglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3\u03b2, Snail1, and \u03b2-catenin in renal proximal tubule cells,\u201d American Journal of Physiology-Renal Physiology, vol. 298, no. 5, pp. F1263\u2013F1275, 2010.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lee%2C%20Y.J.%20Han%2C%20H.J.%20Troglitazone%20ameliorates%20high%20glucose-induced%20EMT%20and%20dysfunction%20of%20SGLTs%20through%20PI3K/Akt%2C%20GSK-3%CE%B2%2C%20Snail1%2C%20and%20%CE%B2-catenin%20in%20renal%20proximal%20tubule%20cells%2C%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lee%2C%20Y.J.%20Han%2C%20H.J.%20Troglitazone%20ameliorates%20high%20glucose-induced%20EMT%20and%20dysfunction%20of%20SGLTs%20through%20PI3K/Akt%2C%20GSK-3%CE%B2%2C%20Snail1%2C%20and%20%CE%B2-catenin%20in%20renal%20proximal%20tubule%20cells%2C%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lee%2C%20Y.J.%20Han%2C%20H.J.%20Troglitazone%20ameliorates%20high%20glucose-induced%20EMT%20and%20dysfunction%20of%20SGLTs%20through%20PI3K/Akt%2C%20GSK-3%CE%B2%2C%20Snail1%2C%20and%20%CE%B2-catenin%20in%20renal%20proximal%20tubule%20cells%2C%202010"
        },
        {
            "id": "61",
            "alt_id": "Guillam_et+al_1997_a",
            "entry": "[61] M.-T. Guillam, E. Hummler, E. Schaerer et al., \u201cEarly diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2,\u201d Nature Genetics, vol. 17, no. 3, pp. 327\u2013330, 1997.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Guillam%2C%20M.-T.%20Hummler%2C%20E.%20Schaerer%2C%20E.%20Early%20diabetes%20and%20abnormal%20postnatal%20pancreatic%20islet%20development%20in%20mice%20lacking%20Glut-2%2C%201997",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Guillam%2C%20M.-T.%20Hummler%2C%20E.%20Schaerer%2C%20E.%20Early%20diabetes%20and%20abnormal%20postnatal%20pancreatic%20islet%20development%20in%20mice%20lacking%20Glut-2%2C%201997",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Guillam%2C%20M.-T.%20Hummler%2C%20E.%20Schaerer%2C%20E.%20Early%20diabetes%20and%20abnormal%20postnatal%20pancreatic%20islet%20development%20in%20mice%20lacking%20Glut-2%2C%201997"
        },
        {
            "id": "62",
            "alt_id": "Murakami_et+al_1998_a",
            "entry": "[62] K. Murakami, K. Tobe, T. Ide et al., \u201cA novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats,\u201d Diabetes, vol. 47, no. 12, pp. 1841\u20131847, 1998.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Murakami%2C%20K.%20Tobe%2C%20K.%20Ide%2C%20T.%20A%20novel%20insulin%20sensitizer%20acts%20as%20a%20coligand%20for%20peroxisome%20proliferator-activated%20receptor-alpha%20%28PPAR-alpha%29%20and%20PPAR-gamma%3A%20effect%20of%20PPAR-alpha%20activation%20on%20abnormal%20lipid%20metabolism%20in%20liver%20of%20Zucker%20fatty%20rats%2C%201998",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Murakami%2C%20K.%20Tobe%2C%20K.%20Ide%2C%20T.%20A%20novel%20insulin%20sensitizer%20acts%20as%20a%20coligand%20for%20peroxisome%20proliferator-activated%20receptor-alpha%20%28PPAR-alpha%29%20and%20PPAR-gamma%3A%20effect%20of%20PPAR-alpha%20activation%20on%20abnormal%20lipid%20metabolism%20in%20liver%20of%20Zucker%20fatty%20rats%2C%201998",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Murakami%2C%20K.%20Tobe%2C%20K.%20Ide%2C%20T.%20A%20novel%20insulin%20sensitizer%20acts%20as%20a%20coligand%20for%20peroxisome%20proliferator-activated%20receptor-alpha%20%28PPAR-alpha%29%20and%20PPAR-gamma%3A%20effect%20of%20PPAR-alpha%20activation%20on%20abnormal%20lipid%20metabolism%20in%20liver%20of%20Zucker%20fatty%20rats%2C%201998"
        },
        {
            "id": "63",
            "alt_id": "Mochizukiohashi_et+al_2017_a",
            "entry": "[63] B. MochizukiOhashi, B. Parim, V. R. Chunduri et al., \u201cAntiobesity potential of piperonal: promising modulation of body composition, lipid profiles and obesogenic marker expression in HFD-induced obese rats,\u201d Nutrition & Metabolism, vol. 14, no. 1, p. 72, 2017.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=MochizukiOhashi%2C%20B.%20Parim%2C%20B.%20Chunduri%2C%20V.R.%20Antiobesity%20potential%20of%20piperonal%3A%20promising%20modulation%20of%20body%20composition%2C%20lipid%20profiles%20and%20obesogenic%20marker%20expression%20in%20HFD-induced%20obese%20rats%2C%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=MochizukiOhashi%2C%20B.%20Parim%2C%20B.%20Chunduri%2C%20V.R.%20Antiobesity%20potential%20of%20piperonal%3A%20promising%20modulation%20of%20body%20composition%2C%20lipid%20profiles%20and%20obesogenic%20marker%20expression%20in%20HFD-induced%20obese%20rats%2C%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=MochizukiOhashi%2C%20B.%20Parim%2C%20B.%20Chunduri%2C%20V.R.%20Antiobesity%20potential%20of%20piperonal%3A%20promising%20modulation%20of%20body%20composition%2C%20lipid%20profiles%20and%20obesogenic%20marker%20expression%20in%20HFD-induced%20obese%20rats%2C%202017"
        },
        {
            "id": "64",
            "alt_id": "Das_et+al_2011_a",
            "entry": "[64] N. Das, M. Dhanawat, and S. K. Shrivastava, \u201cBenzoxazinones as human peroxisome proliferator activated receptor gamma (PPARc) agonists: a docking study using glide,\u201d Indian Journal of Pharmaceutical Sciences, vol. 73, no. 2, pp. 159\u2013164, 2011.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Das%2C%20N.%20Dhanawat%2C%20M.%20Shrivastava%2C%20S.K.%20Benzoxazinones%20as%20human%20peroxisome%20proliferator%20activated%20receptor%20gamma%20%28PPARc%29%20agonists%3A%20a%20docking%20study%20using%20glide%2C%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Das%2C%20N.%20Dhanawat%2C%20M.%20Shrivastava%2C%20S.K.%20Benzoxazinones%20as%20human%20peroxisome%20proliferator%20activated%20receptor%20gamma%20%28PPARc%29%20agonists%3A%20a%20docking%20study%20using%20glide%2C%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Das%2C%20N.%20Dhanawat%2C%20M.%20Shrivastava%2C%20S.K.%20Benzoxazinones%20as%20human%20peroxisome%20proliferator%20activated%20receptor%20gamma%20%28PPARc%29%20agonists%3A%20a%20docking%20study%20using%20glide%2C%202011"
        },
        {
            "id": "65",
            "alt_id": "Hiraike_et+al_2017_a",
            "entry": "[65] Y. Hiraike, H. Waki, J. Yu et al., \u201cNFIA co-localizes with PPARc and transcriptionally controls the brown fat gene program,\u201d Nature Cell Biology, vol. 19, no. 9, pp. 1081\u20131092, 2017.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Hiraike%2C%20Y.%20Waki%2C%20H.%20Yu%2C%20J.%20NFIA%20co-localizes%20with%20PPARc%20and%20transcriptionally%20controls%20the%20brown%20fat%20gene%20program%2C%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Hiraike%2C%20Y.%20Waki%2C%20H.%20Yu%2C%20J.%20NFIA%20co-localizes%20with%20PPARc%20and%20transcriptionally%20controls%20the%20brown%20fat%20gene%20program%2C%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Hiraike%2C%20Y.%20Waki%2C%20H.%20Yu%2C%20J.%20NFIA%20co-localizes%20with%20PPARc%20and%20transcriptionally%20controls%20the%20brown%20fat%20gene%20program%2C%202017"
        },
        {
            "id": "66",
            "alt_id": "Kim_et+al_2016_a",
            "entry": "[66] J. Kim, Y.-J. Lee, J. M. Kim et al., \u201cPPARc agonists induce adipocyte differentiation by modulating the expression of Lipin-1, which acts as a PPARc phosphatase,\u201d e International Journal of Biochemistry & Cell Biology, vol. 81, pp. 57\u201366, 2016.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kim%2C%20J.%20Lee%2C%20Y.-J.%20M%2C%20J.%20Kim%20et%20al.%2C%20%E2%80%9CPPARc%20agonists%20induce%20adipocyte%20differentiation%20by%20modulating%20the%20expression%20of%20Lipin-1%2C%20which%20acts%20as%20a%20PPARc%20phosphatase%2C%E2%80%9D%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kim%2C%20J.%20Lee%2C%20Y.-J.%20M%2C%20J.%20Kim%20et%20al.%2C%20%E2%80%9CPPARc%20agonists%20induce%20adipocyte%20differentiation%20by%20modulating%20the%20expression%20of%20Lipin-1%2C%20which%20acts%20as%20a%20PPARc%20phosphatase%2C%E2%80%9D%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kim%2C%20J.%20Lee%2C%20Y.-J.%20M%2C%20J.%20Kim%20et%20al.%2C%20%E2%80%9CPPARc%20agonists%20induce%20adipocyte%20differentiation%20by%20modulating%20the%20expression%20of%20Lipin-1%2C%20which%20acts%20as%20a%20PPARc%20phosphatase%2C%E2%80%9D%202016"
        },
        {
            "id": "67",
            "alt_id": "Huret_et+al_2000_a",
            "entry": "[67] J.-L. Huret, S. L. Minor, F. Dorkeld, P. Dessen, and A. Bernheim, \u201cAtlas of genetics and cytogenetics in oncology and haematology, an interactive database,\u201d Nucleic Acids Research, vol. 28, no. 1, pp. 349\u2013351, 2000.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Huret%2C%20J.-L.%20Minor%2C%20S.L.%20Dorkeld%2C%20F.%20Dessen%2C%20P.%20Atlas%20of%20genetics%20and%20cytogenetics%20in%20oncology%20and%20haematology%2C%20an%20interactive%20database%2C%202000",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Huret%2C%20J.-L.%20Minor%2C%20S.L.%20Dorkeld%2C%20F.%20Dessen%2C%20P.%20Atlas%20of%20genetics%20and%20cytogenetics%20in%20oncology%20and%20haematology%2C%20an%20interactive%20database%2C%202000",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Huret%2C%20J.-L.%20Minor%2C%20S.L.%20Dorkeld%2C%20F.%20Dessen%2C%20P.%20Atlas%20of%20genetics%20and%20cytogenetics%20in%20oncology%20and%20haematology%2C%20an%20interactive%20database%2C%202000"
        },
        {
            "id": "68",
            "alt_id": "Lyu_et+al_2018_a",
            "entry": "[68] Z. Lyu, Z. Mao, Q. Li et al., \u201cPPARc maintains the metabolic heterogeneity and homeostasis of renal tubules,\u201d EBioMedicine, vol. 38, pp. 178\u2013190, 2018.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lyu%2C%20Z.%20Mao%2C%20Z.%20Li%2C%20Q.%20PPARc%20maintains%20the%20metabolic%20heterogeneity%20and%20homeostasis%20of%20renal%20tubules%2C%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lyu%2C%20Z.%20Mao%2C%20Z.%20Li%2C%20Q.%20PPARc%20maintains%20the%20metabolic%20heterogeneity%20and%20homeostasis%20of%20renal%20tubules%2C%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lyu%2C%20Z.%20Mao%2C%20Z.%20Li%2C%20Q.%20PPARc%20maintains%20the%20metabolic%20heterogeneity%20and%20homeostasis%20of%20renal%20tubules%2C%202018"
        },
        {
            "id": "69",
            "alt_id": "Szeto_et+al_2016_a",
            "entry": "[69] H. H. Szeto, S. Liu, Y. Soong, N. Alam, G. T. Prusky, and S. V. Seshan, \u201cProtection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury,\u201d Kidney International, vol. 90, no. 5, pp. 997\u20131011, 2016.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Szeto%2C%20H.H.%20Liu%2C%20S.%20Soong%2C%20Y.%20Alam%2C%20N.%20Protection%20of%20mitochondria%20prevents%20high-fat%20diet-induced%20glomerulopathy%20and%20proximal%20tubular%20injury%2C%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Szeto%2C%20H.H.%20Liu%2C%20S.%20Soong%2C%20Y.%20Alam%2C%20N.%20Protection%20of%20mitochondria%20prevents%20high-fat%20diet-induced%20glomerulopathy%20and%20proximal%20tubular%20injury%2C%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Szeto%2C%20H.H.%20Liu%2C%20S.%20Soong%2C%20Y.%20Alam%2C%20N.%20Protection%20of%20mitochondria%20prevents%20high-fat%20diet-induced%20glomerulopathy%20and%20proximal%20tubular%20injury%2C%202016"
        },
        {
            "id": "70",
            "alt_id": "Moorhead_et+al_1982_a",
            "entry": "[70] J. F. Moorhead, M. El-Nahas, M. K. Chan, and Z. Varghese, \u201cLipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease,\u201d e Lancet, vol. 320, no. 8311, pp. 1309\u20131311, 1982.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Moorhead%2C%20J.F.%20El-Nahas%2C%20M.%20Chan%2C%20M.K.%20Varghese%2C%20Z.%20Lipid%20nephrotoxicity%20in%20chronic%20progressive%20glomerular%20and%20tubulo-interstitial%20disease%2C%201982",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Moorhead%2C%20J.F.%20El-Nahas%2C%20M.%20Chan%2C%20M.K.%20Varghese%2C%20Z.%20Lipid%20nephrotoxicity%20in%20chronic%20progressive%20glomerular%20and%20tubulo-interstitial%20disease%2C%201982",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Moorhead%2C%20J.F.%20El-Nahas%2C%20M.%20Chan%2C%20M.K.%20Varghese%2C%20Z.%20Lipid%20nephrotoxicity%20in%20chronic%20progressive%20glomerular%20and%20tubulo-interstitial%20disease%2C%201982"
        },
        {
            "id": "71",
            "alt_id": "A_2016_a",
            "entry": "[71] A. Izquierdo-Lahuerta, C. Mart\u0131nez-Garc\u0131a, and G. MedinaGomez, \u201cLipotoxicity as a trigger factor of renal disease,\u201d Journal of Nephrology, vol. 29, no. 5, pp. 603\u2013610, 2016.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=A.%20Izquierdo-Lahuerta%2C%20C.%20Mart%C4%B1nez-Garc%C4%B1a%20G%20MedinaGomez%2C%20%E2%80%9CLipotoxicity%20as%20a%20trigger%20factor%20of%20renal%20disease%2C%E2%80%9D%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=A.%20Izquierdo-Lahuerta%2C%20C.%20Mart%C4%B1nez-Garc%C4%B1a%20G%20MedinaGomez%2C%20%E2%80%9CLipotoxicity%20as%20a%20trigger%20factor%20of%20renal%20disease%2C%E2%80%9D%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=A.%20Izquierdo-Lahuerta%2C%20C.%20Mart%C4%B1nez-Garc%C4%B1a%20G%20MedinaGomez%2C%20%E2%80%9CLipotoxicity%20as%20a%20trigger%20factor%20of%20renal%20disease%2C%E2%80%9D%202016"
        },
        {
            "id": "72",
            "alt_id": "Martinez-Garcia_et+al_2012_a",
            "entry": "[72] C. Martinez-Garcia, A. Izquierdo, V. Velagapudi et al., \u201cAccelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model,\u201d Disease Models & Mechanisms, vol. 5, no. 5, pp. 636\u2013648, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Martinez-Garcia%2C%20C.%20Izquierdo%2C%20A.%20Velagapudi%2C%20V.%20Accelerated%20renal%20disease%20is%20associated%20with%20the%20development%20of%20metabolic%20syndrome%20in%20a%20glucolipotoxic%20mouse%20model%2C%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Martinez-Garcia%2C%20C.%20Izquierdo%2C%20A.%20Velagapudi%2C%20V.%20Accelerated%20renal%20disease%20is%20associated%20with%20the%20development%20of%20metabolic%20syndrome%20in%20a%20glucolipotoxic%20mouse%20model%2C%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Martinez-Garcia%2C%20C.%20Izquierdo%2C%20A.%20Velagapudi%2C%20V.%20Accelerated%20renal%20disease%20is%20associated%20with%20the%20development%20of%20metabolic%20syndrome%20in%20a%20glucolipotoxic%20mouse%20model%2C%202012"
        },
        {
            "id": "73",
            "alt_id": "Medina-Gomez_et+al_2009_a",
            "entry": "[73] G. Medina-Gomez, L. Yetukuri, V. Velagapudi et al., \u201cAdaptation and failure of pancreatic cells in murine models with different degrees of metabolic syndrome,\u201d Disease Models & Mechanisms, vol. 2, no. 11-12, pp. 582\u2013592, 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Medina-Gomez%2C%20G.%20Yetukuri%2C%20L.%20Velagapudi%2C%20V.%20Adaptation%20and%20failure%20of%20pancreatic%20cells%20in%20murine%20models%20with%20different%20degrees%20of%20metabolic%20syndrome%2C%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Medina-Gomez%2C%20G.%20Yetukuri%2C%20L.%20Velagapudi%2C%20V.%20Adaptation%20and%20failure%20of%20pancreatic%20cells%20in%20murine%20models%20with%20different%20degrees%20of%20metabolic%20syndrome%2C%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Medina-Gomez%2C%20G.%20Yetukuri%2C%20L.%20Velagapudi%2C%20V.%20Adaptation%20and%20failure%20of%20pancreatic%20cells%20in%20murine%20models%20with%20different%20degrees%20of%20metabolic%20syndrome%2C%202009"
        },
        {
            "id": "74",
            "alt_id": "Mart\u0131nez-Garc\u0131a_et+al_2015_a",
            "entry": "[74] C. Mart\u0131nez-Garc\u0131a, A. Izquierdo-Lahuerta, Y. Vivas et al., \u201cRenal lipotoxicity-associated inflammation and insulin resistance affects actin cytoskeleton organization in podocytes,\u201d PLoS One, vol. 10, no. 11, Article ID e0142291, 2015.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Mart%C4%B1nez-Garc%C4%B1a%2C%20C.%20Izquierdo-Lahuerta%2C%20A.%20Vivas%2C%20Y.%20Renal%20lipotoxicity-associated%20inflammation%20and%20insulin%20resistance%20affects%20actin%20cytoskeleton%20organization%20in%20podocytes%2C%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Mart%C4%B1nez-Garc%C4%B1a%2C%20C.%20Izquierdo-Lahuerta%2C%20A.%20Vivas%2C%20Y.%20Renal%20lipotoxicity-associated%20inflammation%20and%20insulin%20resistance%20affects%20actin%20cytoskeleton%20organization%20in%20podocytes%2C%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Mart%C4%B1nez-Garc%C4%B1a%2C%20C.%20Izquierdo-Lahuerta%2C%20A.%20Vivas%2C%20Y.%20Renal%20lipotoxicity-associated%20inflammation%20and%20insulin%20resistance%20affects%20actin%20cytoskeleton%20organization%20in%20podocytes%2C%202015"
        },
        {
            "id": "75",
            "alt_id": "Roszer_et+al_2011_a",
            "entry": "[75] T. Roszer, M. P. Menendez-Gutierrez, M. I. Lefterova et al., \u201cAutoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency,\u201d Journal of Immunology, vol. 186, no. 1, pp. 621\u2013631, 2011.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Roszer%2C%20T.%20Menendez-Gutierrez%2C%20M.P.%20Lefterova%2C%20M.I.%20Autoimmune%20kidney%20disease%20and%20impaired%20engulfment%20of%20apoptotic%20cells%20in%20mice%20with%20macrophage%20peroxisome%20proliferator-activated%20receptor%20gamma%20or%20retinoid%20X%20receptor%20alpha%20deficiency%2C%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Roszer%2C%20T.%20Menendez-Gutierrez%2C%20M.P.%20Lefterova%2C%20M.I.%20Autoimmune%20kidney%20disease%20and%20impaired%20engulfment%20of%20apoptotic%20cells%20in%20mice%20with%20macrophage%20peroxisome%20proliferator-activated%20receptor%20gamma%20or%20retinoid%20X%20receptor%20alpha%20deficiency%2C%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Roszer%2C%20T.%20Menendez-Gutierrez%2C%20M.P.%20Lefterova%2C%20M.I.%20Autoimmune%20kidney%20disease%20and%20impaired%20engulfment%20of%20apoptotic%20cells%20in%20mice%20with%20macrophage%20peroxisome%20proliferator-activated%20receptor%20gamma%20or%20retinoid%20X%20receptor%20alpha%20deficiency%2C%202011"
        },
        {
            "id": "76",
            "alt_id": "Fischerricote_et+al_2007_a",
            "entry": "[76] M. A. FischerRicote, B. Derudas, E. Rigamonti et al., \u201cPPARc activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties,\u201d Cell Metabolism, vol. 6, no. 2, pp. 137\u2013143, 2007.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=FischerRicote%2C%20M.A.%20Derudas%2C%20B.%20Rigamonti%2C%20E.%20PPARc%20activation%20primes%20human%20monocytes%20into%20alternative%20M2%20macrophages%20with%20anti-inflammatory%20properties%2C%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=FischerRicote%2C%20M.A.%20Derudas%2C%20B.%20Rigamonti%2C%20E.%20PPARc%20activation%20primes%20human%20monocytes%20into%20alternative%20M2%20macrophages%20with%20anti-inflammatory%20properties%2C%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=FischerRicote%2C%20M.A.%20Derudas%2C%20B.%20Rigamonti%2C%20E.%20PPARc%20activation%20primes%20human%20monocytes%20into%20alternative%20M2%20macrophages%20with%20anti-inflammatory%20properties%2C%202007"
        },
        {
            "id": "77",
            "alt_id": "Akiyama_et+al_2002_a",
            "entry": "[77] T. E. Akiyama, S. Sakai, G. Lambert et al., \u201cConditional disruption of the peroxisome proliferator-activated receptor gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux,\u201d Molecular and Cellular Biology, vol. 22, no. 8, pp. 2607\u20132619, 2002.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Akiyama%2C%20T.E.%20Sakai%2C%20S.%20Lambert%2C%20G.%20Conditional%20disruption%20of%20the%20peroxisome%20proliferator-activated%20receptor%20gene%20in%20mice%20results%20in%20lowered%20expression%20of%20ABCA1%2C%20ABCG1%2C%20and%20apoE%20in%20macrophages%20and%20reduced%20cholesterol%20efflux%2C%202002",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Akiyama%2C%20T.E.%20Sakai%2C%20S.%20Lambert%2C%20G.%20Conditional%20disruption%20of%20the%20peroxisome%20proliferator-activated%20receptor%20gene%20in%20mice%20results%20in%20lowered%20expression%20of%20ABCA1%2C%20ABCG1%2C%20and%20apoE%20in%20macrophages%20and%20reduced%20cholesterol%20efflux%2C%202002",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Akiyama%2C%20T.E.%20Sakai%2C%20S.%20Lambert%2C%20G.%20Conditional%20disruption%20of%20the%20peroxisome%20proliferator-activated%20receptor%20gene%20in%20mice%20results%20in%20lowered%20expression%20of%20ABCA1%2C%20ABCG1%2C%20and%20apoE%20in%20macrophages%20and%20reduced%20cholesterol%20efflux%2C%202002"
        },
        {
            "id": "78",
            "alt_id": "Ricote_et+al_1998_a",
            "entry": "[78] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, \u201c e peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation,\u201d Nature, vol. 391, no. 6662, pp. 79\u201382, 1998.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Ricote%2C%20M.%20Li%2C%20A.C.%20Willson%2C%20T.M.%20Kelly%2C%20C.J.%20Glass%2C%20%E2%80%9Ce%20peroxisome%20proliferator-activated%20receptor-gamma%20is%20a%20negative%20regulator%20of%20macrophage%20activation%2C%E2%80%9D%201998",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Ricote%2C%20M.%20Li%2C%20A.C.%20Willson%2C%20T.M.%20Kelly%2C%20C.J.%20Glass%2C%20%E2%80%9Ce%20peroxisome%20proliferator-activated%20receptor-gamma%20is%20a%20negative%20regulator%20of%20macrophage%20activation%2C%E2%80%9D%201998",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Ricote%2C%20M.%20Li%2C%20A.C.%20Willson%2C%20T.M.%20Kelly%2C%20C.J.%20Glass%2C%20%E2%80%9Ce%20peroxisome%20proliferator-activated%20receptor-gamma%20is%20a%20negative%20regulator%20of%20macrophage%20activation%2C%E2%80%9D%201998"
        },
        {
            "id": "79",
            "alt_id": "Glass_2010_a",
            "entry": "[79] C. K. Glass and K. Saijo, \u201cNuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells,\u201d Nature Reviews Immunology, vol. 10, no. 5, pp. 365\u2013376, 2010.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Glass%2C%20C.K.%20Saijo%2C%20K.%20Nuclear%20receptor%20transrepression%20pathways%20that%20regulate%20inflammation%20in%20macrophages%20and%20T%20cells%2C%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Glass%2C%20C.K.%20Saijo%2C%20K.%20Nuclear%20receptor%20transrepression%20pathways%20that%20regulate%20inflammation%20in%20macrophages%20and%20T%20cells%2C%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Glass%2C%20C.K.%20Saijo%2C%20K.%20Nuclear%20receptor%20transrepression%20pathways%20that%20regulate%20inflammation%20in%20macrophages%20and%20T%20cells%2C%202010"
        },
        {
            "id": "80",
            "alt_id": "Menendez-Gutierrez_et+al_2012_a",
            "entry": "[80] M. P. Menendez-Gutierrez, T. Roszer, and M. Ricote, \u201cBiology and therapeutic applications of peroxisome proliferator-activated receptors,\u201d Current Topics in Medicinal Chemistry, vol. 12, no. 6, pp. 48\u2013584, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Menendez-Gutierrez%2C%20M.P.%20Roszer%2C%20T.%20Ricote%2C%20M.%20Biology%20and%20therapeutic%20applications%20of%20peroxisome%20proliferator-activated%20receptors%2C%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Menendez-Gutierrez%2C%20M.P.%20Roszer%2C%20T.%20Ricote%2C%20M.%20Biology%20and%20therapeutic%20applications%20of%20peroxisome%20proliferator-activated%20receptors%2C%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Menendez-Gutierrez%2C%20M.P.%20Roszer%2C%20T.%20Ricote%2C%20M.%20Biology%20and%20therapeutic%20applications%20of%20peroxisome%20proliferator-activated%20receptors%2C%202012"
        },
        {
            "id": "81",
            "alt_id": "Lash_et+al_2009_a",
            "entry": "[81] J. P. Lash, A. S. Go, L. J. Appel et al., \u201cChronic renal insufficiency cohort (CRIC) study: baseline characteristics and associations with kidney function,\u201d Clinical Journal of the American Society of Nephrology, vol. 4, no. 8, pp. 1302\u20131311, 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lash%2C%20J.P.%20Go%2C%20A.S.%20Appel%2C%20L.J.%20Chronic%20renal%20insufficiency%20cohort%20%28CRIC%29%20study%3A%20baseline%20characteristics%20and%20associations%20with%20kidney%20function%2C%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lash%2C%20J.P.%20Go%2C%20A.S.%20Appel%2C%20L.J.%20Chronic%20renal%20insufficiency%20cohort%20%28CRIC%29%20study%3A%20baseline%20characteristics%20and%20associations%20with%20kidney%20function%2C%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lash%2C%20J.P.%20Go%2C%20A.S.%20Appel%2C%20L.J.%20Chronic%20renal%20insufficiency%20cohort%20%28CRIC%29%20study%3A%20baseline%20characteristics%20and%20associations%20with%20kidney%20function%2C%202009"
        },
        {
            "id": "82",
            "alt_id": "Szkup_et+al_2018_a",
            "entry": "[82] M. Szkup, A. J. Owczarek, D. Schneider-Matyka, J. Brodowski, B. \u0141oo, and E. Grochans, \u201cAssociations between the components of metabolic syndrome and the polymorphisms in the peroxisome proliferator-activated receptor gamma (PPAR-c), the fat mass and obesity-associated (FTO), and the melanocortin-4 receptor (MC4R) genes,\u201d Aging, vol. 10, no. 1, pp. 72\u201382, 2018.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Szkup%2C%20M.%20Owczarek%2C%20A.J.%20Schneider-Matyka%2C%20D.%20Brodowski%2C%20J.%20Associations%20between%20the%20components%20of%20metabolic%20syndrome%20and%20the%20polymorphisms%20in%20the%20peroxisome%20proliferator-activated%20receptor%20gamma%20%28PPAR-c%29%2C%20the%20fat%20mass%20and%20obesity-associated%20%28FTO%29%2C%20and%20the%20melanocortin-4%20receptor%20%28MC4R%29%20genes%2C%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Szkup%2C%20M.%20Owczarek%2C%20A.J.%20Schneider-Matyka%2C%20D.%20Brodowski%2C%20J.%20Associations%20between%20the%20components%20of%20metabolic%20syndrome%20and%20the%20polymorphisms%20in%20the%20peroxisome%20proliferator-activated%20receptor%20gamma%20%28PPAR-c%29%2C%20the%20fat%20mass%20and%20obesity-associated%20%28FTO%29%2C%20and%20the%20melanocortin-4%20receptor%20%28MC4R%29%20genes%2C%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Szkup%2C%20M.%20Owczarek%2C%20A.J.%20Schneider-Matyka%2C%20D.%20Brodowski%2C%20J.%20Associations%20between%20the%20components%20of%20metabolic%20syndrome%20and%20the%20polymorphisms%20in%20the%20peroxisome%20proliferator-activated%20receptor%20gamma%20%28PPAR-c%29%2C%20the%20fat%20mass%20and%20obesity-associated%20%28FTO%29%2C%20and%20the%20melanocortin-4%20receptor%20%28MC4R%29%20genes%2C%202018"
        },
        {
            "id": "83",
            "alt_id": "Iglarz_et+al_2003_a",
            "entry": "[83] M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin, \u201cEffect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension,\u201d Arteriosclerosis, rombosis, and Vascular Biology, vol. 23, no. 1, pp. 45\u201351, 2003.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Iglarz%2C%20M.%20Touyz%2C%20R.M.%20Amiri%2C%20F.%20Lavoie%2C%20M.-F.%20Effect%20of%20peroxisome%20proliferator-activated%20receptor-alpha%20and%20-gamma%20activators%20on%20vascular%20remodeling%20in%20endothelin-dependent%20hypertension%2C%202003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Iglarz%2C%20M.%20Touyz%2C%20R.M.%20Amiri%2C%20F.%20Lavoie%2C%20M.-F.%20Effect%20of%20peroxisome%20proliferator-activated%20receptor-alpha%20and%20-gamma%20activators%20on%20vascular%20remodeling%20in%20endothelin-dependent%20hypertension%2C%202003",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Iglarz%2C%20M.%20Touyz%2C%20R.M.%20Amiri%2C%20F.%20Lavoie%2C%20M.-F.%20Effect%20of%20peroxisome%20proliferator-activated%20receptor-alpha%20and%20-gamma%20activators%20on%20vascular%20remodeling%20in%20endothelin-dependent%20hypertension%2C%202003"
        },
        {
            "id": "84",
            "alt_id": "Wu_et+al_2004_a",
            "entry": "[84] L. Wu, R. Wang, J. De Champlain, and T. W. Wilson, \u201cBeneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats,\u201d American Journal of Hypertension, vol. 17, no. 9, pp. 749\u2013756, 2004.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wu%2C%20L.%20Wang%2C%20R.%20Champlain%2C%20J.De%20Wilson%2C%20T.W.%20Beneficial%20and%20deleterious%20effects%20of%20rosiglitazone%20on%20hypertension%20development%20in%20spontaneously%20hypertensive%20rats%2C%202004",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Wu%2C%20L.%20Wang%2C%20R.%20Champlain%2C%20J.De%20Wilson%2C%20T.W.%20Beneficial%20and%20deleterious%20effects%20of%20rosiglitazone%20on%20hypertension%20development%20in%20spontaneously%20hypertensive%20rats%2C%202004",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Wu%2C%20L.%20Wang%2C%20R.%20Champlain%2C%20J.De%20Wilson%2C%20T.W.%20Beneficial%20and%20deleterious%20effects%20of%20rosiglitazone%20on%20hypertension%20development%20in%20spontaneously%20hypertensive%20rats%2C%202004"
        },
        {
            "id": "85",
            "alt_id": "Zhang_et+al_2019_a",
            "entry": "[85] M. Zhang, J. Zhang, L. Li, Q. Wang, and L. Feng, \u201cAssociation between peroxisome proliferator-activated receptor c-2 gene Pro12Ala polymorphisms and risk of hypertension: an updated meta-analysis,\u201d Bioscience Reports, vol. 39, no. 2, 2019.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhang%2C%20M.%20Zhang%2C%20J.%20Li%2C%20L.%20Wang%2C%20Q.%20Association%20between%20peroxisome%20proliferator-activated%20receptor%20c-2%20gene%20Pro12Ala%20polymorphisms%20and%20risk%20of%20hypertension%3A%20an%20updated%20meta-analysis%2C%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhang%2C%20M.%20Zhang%2C%20J.%20Li%2C%20L.%20Wang%2C%20Q.%20Association%20between%20peroxisome%20proliferator-activated%20receptor%20c-2%20gene%20Pro12Ala%20polymorphisms%20and%20risk%20of%20hypertension%3A%20an%20updated%20meta-analysis%2C%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhang%2C%20M.%20Zhang%2C%20J.%20Li%2C%20L.%20Wang%2C%20Q.%20Association%20between%20peroxisome%20proliferator-activated%20receptor%20c-2%20gene%20Pro12Ala%20polymorphisms%20and%20risk%20of%20hypertension%3A%20an%20updated%20meta-analysis%2C%202019"
        },
        {
            "id": "86",
            "alt_id": "Nicol_et+al_2005_a",
            "entry": "[86] C. J. Nicol, M. Adachi, T. E. Akiyama, and F. J. Gonzalez, \u201cPPARgamma in endothelial cells influences high fat dietinduced hypertension,\u201d American Journal of Hypertension, vol. 18, no. 4, pp. 549\u2013556, 2005.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Nicol%2C%20C.J.%20Adachi%2C%20M.%20Akiyama%2C%20T.E.%20Gonzalez%2C%20F.J.%20PPARgamma%20in%20endothelial%20cells%20influences%20high%20fat%20dietinduced%20hypertension%2C%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Nicol%2C%20C.J.%20Adachi%2C%20M.%20Akiyama%2C%20T.E.%20Gonzalez%2C%20F.J.%20PPARgamma%20in%20endothelial%20cells%20influences%20high%20fat%20dietinduced%20hypertension%2C%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Nicol%2C%20C.J.%20Adachi%2C%20M.%20Akiyama%2C%20T.E.%20Gonzalez%2C%20F.J.%20PPARgamma%20in%20endothelial%20cells%20influences%20high%20fat%20dietinduced%20hypertension%2C%202005"
        },
        {
            "id": "87",
            "alt_id": "Benkirane_et+al_2006_a",
            "entry": "[87] K. Benkirane, E. C. Viel, F. Amiri, and E. L. Schiffrin, \u201cPeroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo,\u201d Hypertension, vol. 47, no. 1, pp. 102\u2013108, 2006.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Benkirane%2C%20K.%20Viel%2C%20E.C.%20Amiri%2C%20F.%20Schiffrin%2C%20E.L.%20Peroxisome%20proliferator-activated%20receptor%20gamma%20regulates%20angiotensin%20II-stimulated%20phosphatidylinositol%203-kinase%20and%20mitogen-activated%20protein%20kinase%20in%20blood%20vessels%20in%20vivo%2C%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Benkirane%2C%20K.%20Viel%2C%20E.C.%20Amiri%2C%20F.%20Schiffrin%2C%20E.L.%20Peroxisome%20proliferator-activated%20receptor%20gamma%20regulates%20angiotensin%20II-stimulated%20phosphatidylinositol%203-kinase%20and%20mitogen-activated%20protein%20kinase%20in%20blood%20vessels%20in%20vivo%2C%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Benkirane%2C%20K.%20Viel%2C%20E.C.%20Amiri%2C%20F.%20Schiffrin%2C%20E.L.%20Peroxisome%20proliferator-activated%20receptor%20gamma%20regulates%20angiotensin%20II-stimulated%20phosphatidylinositol%203-kinase%20and%20mitogen-activated%20protein%20kinase%20in%20blood%20vessels%20in%20vivo%2C%202006"
        },
        {
            "id": "88",
            "alt_id": "Schiffrin_2005_a",
            "entry": "[88] E. L. Schiffrin, \u201cPeroxisome proliferator-activated receptors and cardiovascular remodeling,\u201d American Journal of Physiology-Heart and Circulatory Physiology, vol. 288, no. 3, pp. H1037\u2013H1043, 2005.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Schiffrin%2C%20E.L.%20Peroxisome%20proliferator-activated%20receptors%20and%20cardiovascular%20remodeling%2C%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Schiffrin%2C%20E.L.%20Peroxisome%20proliferator-activated%20receptors%20and%20cardiovascular%20remodeling%2C%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Schiffrin%2C%20E.L.%20Peroxisome%20proliferator-activated%20receptors%20and%20cardiovascular%20remodeling%2C%202005"
        },
        {
            "id": "89",
            "alt_id": "Magri_et+al_2011_a",
            "entry": "[89] C. J. Magri, N. Gatt, R. G. Xuereb, and S. Fava, \u201cPeroxisome proliferator-activated receptor-c and the endothelium: implications in cardiovascular disease,\u201d Expert Review of Cardiovascular erapy, vol. 9, no. 10, pp. 1279\u20131294, 2011.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Magri%2C%20C.J.%20Gatt%2C%20N.%20Xuereb%2C%20R.G.%20Fava%2C%20S.%20Peroxisome%20proliferator-activated%20receptor-c%20and%20the%20endothelium%3A%20implications%20in%20cardiovascular%20disease%2C%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Magri%2C%20C.J.%20Gatt%2C%20N.%20Xuereb%2C%20R.G.%20Fava%2C%20S.%20Peroxisome%20proliferator-activated%20receptor-c%20and%20the%20endothelium%3A%20implications%20in%20cardiovascular%20disease%2C%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Magri%2C%20C.J.%20Gatt%2C%20N.%20Xuereb%2C%20R.G.%20Fava%2C%20S.%20Peroxisome%20proliferator-activated%20receptor-c%20and%20the%20endothelium%3A%20implications%20in%20cardiovascular%20disease%2C%202011"
        },
        {
            "id": "90",
            "alt_id": "Barroso_et+al_1999_a",
            "entry": "[90] I. Barroso, M. Gurnell, V. E. Crowley et al., \u201cDominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension,\u201d Nature, vol. 402, no. 6764, pp. 880\u2013883, 1999.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Barroso%2C%20I.%20Gurnell%2C%20M.%20Crowley%2C%20V.E.%20Dominant%20negative%20mutations%20in%20human%20PPARgamma%20associated%20with%20severe%20insulin%20resistance%2C%20diabetes%20mellitus%20and%20hypertension%2C%201999",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Barroso%2C%20I.%20Gurnell%2C%20M.%20Crowley%2C%20V.E.%20Dominant%20negative%20mutations%20in%20human%20PPARgamma%20associated%20with%20severe%20insulin%20resistance%2C%20diabetes%20mellitus%20and%20hypertension%2C%201999",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Barroso%2C%20I.%20Gurnell%2C%20M.%20Crowley%2C%20V.E.%20Dominant%20negative%20mutations%20in%20human%20PPARgamma%20associated%20with%20severe%20insulin%20resistance%2C%20diabetes%20mellitus%20and%20hypertension%2C%201999"
        },
        {
            "id": "91",
            "alt_id": "Wang_et+al_2008_a",
            "entry": "[91] N. Wang, G. Yang, Z. Jia et al., \u201cVascular PPARgamma controls circadian variation in blood pressure and heart rate through Bmal1,\u201d Cell Metabolism, vol. 8, no. 6, pp. 482\u2013491, 2008.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wang%2C%20N.%20Yang%2C%20G.%20Jia%2C%20Z.%20Vascular%20PPARgamma%20controls%20circadian%20variation%20in%20blood%20pressure%20and%20heart%20rate%20through%20Bmal1%2C%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Wang%2C%20N.%20Yang%2C%20G.%20Jia%2C%20Z.%20Vascular%20PPARgamma%20controls%20circadian%20variation%20in%20blood%20pressure%20and%20heart%20rate%20through%20Bmal1%2C%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Wang%2C%20N.%20Yang%2C%20G.%20Jia%2C%20Z.%20Vascular%20PPARgamma%20controls%20circadian%20variation%20in%20blood%20pressure%20and%20heart%20rate%20through%20Bmal1%2C%202008"
        },
        {
            "id": "92",
            "alt_id": "Guan_et+al_2005_a",
            "entry": "[92] Y. Guan, C. Hao, D. R. Cha et al., \u201c iazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption,\u201d Nature Medicine, vol. 11, no. 8, pp. 861\u2013866, 2005.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Guan%2C%20Y.%20Hao%2C%20C.%20Cha%2C%20D.R.%20iazolidinediones%20expand%20body%20fluid%20volume%20through%20PPARgamma%20stimulation%20of%20ENaC-mediated%20renal%20salt%20absorption%2C%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Guan%2C%20Y.%20Hao%2C%20C.%20Cha%2C%20D.R.%20iazolidinediones%20expand%20body%20fluid%20volume%20through%20PPARgamma%20stimulation%20of%20ENaC-mediated%20renal%20salt%20absorption%2C%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Guan%2C%20Y.%20Hao%2C%20C.%20Cha%2C%20D.R.%20iazolidinediones%20expand%20body%20fluid%20volume%20through%20PPARgamma%20stimulation%20of%20ENaC-mediated%20renal%20salt%20absorption%2C%202005"
        },
        {
            "id": "93",
            "alt_id": "Kliewer_et+al_2001_a",
            "entry": "[93] S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson, \u201cPeroxisome proliferator-activated receptors: from genes to physiology,\u201d Recent Progress in Hormone Research, vol. 56, no. 1, pp. 239\u2013263, 2001.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kliewer%2C%20S.A.%20Xu%2C%20H.E.%20Lambert%2C%20M.H.%20Willson%2C%20T.M.%20Peroxisome%20proliferator-activated%20receptors%3A%20from%20genes%20to%20physiology%2C%202001",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kliewer%2C%20S.A.%20Xu%2C%20H.E.%20Lambert%2C%20M.H.%20Willson%2C%20T.M.%20Peroxisome%20proliferator-activated%20receptors%3A%20from%20genes%20to%20physiology%2C%202001",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kliewer%2C%20S.A.%20Xu%2C%20H.E.%20Lambert%2C%20M.H.%20Willson%2C%20T.M.%20Peroxisome%20proliferator-activated%20receptors%3A%20from%20genes%20to%20physiology%2C%202001"
        },
        {
            "id": "94",
            "alt_id": "Yang_et+al_2009_b",
            "entry": "[94] J. Yang, D. Zhang, J. Li, X. Zhang, F. Fan, and Y. Guan, \u201cRole of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential,\u201d Clinical Science, vol. 116, no. 1, pp. 17\u201326, 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Yang%2C%20J.%20Zhang%2C%20D.%20Li%2C%20J.%20Zhang%2C%20X.%20Role%20of%20PPARgamma%20in%20renoprotection%20in%20Type%202%20diabetes%3A%20molecular%20mechanisms%20and%20therapeutic%20potential%2C%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Yang%2C%20J.%20Zhang%2C%20D.%20Li%2C%20J.%20Zhang%2C%20X.%20Role%20of%20PPARgamma%20in%20renoprotection%20in%20Type%202%20diabetes%3A%20molecular%20mechanisms%20and%20therapeutic%20potential%2C%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Yang%2C%20J.%20Zhang%2C%20D.%20Li%2C%20J.%20Zhang%2C%20X.%20Role%20of%20PPARgamma%20in%20renoprotection%20in%20Type%202%20diabetes%3A%20molecular%20mechanisms%20and%20therapeutic%20potential%2C%202009"
        },
        {
            "id": "95",
            "alt_id": "Sarafidis_et+al_2010_a",
            "entry": "[95] P. A. Sarafidis, P. C. Stafylas, P. I. Georgianos, A. N. Saratzis, and A. N. Lasaridis, \u201cEffect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis,\u201d American Journal of Kidney Diseases, vol. 55, no. 5, pp. 835\u2013847, 2010.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Sarafidis%2C%20P.A.%20Stafylas%2C%20P.C.%20Georgianos%2C%20P.I.%20Saratzis%2C%20A.N.%20Effect%20of%20thiazolidinediones%20on%20albuminuria%20and%20proteinuria%20in%20diabetes%3A%20a%20meta-analysis%2C%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Sarafidis%2C%20P.A.%20Stafylas%2C%20P.C.%20Georgianos%2C%20P.I.%20Saratzis%2C%20A.N.%20Effect%20of%20thiazolidinediones%20on%20albuminuria%20and%20proteinuria%20in%20diabetes%3A%20a%20meta-analysis%2C%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Sarafidis%2C%20P.A.%20Stafylas%2C%20P.C.%20Georgianos%2C%20P.I.%20Saratzis%2C%20A.N.%20Effect%20of%20thiazolidinediones%20on%20albuminuria%20and%20proteinuria%20in%20diabetes%3A%20a%20meta-analysis%2C%202010"
        },
        {
            "id": "96",
            "alt_id": "Zuo_et+al_2012_a",
            "entry": "[96] Y. Zuo, H. C. Yang, S. A. Potthoff et al., \u201cProtective effects of PPARgamma agonist in acute nephrotic syndrome,\u201d Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 174\u2013181, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zuo%2C%20Y.%20Yang%2C%20H.C.%20Potthoff%2C%20S.A.%20Protective%20effects%20of%20PPARgamma%20agonist%20in%20acute%20nephrotic%20syndrome%2C%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zuo%2C%20Y.%20Yang%2C%20H.C.%20Potthoff%2C%20S.A.%20Protective%20effects%20of%20PPARgamma%20agonist%20in%20acute%20nephrotic%20syndrome%2C%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zuo%2C%20Y.%20Yang%2C%20H.C.%20Potthoff%2C%20S.A.%20Protective%20effects%20of%20PPARgamma%20agonist%20in%20acute%20nephrotic%20syndrome%2C%202012"
        },
        {
            "id": "97",
            "alt_id": "Yoshihara_et+al_2011_a",
            "entry": "[97] D. Yoshihara, H. Kurahashi, M. Morita et al., \u201cPPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease,\u201d American Journal of Physiology-Renal Physiology, vol. 300, no. 2, pp. F465\u2013F474, 2011.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Yoshihara%2C%20D.%20Kurahashi%2C%20H.%20Morita%2C%20M.%20PPAR-gamma%20agonist%20ameliorates%20kidney%20and%20liver%20disease%20in%20an%20orthologous%20rat%20model%20of%20human%20autosomal%20recessive%20polycystic%20kidney%20disease%2C%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Yoshihara%2C%20D.%20Kurahashi%2C%20H.%20Morita%2C%20M.%20PPAR-gamma%20agonist%20ameliorates%20kidney%20and%20liver%20disease%20in%20an%20orthologous%20rat%20model%20of%20human%20autosomal%20recessive%20polycystic%20kidney%20disease%2C%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Yoshihara%2C%20D.%20Kurahashi%2C%20H.%20Morita%2C%20M.%20PPAR-gamma%20agonist%20ameliorates%20kidney%20and%20liver%20disease%20in%20an%20orthologous%20rat%20model%20of%20human%20autosomal%20recessive%20polycystic%20kidney%20disease%2C%202011"
        },
        {
            "id": "98",
            "alt_id": "Elshazly_2019_a",
            "entry": "[98] S. Elshazly and E. Soliman, \u201cPPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/ reperfusion injury,\u201d Toxicology and Applied Pharmacology, vol. 362, pp. 86\u201394, 2019.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Elshazly%2C%20S.%20Soliman%2C%20E.%20PPAR%20gamma%20agonist%2C%20pioglitazone%2C%20rescues%20liver%20damage%20induced%20by%20renal%20ischemia/%20reperfusion%20injury%2C%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Elshazly%2C%20S.%20Soliman%2C%20E.%20PPAR%20gamma%20agonist%2C%20pioglitazone%2C%20rescues%20liver%20damage%20induced%20by%20renal%20ischemia/%20reperfusion%20injury%2C%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Elshazly%2C%20S.%20Soliman%2C%20E.%20PPAR%20gamma%20agonist%2C%20pioglitazone%2C%20rescues%20liver%20damage%20induced%20by%20renal%20ischemia/%20reperfusion%20injury%2C%202019"
        },
        {
            "id": "99",
            "alt_id": "Sugawara_et+al_2010_a",
            "entry": "[99] A. Sugawara, A. Uruno, M. Kudo, K. Matsuda, C. W. Yang, and S. Ito, \u201cEffects of PPARgamma on hypertension, atherosclerosis, and chronic kidney disease,\u201d Endocrine Journal, vol. 57, no. 10, pp. 847\u2013852, 2010.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Sugawara%2C%20A.%20Uruno%2C%20A.%20Kudo%2C%20M.%20Matsuda%2C%20K.%20Effects%20of%20PPARgamma%20on%20hypertension%2C%20atherosclerosis%2C%20and%20chronic%20kidney%20disease%2C%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Sugawara%2C%20A.%20Uruno%2C%20A.%20Kudo%2C%20M.%20Matsuda%2C%20K.%20Effects%20of%20PPARgamma%20on%20hypertension%2C%20atherosclerosis%2C%20and%20chronic%20kidney%20disease%2C%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Sugawara%2C%20A.%20Uruno%2C%20A.%20Kudo%2C%20M.%20Matsuda%2C%20K.%20Effects%20of%20PPARgamma%20on%20hypertension%2C%20atherosclerosis%2C%20and%20chronic%20kidney%20disease%2C%202010"
        },
        {
            "id": "100",
            "alt_id": "Iglesias_2006_a",
            "entry": "[100] P. Iglesias and J. J. D\u0131ez, \u201cPeroxisome proliferator-activated receptor gamma agonists in renal disease,\u201d European Journal of Endocrinology, vol. 154, no. 5, pp. 613\u2013621, 2006.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Iglesias%2C%20P.%20D%C4%B1ez%2C%20J.J.%20Peroxisome%20proliferator-activated%20receptor%20gamma%20agonists%20in%20renal%20disease%2C%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Iglesias%2C%20P.%20D%C4%B1ez%2C%20J.J.%20Peroxisome%20proliferator-activated%20receptor%20gamma%20agonists%20in%20renal%20disease%2C%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Iglesias%2C%20P.%20D%C4%B1ez%2C%20J.J.%20Peroxisome%20proliferator-activated%20receptor%20gamma%20agonists%20in%20renal%20disease%2C%202006"
        },
        {
            "id": "101",
            "alt_id": "Liu_et+al_2018_a",
            "entry": "[101] L. Liu, Y. Liu, Y. Zhang et al., \u201cHigh phosphate-induced downregulation of PPARc contributes to CKD-associated vascular calcification,\u201d Journal of Molecular and Cellular Cardiology, vol. 114, pp. 264\u2013275, 2018.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Liu%2C%20L.%20Liu%2C%20Y.%20Zhang%2C%20Y.%20High%20phosphate-induced%20downregulation%20of%20PPARc%20contributes%20to%20CKD-associated%20vascular%20calcification%2C%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Liu%2C%20L.%20Liu%2C%20Y.%20Zhang%2C%20Y.%20High%20phosphate-induced%20downregulation%20of%20PPARc%20contributes%20to%20CKD-associated%20vascular%20calcification%2C%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Liu%2C%20L.%20Liu%2C%20Y.%20Zhang%2C%20Y.%20High%20phosphate-induced%20downregulation%20of%20PPARc%20contributes%20to%20CKD-associated%20vascular%20calcification%2C%202018"
        },
        {
            "id": "102",
            "alt_id": "Zhang_et+al_2017_a",
            "entry": "[102] Y.-F. Zhang, Q. Wang, Y.-Y. Su et al., \u201cPPAR-c agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution-induced damage,\u201d Molecular Medicine Reports, vol. 15, no. 4, pp. 1786\u20131792, 2017.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhang%2C%20Y.-F.%20Wang%2C%20Q.%20Su%2C%20Y.-Y.%20PPAR-c%20agonist%20rosiglitazone%20protects%20rat%20peritoneal%20mesothelial%20cells%20against%20peritoneal%20dialysis%20solution-induced%20damage%2C%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhang%2C%20Y.-F.%20Wang%2C%20Q.%20Su%2C%20Y.-Y.%20PPAR-c%20agonist%20rosiglitazone%20protects%20rat%20peritoneal%20mesothelial%20cells%20against%20peritoneal%20dialysis%20solution-induced%20damage%2C%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhang%2C%20Y.-F.%20Wang%2C%20Q.%20Su%2C%20Y.-Y.%20PPAR-c%20agonist%20rosiglitazone%20protects%20rat%20peritoneal%20mesothelial%20cells%20against%20peritoneal%20dialysis%20solution-induced%20damage%2C%202017"
        },
        {
            "id": "103",
            "alt_id": "Barnett_2006_a",
            "entry": "[103] A. Barnett, \u201cPreventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial,\u201d Journal of the American Society of Nephrology, vol. 17, no. 4, pp. S132\u2013S135, 2006.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Barnett%2C%20A.%20Preventing%20renal%20complications%20in%20type%202%20diabetes%3A%20results%20of%20the%20diabetics%20exposed%20to%20telmisartan%20and%20enalapril%20trial%2C%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Barnett%2C%20A.%20Preventing%20renal%20complications%20in%20type%202%20diabetes%3A%20results%20of%20the%20diabetics%20exposed%20to%20telmisartan%20and%20enalapril%20trial%2C%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Barnett%2C%20A.%20Preventing%20renal%20complications%20in%20type%202%20diabetes%3A%20results%20of%20the%20diabetics%20exposed%20to%20telmisartan%20and%20enalapril%20trial%2C%202006"
        },
        {
            "id": "104",
            "alt_id": "Arozal_et+al_2011_a",
            "entry": "[104] W. Arozal, K. Watanabe, P. T. Veeraveedu et al., \u201cTelmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-c agonist actions,\u201d Toxicology, vol. 279, no. 1\u20133, pp. 91\u201399, 2011.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Arozal%2C%20W.%20Watanabe%2C%20K.%20Veeraveedu%2C%20P.T.%20Telmisartan%20prevents%20the%20progression%20of%20renal%20injury%20in%20daunorubicin%20rats%20with%20the%20alteration%20of%20angiotensin%20II%20and%20endothelin-1%20receptor%20expression%20associated%20with%20its%20PPAR-c%20agonist%20actions%2C%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Arozal%2C%20W.%20Watanabe%2C%20K.%20Veeraveedu%2C%20P.T.%20Telmisartan%20prevents%20the%20progression%20of%20renal%20injury%20in%20daunorubicin%20rats%20with%20the%20alteration%20of%20angiotensin%20II%20and%20endothelin-1%20receptor%20expression%20associated%20with%20its%20PPAR-c%20agonist%20actions%2C%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Arozal%2C%20W.%20Watanabe%2C%20K.%20Veeraveedu%2C%20P.T.%20Telmisartan%20prevents%20the%20progression%20of%20renal%20injury%20in%20daunorubicin%20rats%20with%20the%20alteration%20of%20angiotensin%20II%20and%20endothelin-1%20receptor%20expression%20associated%20with%20its%20PPAR-c%20agonist%20actions%2C%202011"
        },
        {
            "id": "105",
            "alt_id": "Schupp_et+al_2005_a",
            "entry": "[105] M. Schupp, M. Clemenz, R. Gineste et al., \u201cMolecular characterization of new selective peroxisome proliferatoractivated receptor c modulators with angiotensin receptor blocking activity,\u201d Diabetes, vol. 54, no. 12, pp. 3442\u20133452, 2005.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Schupp%2C%20M.%20Clemenz%2C%20M.%20Gineste%2C%20R.%20Molecular%20characterization%20of%20new%20selective%20peroxisome%20proliferatoractivated%20receptor%20c%20modulators%20with%20angiotensin%20receptor%20blocking%20activity%2C%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Schupp%2C%20M.%20Clemenz%2C%20M.%20Gineste%2C%20R.%20Molecular%20characterization%20of%20new%20selective%20peroxisome%20proliferatoractivated%20receptor%20c%20modulators%20with%20angiotensin%20receptor%20blocking%20activity%2C%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Schupp%2C%20M.%20Clemenz%2C%20M.%20Gineste%2C%20R.%20Molecular%20characterization%20of%20new%20selective%20peroxisome%20proliferatoractivated%20receptor%20c%20modulators%20with%20angiotensin%20receptor%20blocking%20activity%2C%202005"
        },
        {
            "id": "106",
            "alt_id": "Schneider_et+al_2008_a",
            "entry": "[106] C. A. Schneider, E. Ferrannini, R. Defronzo, G. Schernthaner, J. Yates, and E. Erdmann, \u201cEffect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease,\u201d Journal of the American Society of Nephrology, vol. 19, no. 1, pp. 182\u2013187, 2008.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Schneider%2C%20C.A.%20Ferrannini%2C%20E.%20Defronzo%2C%20R.%20Schernthaner%2C%20G.%20Effect%20of%20pioglitazone%20on%20cardiovascular%20outcome%20in%20diabetes%20and%20chronic%20kidney%20disease%2C%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Schneider%2C%20C.A.%20Ferrannini%2C%20E.%20Defronzo%2C%20R.%20Schernthaner%2C%20G.%20Effect%20of%20pioglitazone%20on%20cardiovascular%20outcome%20in%20diabetes%20and%20chronic%20kidney%20disease%2C%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Schneider%2C%20C.A.%20Ferrannini%2C%20E.%20Defronzo%2C%20R.%20Schernthaner%2C%20G.%20Effect%20of%20pioglitazone%20on%20cardiovascular%20outcome%20in%20diabetes%20and%20chronic%20kidney%20disease%2C%202008"
        },
        {
            "id": "107",
            "alt_id": "Chan_et+al_2011_a",
            "entry": "[107] D. T. Chan, G. F. Watts, A. B. Irish, and G. K. Dogra, \u201cRosiglitazone does not improve vascular function in subjects with chronic kidney disease,\u201d Nephrology Dialysis Transplantation, vol. 26, no. 11, pp. 3543\u20133549, 2011.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Chan%2C%20D.T.%20Watts%2C%20G.F.%20Irish%2C%20A.B.%20Dogra%2C%20G.K.%20Rosiglitazone%20does%20not%20improve%20vascular%20function%20in%20subjects%20with%20chronic%20kidney%20disease%2C%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Chan%2C%20D.T.%20Watts%2C%20G.F.%20Irish%2C%20A.B.%20Dogra%2C%20G.K.%20Rosiglitazone%20does%20not%20improve%20vascular%20function%20in%20subjects%20with%20chronic%20kidney%20disease%2C%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Chan%2C%20D.T.%20Watts%2C%20G.F.%20Irish%2C%20A.B.%20Dogra%2C%20G.K.%20Rosiglitazone%20does%20not%20improve%20vascular%20function%20in%20subjects%20with%20chronic%20kidney%20disease%2C%202011"
        },
        {
            "id": "108",
            "alt_id": "Zanchi_et+al_2014_a",
            "entry": "[108] A. Zanchi, L. Tappy, K.-A. Leet al., \u201cPioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study,\u201d PLoS One, vol. 9, no. 10, Article ID e109134, 2014.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zanchi%2C%20A.%20Tappy%2C%20L.%20al%2C%20K.-A.Leet%20Pioglitazone%20improves%20fat%20distribution%2C%20the%20adipokine%20profile%20and%20hepatic%20insulin%20sensitivity%20in%20non-diabetic%20end-stage%20renal%20disease%20subjects%20on%20maintenance%20dialysis%3A%20a%20randomized%20cross-over%20pilot%20study%2C%202014",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zanchi%2C%20A.%20Tappy%2C%20L.%20al%2C%20K.-A.Leet%20Pioglitazone%20improves%20fat%20distribution%2C%20the%20adipokine%20profile%20and%20hepatic%20insulin%20sensitivity%20in%20non-diabetic%20end-stage%20renal%20disease%20subjects%20on%20maintenance%20dialysis%3A%20a%20randomized%20cross-over%20pilot%20study%2C%202014",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zanchi%2C%20A.%20Tappy%2C%20L.%20al%2C%20K.-A.Leet%20Pioglitazone%20improves%20fat%20distribution%2C%20the%20adipokine%20profile%20and%20hepatic%20insulin%20sensitivity%20in%20non-diabetic%20end-stage%20renal%20disease%20subjects%20on%20maintenance%20dialysis%3A%20a%20randomized%20cross-over%20pilot%20study%2C%202014"
        },
        {
            "id": "109",
            "alt_id": "Han_et+al_2010_a",
            "entry": "[109] S. J. Han, K. Y. Hur, Y. S. Kim et al., \u201cEffects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients,\u201d Nephrology Dialysis Transplantation, vol. 25, no. 3, pp. 976\u2013984, 2010.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Han%2C%20S.J.%20Hur%2C%20K.Y.%20Kim%2C%20Y.S.%20Effects%20of%20pioglitazone%20on%20subclinical%20atherosclerosis%20and%20insulin%20resistance%20in%20nondiabetic%20renal%20allograft%20recipients%2C%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Han%2C%20S.J.%20Hur%2C%20K.Y.%20Kim%2C%20Y.S.%20Effects%20of%20pioglitazone%20on%20subclinical%20atherosclerosis%20and%20insulin%20resistance%20in%20nondiabetic%20renal%20allograft%20recipients%2C%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Han%2C%20S.J.%20Hur%2C%20K.Y.%20Kim%2C%20Y.S.%20Effects%20of%20pioglitazone%20on%20subclinical%20atherosclerosis%20and%20insulin%20resistance%20in%20nondiabetic%20renal%20allograft%20recipients%2C%202010"
        },
        {
            "id": "110",
            "alt_id": "Kuba_et+al_2005_a",
            "entry": "[110] K. Kuba, Y. Imai, S. Rao et al., \u201cA crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury,\u201d Nature Medicine, vol. 11, no. 8, pp. 875\u2013879, 2005.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kuba%2C%20K.%20Imai%2C%20Y.%20Rao%2C%20S.%20A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20%28ACE2%29%20in%20SARS%20coronavirus-induced%20lung%20injury%2C%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kuba%2C%20K.%20Imai%2C%20Y.%20Rao%2C%20S.%20A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20%28ACE2%29%20in%20SARS%20coronavirus-induced%20lung%20injury%2C%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kuba%2C%20K.%20Imai%2C%20Y.%20Rao%2C%20S.%20A%20crucial%20role%20of%20angiotensin%20converting%20enzyme%202%20%28ACE2%29%20in%20SARS%20coronavirus-induced%20lung%20injury%2C%202005"
        },
        {
            "id": "111",
            "alt_id": "Raptis_et+al_2012_a",
            "entry": "[111] A. E. Raptis, D. Bacharaki, M. Mazioti et al., \u201cAnemia due to coadministration of renin-angiotensin-system inhibitors and PPARc agonists in uncomplicated diabetic patients,\u201d Experimental and Clinical Endocrinology & Diabetes, vol. 120, no. 7, pp. 416\u2013419, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Raptis%2C%20A.E.%20Bacharaki%2C%20D.%20Mazioti%2C%20M.%20Anemia%20due%20to%20coadministration%20of%20renin-angiotensin-system%20inhibitors%20and%20PPARc%20agonists%20in%20uncomplicated%20diabetic%20patients%2C%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Raptis%2C%20A.E.%20Bacharaki%2C%20D.%20Mazioti%2C%20M.%20Anemia%20due%20to%20coadministration%20of%20renin-angiotensin-system%20inhibitors%20and%20PPARc%20agonists%20in%20uncomplicated%20diabetic%20patients%2C%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Raptis%2C%20A.E.%20Bacharaki%2C%20D.%20Mazioti%2C%20M.%20Anemia%20due%20to%20coadministration%20of%20renin-angiotensin-system%20inhibitors%20and%20PPARc%20agonists%20in%20uncomplicated%20diabetic%20patients%2C%202012"
        },
        {
            "id": "112",
            "alt_id": "Kung_2012_a",
            "entry": "[112] J. Kung and R. R. Henry, \u201c iazolidinedione safety,\u201d Expert Opinion on Drug Safety, vol. 11, no. 4, pp. 565\u2013579, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kung%2C%20J.%20Henry%2C%20R.R.%20iazolidinedione%20safety%2C%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kung%2C%20J.%20Henry%2C%20R.R.%20iazolidinedione%20safety%2C%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kung%2C%20J.%20Henry%2C%20R.R.%20iazolidinedione%20safety%2C%202012"
        },
        {
            "id": "113",
            "alt_id": "Neumann_et+al_2012_a",
            "entry": "[113] A. Neumann, A. Weill, P. Ricordeau, J. P. Fagot, F. Alla, and H. Allemand, \u201cPioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study,\u201d Diabetologia, vol. 55, no. 7, pp. 1953\u20131962, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Neumann%2C%20A.%20Weill%2C%20A.%20Ricordeau%2C%20P.%20Fagot%2C%20J.P.%20Pioglitazone%20and%20risk%20of%20bladder%20cancer%20among%20diabetic%20patients%20in%20France%3A%20a%20population-based%20cohort%20study%2C%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Neumann%2C%20A.%20Weill%2C%20A.%20Ricordeau%2C%20P.%20Fagot%2C%20J.P.%20Pioglitazone%20and%20risk%20of%20bladder%20cancer%20among%20diabetic%20patients%20in%20France%3A%20a%20population-based%20cohort%20study%2C%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Neumann%2C%20A.%20Weill%2C%20A.%20Ricordeau%2C%20P.%20Fagot%2C%20J.P.%20Pioglitazone%20and%20risk%20of%20bladder%20cancer%20among%20diabetic%20patients%20in%20France%3A%20a%20population-based%20cohort%20study%2C%202012"
        },
        {
            "id": "114",
            "alt_id": "Colmers_et+al_2012_a",
            "entry": "[114] I. N. Colmers, S. L. Bowker, S. R. Majumdar, and J. A. Johnson, \u201cUse of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a metaanalysis,\u201d Canadian Medical Association Journal, vol. 184, no. 12, pp. E675\u2013E683, 2012.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Colmers%2C%20I.N.%20Bowker%2C%20S.L.%20Majumdar%2C%20S.R.%20Johnson%2C%20J.A.%20Use%20of%20thiazolidinediones%20and%20the%20risk%20of%20bladder%20cancer%20among%20people%20with%20type%202%20diabetes%3A%20a%20metaanalysis%2C%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Colmers%2C%20I.N.%20Bowker%2C%20S.L.%20Majumdar%2C%20S.R.%20Johnson%2C%20J.A.%20Use%20of%20thiazolidinediones%20and%20the%20risk%20of%20bladder%20cancer%20among%20people%20with%20type%202%20diabetes%3A%20a%20metaanalysis%2C%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Colmers%2C%20I.N.%20Bowker%2C%20S.L.%20Majumdar%2C%20S.R.%20Johnson%2C%20J.A.%20Use%20of%20thiazolidinediones%20and%20the%20risk%20of%20bladder%20cancer%20among%20people%20with%20type%202%20diabetes%3A%20a%20metaanalysis%2C%202012"
        },
        {
            "id": "115",
            "alt_id": "Nissen_2007_a",
            "entry": "[115] S. E. Nissen and K. Wolski, \u201cEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,\u201d New England Journal of Medicine, vol. 356, no. 24, pp. 2457\u20132471, 2007. ",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Nissen%2C%20S.E.%20Wolski%2C%20K.%20Effect%20of%20rosiglitazone%20on%20the%20risk%20of%20myocardial%20infarction%20and%20death%20from%20cardiovascular%20causes%2C%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Nissen%2C%20S.E.%20Wolski%2C%20K.%20Effect%20of%20rosiglitazone%20on%20the%20risk%20of%20myocardial%20infarction%20and%20death%20from%20cardiovascular%20causes%2C%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Nissen%2C%20S.E.%20Wolski%2C%20K.%20Effect%20of%20rosiglitazone%20on%20the%20risk%20of%20myocardial%20infarction%20and%20death%20from%20cardiovascular%20causes%2C%202007"
        }
    ],
    "facts": [
        "CKD can progress to irreversible end-stage renal diseases",
        "the key process involved in the disease development may lead to novel interventive strategies",
        "such as thiazolidinediones have been applied as effective antidiabetic drugs",
        "As PPAR\u03b3 is abundantly expressed in major kidney cells",
        "its physiological roles in those cells have been studied in both cell and animal models",
        "The function of PPAR\u03b3 in the kidney ranges from energy metabolism",
        "the number of patients with end-stage renal disease is rapidly increasing at a rate of 5%\u20138%",
        "ESRD is pathologically characterized by renal fibrosis",
        "application as clinical treatment was restricted by the side effect",
        "a new type of PPARc agonist with less side-effect may help application of the PPARc agonist into clinical treatment"
    ],
    "claims": [],
    "findings": [],
    "processes": [],
    "key_statements": [
        "end-stage renal disease is pathologically characterized by renal fibrosis, including glomerular sclerosis and renal interstitial fibrosis",
        "Activation of PPARc improves kidney injury. e application as clinical treatment was restricted by the side effect"
    ],
    "top_statements": [
        "Chronic kidney disease (CKD) has become one of the most common diseases in the world",
        "end-stage renal disease is pathologically characterized by renal fibrosis, including glomerular sclerosis and renal interstitial fibrosis",
        "Activation of PPARc improves kidney injury. e application as clinical treatment was restricted by the side effect"
    ],
    "headline": "Activation of PPARc improves kidney injury. e application as clinical treatment was restricted by the side effect",
    "contexts": [],
    "abbreviations": {
        "CKD": "Chronic kidney disease",
        "ESRD": "end-stage renal disease",
        "PPAR\u03b3": "Peroxisome proliferator-activated receptor \u03b3",
        "ECM": "extracellular matrix",
        "T2D": "type 2 diabetes",
        "UUO": "ureteral obstruction",
        "MAPK": "mitogen-activated protein kinase",
        "PDGF": "platelet-derived growth factor",
        "PAN": "puromycin aminonucleoside nephrosis",
        "TNF": "tumor necrosis factor",
        "TGF-\u03b2": "transforming growth factor-\u03b2",
        "PAI-1": "plasminogen activating-inhibiting factor-1",
        "HGF": "hepatocyte growth factor",
        "CTGF": "connective tissue growth factor",
        "DN": "diabetic nephropathy",
        "SGLTs": "sodium-dependent glucose cotransporters",
        "GLUTs": "glucose transporters",
        "DIO": "diet-induced obesity models",
        "NFIA": "nuclear factor I-A",
        "FFAs": "free fatty acids",
        "POKO": "PPARc2 and leptin double knockout mice",
        "STATs": "signal transducer and activator of transcription",
        "VEGF": "vascular endothelial growth factor",
        "BP": "blood pressure",
        "VSMC": "vascular smooth muscle cells",
        "MMP-9": "matrix metalloprotein-9",
        "RAAS": "renin-angiotensin-aldosterone system",
        "PD": "peritoneal dialysis"
    }
}
